(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/075713 A2

(51) International Patent Classification[7]: A61B

(21) International Application Number:
PCT/CA2004/000281

(22) International Filing Date: 26 February 2004 (26.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/450,406 26 February 2003 (26.02.2003) US

(71) Applicant *(for all designated States except US)*: **MOUNT SINAI HOSPITAL** [CA/CA]; 600 University Avenue, Room 970, Toronto, Ontario M5G 1X5 (CA).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **DIAMANDIS, Eleftherios, P.** [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA).

(74) Agent: **KURDYDYK, Linda**; McCarthy Tetrault, 66 Wellington Street West, Suite 4700, P.O. Box 48, Toronto Dominion Bank Tower (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

[Continued on next page]

(54) Title: MULTIPLE MARKER ASSAY FOR DETECTION OF OVARIAN CANCER



(57) Abstract: Methods for diagnosing and monitoring ovarian cancer in a subject comprising measuring a plurality of kallikrein polypeptides, and optionally CA125, or nucleic acids encoding the polypeptides in a sample from the subject. The kallikrein polypeptides include kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

WO 2004/075713 A2

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE: Multiple Marker Assay for Detection of Ovarian Cancer

FIELD OF THE INVENTION

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating ovarian cancer.

BACKGROUND OF THE INVENTION

Epithelial ovarian carcinoma is the most common and most lethal of all gynecologic malignancies. Only 30% of ovarian tumors are diagnosed at an early stage (Stage I/II), when survival rates reach 90%. The rest are diagnosed at an advanced stage, with survival rates of less than 20% (Greenlee RT, Hill-Harmon MB, Murray T, et al., 2001. *CA Cancer J Clin* .2001;51:15-36). Currently, the only well-accepted serological marker is CA125, a large glycoprotein of unknown function (Meyer T, Rustin GJ., *Br J Cancer* .2000;82:1535-1538). However, CA125 has limitations as a diagnostic, prognostic and screening tool (Holschneider CH, Berek JS, *Semin Surg Oncol* .2000;19:3-10). Consequently, there is a need to enhance the overall diagnostic/prognostic capability of CA125.

Kallikreins are a subgroup of secreted serine proteases, encoded by highly conserved and tightly clustered multigene families in humans, rats and mice. The human kallikrein gene family resides on chromosome 19q13.4 and is comprised of 15 members, whose genes are designated as *KLK1* to *KLK15* and the corresponding proteins as hK1 to hK15 (Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204l; Yousef GM, Chang A, Scorilas A, et al., *Biochem Biophys Res Commun.* 2000;276:125-133; Diamandis EP, Yousef GM, Clements J, et al. *Clin Chem* .2000;46:1855-1858). Kallikreins are expressed in a wide variety of tissues and are found in many biological fluids (e.g. cerebrospinal fluid, serum, seminal plasma, milk, etc.) where they are predicted to process specific substrates. Kallikreins may participate in cascade reactions similar to those involved in digestion, fibrinolysis, coagulation, wound healing and apoptosis ((Yousef GM, Diamandis EP., *Endocr Rev* .2001;22:184-204l). Many kallikreins have been found to be differentially expressed in endocrine-related malignancies (Diamandis EP, Yousef GM, *Expert Rev. Mol. Diagn* .2001;1:182-190), including prostate (Barry MJ. Clinical practice, *N Engl J Med* .2001;344:1373-1377; Rittenhouse HG, Finlay JA, Mikolajczyk SD, et al., *Crit Rev Clin Lab Sci* .1998;35:275-368; and Yousef GM, Scorilas A, Jung K, et al., *J Biol Chem* .2001;276:53-61), ovarian (Kim H, Scorilas A, Katsaros D, et al., *Br J Cancer,* 2001;84:643-650; Anisowicz A, Sotiropoulou G, Stenman, et al., *Mol Med* .1996;2:624-636; Tanimoto H, Underwood LJ, Shigemasa K, et al.,. *Cancer* .1999;86:2074-2082; Magklara A, Scorilas A, Katsaros D, et al., *Clin Cancer Res* .2001;7:806-811; Yousef GM, Kyriakopoulou LG, Scorilas A, et al., *Cancer Res* .2001;61:7811-7818; Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118), breast (Yousef GM, Magklara A, Chang A, et al., *Cancer Res* .2001;61:3425-3431;Yousef GM, Chang A, Diamandis EP; *J Biol Chem* .2000;275:11891-11898; and Yousef GM, Magklara A, Diamandis EP, *Genomics* .2000;69:331-341), and testicular cancer (Luo LY, Rajpert-De Meyts ER, Jung K, et al.,2001;85:220-224). In addition, many kallikrein genes examined thus far are under steroid hormone regulation, implicating a role for kallikreins in endrocrine-related tissues (Yousef GM, Diamandis EP., *Endocr Rev.,* 2001;22:184-204). Furthermore, hK6, hK10 and hK11 have been recently identified as novel serological ovarian cancer biomarkers (Luo L, Bunting P, Scorilas A, Diamandis EP., *Clin Chim Acta* .2001;306:111-118 Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P., *Clin Biochem.* 2000;33:579-

583, and Diamandis EP, Okui A, Mitsui S, et al., *Cancer Res* .2002;62:295-300).

SUMMARY OF THE INVENTION

The present invention seeks to overcome the drawbacks inherent in the prior art and seeks to provide sensitive and accurate multimarker methods for the detection of ovarian cancer. A plurality of kallikrein polypeptides and polynucleotides encoding the polypeptides, optionally in combination with CA125 and polynucleotides encoding CA125 can have particular application in the detection of ovarian cancer. A plurality of kallikrein markers (i.e. two or more of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11) and polynucleotides encoding the polypeptides, optionally in combination with CA125 and polynucleotides encoding CA125, constitute biomarkers for the diagnosis, monitoring, progression, treatment, and prognosis of ovarian cancer, and they may be used as biomarkers before surgery or after relapse.

In accordance with the methods of the invention, the presence of levels of markers in a sample can be assessed, for example by detecting the presence in the sample of (a) polypeptides or polypeptide fragments corresponding to the markers; (b) metabolites which are produced directly or indirectly by polypeptides corresponding to the markers; (c) transcribed nucleic acids or fragments thereof having at least a portion with which the markers are substantially identical; and/or (c) transcribed nucleic acids or fragments thereof, wherein the nucleic acids hybridize with the markers.

In an aspect of the invention, a method is provided for detecting ovarian cancer in a patient comprising detecting a plurality of kallikrein polypeptides, optionally in combination with CA125, in a sample from the patient wherein the method provides substantially increased sensitivity compared to methods using CA125 alone. In an embodiment, sensitivity is increased by at least 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, and 35% compared to using CA125 alone.

In an embodiment, the invention provides a method for detecting a plurality of kallikrein markers, and optionally CA125, associated with ovarian cancer in a patient comprising:

(a) obtaining a sample from a patient;

(b) detecting or identifying in the sample kallikrein markers, optionally in combination with CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(c) comparing the detected amounts with amounts detected for a standard.

The term "detect" or "detecting" includes assaying, assessing, imaging or otherwise establishing the presence or absence of the target kallikrein and CA125 polypeptides or polynucleotides encoding the polypeptides, subunits thereof, or combinations of reagent bound targets, and the like, or assaying for, imaging, ascertaining, establishing, or otherwise determining one or more factual characteristics of ovarian cancer, metastasis, stage, or similar conditions. The term encompasses diagnostic, prognostic, and monitoring applications. The kallikrein polypeptides and CA125 can be detected individually, sequentially, or simultaneously.

According to a method involving kallikrein markers optionally in combination with CA125, the levels in the sample of the kallikrein markers (2, 3, 4, 5, or 6) and optionally CA125, wherein the markers comprise or are selected from kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein

11, are compared with the normal levels of the kallikrein markers, and optionally CA125, in samples of the same type obtained from controls (e.g. samples from individuals not afflicted with ovarian cancer). Significantly different levels in the sample of the kallkrein markers (and optionally CA125) relative to the normal levels in a control is indicative of ovarian cancer.

In an embodiment, the invention provides a method for diagnosing and monitoring ovarian carcinoma in a subject comprising detecting in a sample from the subject kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. The kallikrein markers and CA125 can be detected using antibodies that bind to the kallikrein markers and CA125 or parts thereof.

Thus, the invention provides a method of assessing whether a patient is afflicted with or has a pre-disposition for ovarian cancer, the method comprising comparing:

(a) levels of kallikrein markers, and optionally CA125, in a sample from the patient, wherein the kallikrein markers comprise kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(b) normal levels of kallikrein markers, and optionally CA125, in samples of the same type obtained from control patients not afflicted with ovarian cancer, wherein significantly different levels of the kallikrein markers and optionally CA125, relative to the corresponding normal levels of the kallikrein markers, and optionally CA125, is an indication that the patient is afflicted with ovarian cancer.

In an embodiment of a method of assessing whether a patient is afflicted with ovarian cancer (e.g. screening, detection of a recurrence, reflex testing), the method comprises comparing:

(a) levels of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(b) normal levels of the kallikrein markers, and optionally CA125, in a control non-ovarian cancer sample.

A significant difference between the levels of the kallikrein markers, and optionally CA125, in the patient sample and the normal levels is an indication that the patient is afflicted with ovarian cancer.

The invention further relates to a method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient. This method comprises comparing:

(a) levels of kallikrein markers, and optionally CA125, in a first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11 ; and

(b) levels of the kallikrein markers, and optionally CA125, in a second sample obtained from the patient following therapy.

A significant difference between the levels of the kallikrein markers, and optionally CA125, in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer.

The "therapy" may be any therapy for treating ovarian cancer including but not limited to chemotherapy, immunotherapy, gene therapy, radiation therapy, and surgical removal of tissue. Therefore, the method can be used to evaluate a patient before, during, and after therapy, for example, to evaluate the reduction in tumor burden.

In an aspect, the invention provides a method for monitoring the progression of ovarian cancer in a patient, the method comprising:

(a) detecting in a patient sample at a first time point, kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(b) repeating step (a) at a subsequent point in time; and

(c) comparing the levels detected in (a) and (b), and therefrom monitoring the progression of ovarian cancer in the patient.

In another aspect, the invention provides a method for assessing the aggressiveness or indolence of ovarian cancer (e.g. staging), the method comprising comparing:

(a) levels of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(b) normal levels of the kallikrein markers, and optionally CA125 in a control sample.

A significant difference between the levels in the sample and the normal levels is an indication that the cancer is aggressive or indolent.

The invention provides a method for determining whether ovarian cancer has metastasized or is likely to metastasize in the future, the method comprising comparing:

(a) levels of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(b) normal levels (or non-metastatic levels) of the kallikrein markers, and optionally CA125, in a control sample.

A significant difference between the levels in the patient sample and the normal levels is an indication that the cancer has metastasized or is likely to metastasize in the future.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, and a method of selecting an agent for inhibiting ovarian cancer in a patient.

The invention further provides a method of inhibiting ovarian cancer in a patient comprising:

(a) obtaining a sample comprising cancer cells from the patient;

(b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;

(c) comparing levels of kallikrein markers, and optionally CA125, in each of the aliquots, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11;

(d) administering to the patient at least one of the test agents which alters the levels of the

kallikrein markers, and optionally CA125, in the aliquot containing that test agent, relative to other test agents.

The invention also contemplates a method of assessing the ovarian carcinogenic potential of a test compound comprising:

(a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and

(b) comparing levels of kallikrein markers, and optionally CA125, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the kallikrein markers, and optionally CA125, in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses ovarian carcinogenic potential.

In preferred embodiments of the methods of the invention, the kallikrein markers comprise a plurality of kallikrein markers, for example, at least three, four, five, or six of the markers. In particular, a plurality of kallikrein markers may be selected from the group consisting of kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10, from the group consisting of kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, or from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

Other methods of the invention employ one or more polynucleotides capable of hybridizing to polynucleotides encoding kallikrein markers, and optionally CA125. Methods for detecting polynucleotides encoding a kallikrein markers, and optionally CA125, can be used to monitor ovarian cancer by detecting the nucleic acids.

Thus, the present invention relates to a method for diagnosing and monitoring ovarian cancer in a sample from a subject comprising isolating nucleic acids, preferably mRNA, from the sample; and detecting polynucleotides encoding kallikrein markers, and optionally CA125, in the sample. The presence of different levels of polynucleotides encoding kallikrein markers, and optionally CA125, in the sample compared to a standard or control is indicative of disease, disease stage, and/or prognosis, e.g. longer progression-free and overall survival.

In an embodiment, the invention provides methods for determining the presence or absence of ovarian cancer in a subject comprising (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125; and (b) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of ovarian cancer in the subject. Within certain embodiments, mRNA is detected via polymerase chain reaction using, for example oligonucleotide primers that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, or complements of such polynucleotides. Within other embodiments, the amount of mRNA is detected using a hybridization technique, employing oligonucleotide probes that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, or complements of such polynucleotides.

When using mRNA detection, the method may be carried out by combining isolated mRNA with

reagents to convert to cDNA according to standard methods; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with an appropriate mixture of nucleic acid primers; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of polynucleotides encoding kallikrein markers, and optionally CA125, in the sample. For mRNA the analyzing step may be accomplished using Northern Blot analysis to detect the presence of polynucleotides encoding kallikrein markers, and optionally CA125. The analysis step may be further accomplished by quantitatively detecting the presence of polynucleotides encoding kallikrein markers, and optionally CA125, in the amplification product, and comparing the quantity of markers detected against a panel of expected values for the known presence or absence of the kallikrein markers in normal and malignant tissue derived using similar primers.

In embodiments of the methods of the invention, a plurality (eg. three, four, five or six) polynucleotides encoding kallikrein polypeptides are employed. In particular, a plurality of polynucleotides encoding kallikrein markers may be selected from the group consisting of polynucleotides encoding (i) kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10; (ii) polynucleotides encoding kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (iii) polynucleotides encloding kallikrein 5, kallikrein 6, kallikrein7, kallikrein 8, kallikrein 10 and kallikrein 11.

The invention also provides a diagnostic composition comprising a plurality of kallikrein polypeptides and optionally CA125 polypeptide, or polynucleotides encoding the polypeptides, or agents that bind to the polypeptides or polynucleotides.

In an embodiment, the composition comprises probes that specifically hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, or fragments thereof. In another embodiment a composition is provided comprising specific primer pairs capable of amplifying polynucleotides encoding kallikrein markers, and optionally CA125, using polymerase chain reaction methodologies. In a still further embodiment, the composition comprises agents that bind to kallikrein markers, and optionally CA125, (e.g. antibodies) or fragments thereof. Probes, primers, and agents can be labeled with detectable substances.

In an aspect the invention provides an *in vivo* method comprising administering to a subject agents that have been constructed to target kallikrein markers, and optionally CA125.

The invention therefore contemplates an *in vivo* method comprising administering to a mammal imaging agents that carry labels for imaging and that bind to kallikrein markers, and optionally CA125, and then imaging the mammal.

Still further the invention relates to therapeutic applications for ovarian cancer employing kallikrein markers, and optionally CA125, nucleic acids encoding the polypeptides, and/or agents identified using methods of the invention.

The invention also includes kits for carrying out methods of the invention. In an embodiment, the kit is for assessing whether a patient is afflicted with ovarian cancer and it comprises reagents for assessing kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consising of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

In another aspect the invention relates to a kit for assessing the suitability of each of a plurality of test compounds for inhibiting ovarian cancer in a patient. The kit comprises reagents for assessing kallikrein

markers, and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. The kit may also comprise a plurality of test agents or compounds.

The invention contemplates a kit for assessing the presence of ovarian cancer cells, wherein the kit comprises antibodies specific for selected kallikrein markers, and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

Additionally the invention provides a kit for assessing the ovarian carcinogenic potential of a test compound. The kit comprises ovarian cells and reagents for assessing kallikrein markers, and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

In an aspect the invention provides a method of treating a patient afflicted with ovarian cancer comprising providing to cells of a patient antisense oligonucleotides complementary to polynucleotides encoding kallikrein markers, and optionally CA125, which are overexpressed in ovarian cancer. In an alternative method, expression of genes corresponding to kallikrein markers, and optionally CA125, which are underexpressed in ovarian cancer are increased.

The invention relates to a method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer comprising inhibiting or increasing expression (or overexpression) of genes encoding kallikrein markers and optionally CA125, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, that are either overexpressed or underexpressed, in ovarian cancer.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

The invention will now be described in relation to the drawings in which

Figure 1 is a graph showing hk5 concentration in serum from non-cancer and cancer patients.

Figure 2 is a graph showing hk6 concentration in serum from non-cancer and cancer patients.

Figure 3 is a graph showing hk7 concentration in serum from non-cancer and cancer patients.

Figure 4 is a graph showing hk8 concentration in serum from non-cancer and cancer patients.

Figure 5 is a graph showing hk10 concentration in serum from non-cancer and cancer patients.

Figure 6 is a graph showing hk11 concentration in serum from non-cancer and cancer patients.

Figure 7 is a graph showing CA125 concentration in serum from non-cancer and cancer patients.

Figure 8 is a ROC curve illustrating the added value of using kallikreins and CA125 together in a multivariate function.

DETAILED DESCRIPTION OF THE INVENTION

The invention relates to newly discovered correlations between expression of certain markers and

ovarian cancer. The combinations of markers described herein may provide sensitive methods for detecting ovarian cancer. The levels of expression of a combination of markers described herein may correlate with the presence of ovarian cancer or a pre-malignant condition in a patient. Methods are provided for detecting the presence of ovarian cancer in a sample, the absence of ovarian cancer in a sample, the stage of an ovarian cancer, the grade of an ovarian cancer, the benign or malignant nature of an ovarian cancer, the metastatic potential of an ovarian cancer, assessing the histological type of neoplasm associated with the ovarian cancer, the indolence or aggressiveness of the cancer, and other characteristics of ovarian cancer that are relevant to prevention, diagnosis, characterization, and therapy of ovarian cancer in a patient. Methods are also provided for assessing the efficacy of one or more test agents for inhibiting ovarian cancer, assessing the efficacy of a therapy for ovarian cancer, monitoring the progression of ovarian cancer, selecting an agent or therapy for inhibiting ovarian cancer, treating a patient afflicted with ovarian cancer, inhibiting ovarian cancer in a patient, and assessing the carcinogenic potential of a test compound.

Glossary

The terms “sample”, "biological sample", and the like, mean a material known or suspected of expressing or containing a plurality of kallikrien markers or polypeptides (2, 3, 4, 5, or 6 polypeptides), and optionally CA125 polypeptide, or polynucleotides encoding the polypeptides. The test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample. The sample can be derived from any biological source, such as tissues, extracts, or cell cultures, including cells (e.g. tumor cells), cell lysates, and physiological fluids, such as, for example, whole blood, plasma, serum, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, synovial fluid, peritoneal fluid and the like. The sample can be obtained from animals, preferably mammals, most preferably humans. The sample can be treated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, the addition of reagents, and the like. Nucleic acids and polypeptides may be isolated from the samples and utilized in the methods of the invention. In a preferred embodiment, the sample is a serum sample.

The term "subject" or “patient” refers to a warm-blooded animal such as a mammal, which is suspected of having ovarian cancer, or a condition, disease, or syndrome associated with ovarian cancer. Preferably, “subject” refers to a human.

“CA125”, “CA125 polypeptide”, or “carbohydrate antigen 125” refers to a high-molecular weight mucin, which can be defined by its ability to bind to monoclonal antibody OC125. The CA125 protein core comprises a short cytoplasmic core tail, a transmembrane domain, and a large and heavily glycosylated extracellular domain dominated by a repeat domain of 156 amino acids rich in serine, threonine, and proline (Yin BW and Lloyd KO, J Biol Chem. 2001, 276:27371-27375; O’Brian TJ et al, Tumor Biol., 2001 22:348-366; and Hovig E. et al, Tumor Biol. 2001, 22:345-347). The sequence of CA125 is shown in GenBank Accession No. NP_078966, AAL65133 and AF414442 (SEQ ID NO. 1). The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The term also includes the native sequence polypeptide, including polypeptide variants and polypeptides with substantial sequence identity (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or

99% sequence identity) to the sequence of GenBank Accession No.NP_078966 (SEQ ID NO. 1), and that preferably retain the immunogenic activity of the corresponding native sequence polypeptide.

"Kallikrein polypeptides" or "kallikrein markers" comprise kallilkrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. The term includes the native-sequence polypeptides, isoforms, precursors and chimeric polypeptides. The amino acid sequences for native kallikrein polypeptides employed in the present invention include the sequences found in GenBank for each polypeptide as shown in Table 1, and in SEQ ID NO: 3 (kallilkrein 5), NO.6 (kallikrein 6), NO. 10 (kallikrein 7), NO. 13 (kallikrein 8), NO. 16 (kallikrein 10), and NOs. 19 and 20 (kallikrein 11), or a portion thereof. Other useful polypeptides are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity), and preferably retain the immunogenic activity of the corresponding native-sequence kallikrein polypeptide.

A "native-sequence polypeptide" comprises a polypeptide having the same amino acid sequence of a polypeptide derived from nature. Such native-sequence polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.

The term "native-sequence polypeptide" specifically encompasses naturally occurring truncated or secreted forms of a polypeptide, polypeptide variants including naturally occurring variant forms (e.g., alternatively spliced forms or splice variants), and naturally occurring allelic variants.

The term "polypeptide variant" means a polypeptide having at least about 70-80%, preferably at least about 85%, more preferably at least about 90%, most preferably at least about 95% amino acid sequence identity with a native-sequence polypeptide, in particular having at least 70-80%, 85%, 90%, 95% amino acid sequence identity to the sequences identified in the GenBank Accession Nos. in Table 1 and Accession No. NP_078966, AF414442 and AAL65133 and shown in SEQ ID NOS: 1, 2, 3, 6, 10, 13, 16, 19 and 20. Such variants include, for instance, polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of SEQ ID NOS: 1, 2, 3, 6, 10, 13, 16, 19 and 20, including variants from other species, but excludes a native-sequence polypeptide.

An allelic variant may also be created by introducing substitutions, additions, or deletions into a nucleic acid encoding a native polypeptide sequence such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations may be introduced by standard methods, such as site-directed mutagenesis and PCR-mediated mutagenesis. In an embodiment, conservative substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which an animo acid residue is replaced with an amino acid residue with a similar side chain. Amino acids with similar side chains are known in the art and include amino acids with basic side chains (e.g. Lys, Arg, His), acidic side chains (e.g. Asp, Glu), uncharged polar side chains (e.g. Gly, Asp, Glu, Ser, Thr, Tyr and Cys), nonpolar side chains (e.g. Ala, Val, Leu, Iso, Pro, Trp), beta-branched side chains (e.g. Thr, Val, Iso), and aromatic side chains (e.g. Tyr, Phe, Trp, His). Mutations can also be introduced randomly along part or all of the native sequence, for example, by saturation mutagenesis. Following mutagenesis the variant polypeptide can be recombinantly expressed and the activity of the polypeptide may be determined.

Polypeptide variants include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of a native polypeptide which include fewer amino acids than the full length polypeptides. A portion of a polypeptide can be a polypeptide which is for example, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100 or more amino acids in length. Portions in which regions of a polypeptide are deleted can be prepared by recombinant techniques and can be evaluated for one or more functional activities such as the ability to form antibodies specific for a polypeptide.

A naturally occurring allelic variant may contain conservative amino acid substitutions from the native polypeptide sequence or it may contain a substitution of an amino acid from a corresponding position in a CA125 or kallikrein polypeptide homolog, for example, the murine CA125 or kallikrein polypeptide.

Percent identity of two amino acid sequences, or of two nucleic acid sequences identified herein is defined as the percentage of amino acid residues or nucleotides in a candidate sequence that are identical with the amino acid residues in a CA125 or kallikrein polypeptide or nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid or nucleic acid sequence identity can be achieved in various conventional ways, for instance, using publicly available computer software including the GCG program package (Devereux J. et al., Nucleic Acids Research 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. J. Molec. Biol. 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. J. Mol. Biol. 215: 403-410, 1990). Skilled artisans can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Methods to determine identity and similarity are codified in publicly available computer programs.

CA125 and kallikrien polypeptides include chimeric or fusion proteins. A "chimeric protein" or "fusion protein" comprises all or part (preferably biologically active) of a CA125 or kallikrein polypeptide operably linked to a heterologous polypeptide (i.e., a polypeptide other than the same CA125 or kallikrein polypeptide). Within the fusion protein, the term "operably linked" is intended to indicate that the CA125 or kallikrein polypeptide and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the N-terminus or C-terminus of the CA125 or kallikrein polypeptide. A useful fusion protein is a GST fusion protein in which a kallikrein polypeptide is fused to the C-terminus of GST sequences. Another example of a fusion protein is an immunoglobulin fusion protein in which all or part of a CA125 or kallikrein polypeptide is fused to sequences derived from a member of the immunoglobulin protein family. Chimeric and fusion proteins can be produced by standard recombinant DNA techniques.

CA125 and kallikrein polypeptides may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods, or by any combination of these and similar techniques.

"CA125 polynucleotides" or "polynucleotides encoding CA125" include nucleic acids that encode a native-sequence polypeptide, a polypeptide variant including a portion of a CA125 polypeptide, an isoform, precursor, and chimeric polypeptide. A nucleic acid sequence encoding native CA125 employed in the

present invention includes the nucleic acid sequence in GenBank Accession No. AF414442 and SEQ ID NO. 2, or a fragment thereof.

"Kallikrein polynucleotides" or "polynucleotides encoding kallikrein markers/polypeptides" refers to kallillkrein 5 nucleic acids (KLK5), kallikrein 6 nucleic acids (KLK6), kallikrein 7 nucleic acids (KLK7), kallikrein 8 nucleic acids (KLK8), kallikrein 10 nucleic acids (KLK10), and/or kallikrein 11 nucleic acids (KLK11). The term includes nucleic acids that encode a native-sequence polypeptide, a polypeptide variant including a portion of a kallikrein polypeptide, an isoform, precursor, and chimeric polypeptide.

The polynucleotide sequences encoding native kallikrein polypeptides employed in the present invention include the nucleic acid sequences of the GenBank Accession Nos. identified in Table 1, and in SEQ ID NOs: 4 and 5 (KLK5), NOs. 7, 8, and 9 (KLK6), NOs. 11 and 12 (KLK 7), NOs. 14 and 15 (KLK8), NOs. 17 and 18 (KLK10), and NOs. 21 and 22 (KLK11), or a fragment thereof.

Polynucleotides encoding kallikrien polypeptides and CA125 include nucleic acid sequences complementary to these polynucleotides, and polynucleotides that are substantially identical to these sequences (e.g. at least about 45%, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, 97%, 98%, or 99% sequence identity).

CA125 and kallikrein polynucleotides also include sequences which differ from a nucleic acid sequence of GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 4, 5, 7, 8, 9, 11, 12, 14, 15, 17, 18, 21, and 22, due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a CA125 or kallikrein polypeptide may result in silent mutations which do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to natural allelic variation. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of CA125 or a kallikrein polypeptide.

CA125 and kallikrein polynucleotides also include nucleic acids that hybridize under stringent conditions, preferably high stringency conditions to a nucleic acid sequence of the GenBank Accession Nos. identified in Table 1 and SEQ ID NOS: 2, 4, 5, 7, 8, 9, 11, 12, 14, 15, 17, 18, 21, and 22. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

CA125 and kallikrein polynucleotides also include truncated nucleic acids or fragments and variant forms of the polynucleotides that arise by alternative splicing of an mRNA corresponding to a DNA.

The CA125 and kallikrien polynucleotides are intended to include DNA and RNA (e.g. mRNA) and can be either double stranded or single stranded. A polynucleotide may, but need not, include additional coding or non-coding sequences, or it may, but need not, be linked to other molecules and/or carrier or support materials. The polynucleotides for use in the methods of the invention may be of any length suitable for a particular method.

A purality of kallikrein polypeptides or kallikrein polynucleotides are generally detected in the present invention. "Plurality" refers to 2, 3, 4, 5, or 6 kallikrein polypeptides or polynucleotides, in particular 3, 4, 5, or 6, preferably 4, 5, or 6, more preferably 5 or 6 kallikrein polypeptides or polynucleotides.

In an embodiment a plurality of kallikrein polypeptides is selected from the group consisting of kallikrein 5, kallikrein 7, and kallikrein 8; kallikrein 5, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; or kallikrein 5, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11. In another embodiment, a plurality of kallikrein polypeptides is selected from the group consisting of kallilkrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

In an embodiment, a pluraity of kallikrein polynucleotides is selected from the group consisting of KLK5, KLK7, and KLK8; KLK5, KLK8 and KLK10; KLK7, KLK8 and KLK10; KLK5, KLK7, KLK8, and KLK10; KLK7, KLK8, KLK10 and KLK11, or KLK5, KLK7, KLK8, KLK10 and KLK11. In another embodiment, a plurality of kallikrein polynucleotides is selected from the group consisting of KLK5, KLK6, KLK7, KLK8, KLK10, and KLK11.

General Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of ovarian cancer involving kallikrein polypeptides, and optionally CA125 polypeptide, and polynucleotides encoding the polypeptides, and the identification of subjects with a predisposition to such disorders. Such methods may, for example, utilize polynucleotides encoding kallikrein polypeptides, and optionally CA125, and fragments thereof, and binding agents (e.g. antibodies aptamers) against kallikrein polypeptides, and optionally CA125 polypeptide, including peptide fragments. In particular, the polynucleotides and antibodies may be used, for example, for (1) the detection of either over- or under-expression of kallikrein polynucleotides, and optionally CA125, relative to a non-disorder state; and (2) the detection of either an over- or an under-abundance of kallikrein polypeptides, and optionally CA125, relative to a non-disorder state or the presence of modified (e.g., less than full length) kallikrein polypeptides, and optionally CA125, that correlate with a disorder state, or a progression toward a disorder state.

The invention also contemplates a method for detecting ovarian cancer comprising producing a profile of levels of a plurality of kallikrein markers, and optionally CA125, in cells from a patient, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and comparing the profile with a reference to identify a protein profile for the test cells indicative of disease.

The methods described herein may be used to evaluate the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such methods can be used to detect tumors, quantitate their growth, and help in the diagnosis and prognosis of disease. The methods can be used to detect the presence of cancer metastasis, as well as confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy, and/or radiation therapy. They can further be used to monitor cancer chemotherapy and tumor reappearance.

The methods described herein can be adapted for diagnosing and monitoring ovarian cancer by detecting a plurality of kallikrein polypeptides, and optionally CA125 polypeptide, or nucleic acids encoding the polypeptides in biological samples from a subject. These applications require that the amount of

polypeptides or nucleic acids quantitated in a sample from a subject being tested be compared to a predetermined standard. The standard may correspond to levels quantitated for another sample or an earlier sample from the subject, or levels quantitated for a control sample. Levels for control samples from healthy subjects or ovarian cancer subjects may be established by prospective and/or retrospective statistical studies. Healthy or normal subjects who have no clinically evident disease or abnormalities may be selected for statistical studies. Diagnosis may be made by a finding of statistically different levels of a plurality of kallikrein polypeptides, and optionally CA125, or nucleic acids encoding same, compared to a control sample or previous levels quantitated for the same subject. A "significant difference" in levels of kallikrein markers or polynucleotides encoding the kallikrein markers in a patient sample compared to a control or standard (e.g. normal levels or levels in other samples from a patient) may represent levels that are higher or lower than the standard error of the detection assay, preferably the levels are at least about 1.5, 2, 3, 4, 5, or 6 times higher or lower, respectively, than the control or standard. The difference in levels of markers or polynucleotides may be a "statistically significant difference"

Nucleic Acid Methods/Assays

As noted herein an ovarian cancer may be detected based on the levels of polynucleoitdes encoding kallikrein polypeptides, and optionally CA125, in a sample. Techniques for detecting polynucleotides such as polymerase chain reaction (PCR) and hybridization assays are well known in the art.

Nucleotide probes for use in the detection of nucleic acid sequences in samples may be constructed using conventional methods known in the art. Suitable probes may be based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of nucleic acids encoding kallikrein polypeptides, and optionally CA125, preferably they comprise 15 to 40 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P, ^{3}H, ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect polynucleoitides encoding kallikrein polypeptides, and optionally CA125, preferably in human cells. The nucleotide probes may also be useful in the diagnosis of ovarian cancer involving polynucleoitides encoding kallikrein polypeptides, and optionally CA125, in monitoring the progression of such disorder; or monitoring a therapeutic treatment.

Probes may be used in hybridization techniques to detect nucleic acids encoding a plurality of kallikrein polypeptides, and optionally CA125. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with probes under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

The detection of polynucleotides encoding kallikrein polypeptides and optionally CA125, may involve the amplification of specific gene sequences using an amplification method such as polymerase chain reaction (PCR), followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art.

By way of example, oligonucleotide primers may be employed in a PCR based assay to amplify a portion of nucleic acids encoding each of a plurality of kallikrein polypeptides, and optionally CA125, derived from a sample, wherein the oligonucleotide primers are specific for (i.e. hybridize to) polynucleotides encoding each of the plurality of kallikrein polypeptides, and optionally CA125. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis.

In order to maximize hybridization under assay conditions, primers and probes employed in the methods of the invention generally have at least about 60%, preferably at least about 75% and more preferably at least about 90% identity to a portion of polynucleotides encoding a plurality of kallikrein polypeptides, and CA125. The primers and probes may be at least 10 nucleotides, and preferably at least 20 nucleotides in length. In an embodiment the primers and probes are at least about 10-40 nucleotides in length.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of expression of polynucleotides encoding kallikrein polypeptides, and optionally CA125. For example, RNA may be isolated from a cell type or tissue known to express these polynucleotides and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein.

The primers and probes may be used in the above-described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

In an aspect of the invention, a method is provided employing reverse transcriptase-polymerase chain reaction (RT-PCR), in which PCR is applied in combination with reverse transcription. Generally, RNA is extracted from a sample tissue using standard techniques (for example, guanidine isothiocyanate extraction as described by Chomcynski and Sacchi, Anal. Biochem. 162:156-159, 1987) and is reverse transcribed to produce cDNA. The cDNA is used as a template for a polymerase chain reaction. The cDNA is hybridized to sets of primers specifically designed against each of a plurality of kallikrein polynucleotide sequences, and optionally CA125. Once the primer and template have annealed a DNA polymerase is employed to extend from the primer, to synthesize a copy of the template. The DNA strands are denatured, and the procedure is repeated many times until sufficient DNA is generated to allow visualization by ethidium bromide staining and agarose gel electrophoresis.

Amplification may be performed on samples obtained from a subject with suspected ovarian cancer and an individual who is not afflicted with ovarian cancer. The reaction may be performed on several dilutions of cDNA spanning at least two orders of magnitude. A statistically significant difference in expression in several dilutions of the subject sample as compared to the same dilutions of the non-cancerous sample may be considered positive for the presence of ovarian cancer.

Oligonucleotides or longer fragments derived from polynucleotides encoding each of a plurality of

kallikrein polypeptides and optionally CA125, may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes. The information from the microarray may be used to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (I 995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

Thus, the invention also includes an array comprising a plurality of polynucleotides encoding kallikrein marker(s), and optionally CA125 polynucleotides. The array can be used to assay expression of kallikrein polynucleotides, and optionally CA125 polynucleotides in the array. The invention allows the quantitation of expression of a plurality of kallikrein polynucleotides, and optionally CA125 polynucleotides.

In an embodiment, the array can be used to monitor the time course of expression of a plurality of kallikrein polynucleotides, and optionally CA125 polynucleotides, in the array. This can occur in various biological contexts such as tumor progression.

The array is also useful for ascertaining differential expression patterns of a plurality of kallikrein polynucleotides and optionally CA125 polynucleotides, in normal and abnormal cells. This provides a battery of polynucleotides that could serve as molecular targets for diagnosis or therapeutic intervention.

Protein Methods

Binding agents specific for a plurality of kallikrein markers and CA125 may be used for a variety of diagnostic and assay applications. There are a variety of assay formats known to the skilled artisan for using a binding agent to detect a target molecule in a sample. (For example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). In general, the presence or absence of an ovarian cancer in a subject may be determined by (a) contacting a sample from the subject with binding agents for a plurality of kallikrein polypeptides, and optionally CA125; (b) detecting in the sample levels of polypeptides that bind to the binding agents; and (c) comparing the levels of polypeptides with a predetermined standard or cut-off value.

"Binding agent" refers to a substance such as a polypeptide or antibody that specifically binds to a kallikrein or CA125 polypeptide. A substance "specifically binds" to a polypeptide if it reacts at a detectable level with the kallikrein or CA125 polypeptide, and does not react detectably with peptides containing unrelated sequences or sequences of different polypeptides. Binding properties may be assessed using an ELISA, which may be readily performed by those skilled in the art (see for example, Newton et al , Develop. Dynamics 197: 1-13, 1993).

A binding agent may be a ribosome, with or without a peptide component, an aptamer, an RNA molecule, or a polypeptide. A binding agent may be a polypeptide that comprises a kallikrein polypeptide or CA125 polypeptide sequence, a peptide variant thereof, or a non-peptide mimetic of such a sequence. By way of example a kallikrein polypeptide sequence may be a peptide portion of a kallikrein polypeptide that is capable of modulating a function mediated by the kallikrein polypeptide.

An aptamer includes a DNA or RNA molecule that binds to polynucleotides and polypeptides. An aptamer that binds to a polypeptide (or binding domain) of a kallikrein polypeptide or a polynucleotide encoding a kallikrein polypeptide can be produced using conventional techniques, without undue experimentation. [For example, see the following publications describing *in vitro* selection of aptamers: Klug et al., Mol. Biol. Reports 20:97-107 (1994); Wallis et al., Chem. Biol. 2:543-552 (1995); Ellington, Curr. Biol. 4:427-429 (1994); Lato et al., Chem. Biol. 2:291-303 (1995); Conrad et al., Mol. Div. 1:69-78 (1995); and Uphoff et al., Curr. Opin. Struct. Biol. 6:281-287 (1996)].

In certain other preferred embodiments, the binding agent is an antibody.

In an aspect the present invention provides a diagnostic method for monitoring or diagnosing ovarian cancer in a subject by quantitating a plurality of kallikrein polypeptides, and optionally CA125, in a biological sample from the subject comprising reacting the sample with antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, which are directly or indirectly labelled with detectable substances, and detecting the detectable substances.

In an aspect of the invention, a method for detecting ovarian cancer is provided comprising:

(a) obtaining a sample suspected of containing a plurality of kallikrein polypeptides, and optionally CA125, wherein the kallikrein polypeptides comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11;

(b) contacting the sample with antibodies that specifically bind to the plurality of kallikrein polypeptides, and optionally CA125, under conditions effective to bind the antibodies and form complexes;

(c) measuring the amount of kallikrein polypeptides, and optionally CA125, present in the sample by quantitating the amount of the complexes; and

(d) comparing the amount of kallikrein polypeptides, and optionally CA125, present in the samples with the amount of polypeptides in a control, wherein a change or significant difference in the amount of polypeptides in the sample compared with the amount in the control is indicative of ovarian cancer.

In an embodiment, the invention contemplates a method for monitoring the progression of ovarian cancer in an individual, comprising:

(a) contacting antibodies which bind to each of a plurality of kallikrein polypeptides, and optionally CA125, with a sample from the individual so as to form binary complexes comprising each of the antibodies and polypeptides in the sample;

(b) determining or detecting the presence or amount of complex formation in the sample;

(c) repeating steps (a) and (b) at a point later in time; and

(d) comparing the result of step (b) with the result of step (c), wherein a difference in the amount of complex formation is indicative of the stage and/or progression of the ovarian cancer in said individual.

The amount of complexes may also be compared to a value representative of the amount of the complexes from an individual not at risk of, or afflicted with, ovarian cancer at different stages.

Thus, antibodies specifically reactive with each of a plurality of kallikrein polypeptides, and CA125, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect a plurality of kallikrein polypeptides, and optionally CA125, in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the levels of expression of a plurality of kallikrein polypeptides, and optionally CA125, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of a plurality of kallikrein polypeptides, and optionally CA125. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on ovarian cancer involving a plurality of kallikrein polypeptides, and optionally CA125, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

Antibodies may be used in any known immunoassays that rely on the binding interaction between antigenic determinants of a plurality of kallikrein polypeptides, and optionally CA125, and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests. These terms are well understood by those skilled in the art. A person skilled in the art will know, or can readily discern, other immunoassay formats without undue experimentation.

In particular, the antibodies may be used in immunohistochemical analyses, for example, at the cellular and sub-subcellular level, to detect a plurality of kallikrein polypeptides, and optionally CA125, to localize them to particular ovarian tumor cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Antibodies for use in the present invention include monoclonal or polyclonal antibodies, immunologically active fragments (e.g. a Fab or $(Fab)_2$ fragments), antibody heavy chains, humanized antibodies, antibody light chains, genetically engineered single chain F_v molecules (Ladner et al, U.S. Pat. No. 4,946,778), chimeric antibodies, for example, antibodies which contain the binding specificity of murine antibodies, but in which the remaining portions are of human origin, or derivatives, such as enzyme conjugates or labeled derivatives.

Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art. Isolated native or recombinant kallikrein polypeptides or CA125 may be utilized to prepare antibodies. See, for example, Kohler et al. (1975) Nature 256:495-497; Kozbor et al. (1985) J. Immunol Methods 81:31-42; Cote et al. (1983) Proc Natl Acad Sci 80:2026-2030; and Cole et al. (1984) Mol Cell Biol 62:109-120 for the preparation of monoclonal antibodies; Huse et al. (1989) Science 246:1275-1281 for the preparation of monoclonal Fab fragments; and, Pound (1998) Immunochemical Protocols, Humana Press, Totowa, N.J for the preparation of phagemid or B-lymphocyte immunoglobulin libraries to identify antibodies. The antibodies specific for kallikrein polypeptides or CA125 used in the methods of the invention may also be obtained from scientific or commercial sources.

In an embodiment of the invention, antibodies are reactive against kallikrein polypeptides or CA125 if they bind with a K_a of greater than or equal to 10^{-7} M.

Antibodies that bind to kallikrein polypeptides or CA125 may be labelled with a detectable

substance and localised in biological samples based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g., ^{3}H, ^{14}C, ^{35}S, ^{125}I, ^{131}I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods), and predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a kallikrein polypeptide or CA125. The second antibody may be labeled with a detectable substance to detect the primary antigen-antibody reaction. By way of example, if the antibody having specificity against a kallikrein polypeptide is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Methods for conjugating or labelling the antibodies discussed above may be readily accomplished by one of ordinary skill in the art. (See for example Inman, Methods In Enzymology, Vol. 34, Affinity Techniques, Enzyme Purification: Part B, Jakoby and Wichek (eds.), Academic Press, New York, p. 30, 1974; and Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications,"Anal. Biochem. 171:1-32, 1988 re methods for conjugating or labelling the antibodies with enzyme or ligand binding partner).

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect a plurality of kallikrein polypeptides, and optionally CA125. Generally, antibodies may be labeled with detectable substances and kallikrein polypeptides, and optionally CA125, may be localised in tissues and cells based upon the presence of the detectable substance.

In the context of the methods of the invention, the sample, binding agents (e.g. antibodies) for a plurality of kallikrein polypeptides, and CA125 may be immobilized on a carrier or support. Examples of suitable carriers or supports are agarose, cellulose, nitrocellulose, dextran, Sephadex, Sepharose, liposomes, carboxymethyl cellulose, polyacrylamides, polystyrene, gabbros, filter paper, magnetite, ion-exchange resin, plastic film, plastic tube, glass, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Thus, the carrier may be in the shape of, for example, a tube, test plate, well, beads, disc, sphere, etc. The immobilized material may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling. Binding agents (e.g. antibodies) may be indirectly immobilized using second binding agents specific for the first binding agent. For example, mouse antibodies specific for a kallikrein polypeptide may

be immobilized using sheep anti-mouse IgG Fc fragment specific antibody coated on the carrier or support.

Where radioactive labels are used as a detectable substance, a plurality of kallikrein polypeptides, and optionally CA125, may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

Time-resolved fluorometry may be used to detect a signal. For example, the method described in Christopoulos TK and Diamandis EP Anal Chem 1992:64:342-346 may be used with a conventional time-resolved fluorometer.

Therefore, in accordance with an embodiment of the invention, a method is provided wherein antibodies specific for each of a plurality of kallikrein polypeptides, and optionally CA125, are labelled with enzymes, substrates for the enzymes are added wherein the substrates are selected so that the substrates, or a reaction product of the enzymes and substrates, form fluorescent complexes with lanthanide metals. Lanthanide metals are added and the plurality of kallikrein polypeptides, and optionally CA125, are quantitated in the sample by measuring fluorescence of the fluorescent complexes. Antibodies specific for CA125 and each of a plurality of kallikrein polypeptides may be directly or indirectly labelled with enzymes. Enzymes are selected based on the ability of a substrate of the enzyme, or a reaction product of the enzyme and substrate, to complex with lanthanide metals such as europium and terbium. Examples of suitable enzymes include alkaline phosphatase and β-galactosidase.

Examples of enzymes and substrates for enzymes that provide such fluorescent complexes are described in U.S. Patent No. 5,312,922 to Diamandis. By way of example, when the antibody is directly or indirectly labelled with alkaline phosphatase the substrate employed in the method may be 4-methylumbelliferyl phosphate, 5-fluorosalicyl phosphate, or diflunisal phosphate. The fluorescence intensity of the complexes is typically measured using a time-resolved fluorometer e.g. a CyberFluor 615 Imunoanalyzer (Nordion International, Kanata, Ontario).

Antibodies specific for a plurality of kallikrein polypeptides and CA125 may also be indirectly labelled with enzymes. For example, an antibody may be conjugated to one partner of a ligand binding pair, and the enzyme may be coupled to the other partner of the ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein. In another embodiment, antibodies specific for the anti-kallikrein antibodies or anti- CA125 antibodies are labeled with an enzyme.

In accordance with an embodiment, the present invention provides means for determining a plurality of kallikrein polypeptides, and optionally CA125, in a sample, in particular a serum sample, by measuring a plurality of kallikrein polypeptides, and optionally CA125, by immunoassay. It will be evident to a skilled artisan that a variety of immunoassay methods can be used to measure a plurality of kallikrein polypeptides and CA125 in serum. In general, an immunoassay method may be competitive or noncompetitive. Competitive methods typically employ immobilized or immobilizable antibodies to each of a plurality of kallikrein polypeptides, and optionally CA125, and a labeled form of each of a plurality of kallikrein polypeptides, and optionally CA125. Kallikrein polypeptides and CA125 and labeled kallikrein polypeptides and CA125 compete for binding to anti-kallikrein antibodies and anti-CA125 antibodies. After separation of the resulting labeled kallikrein polypeptides and CA125 that have become bound to anti-

kallikrein polypeptides and anti- CA125 (bound fraction) from that which has remained unbound (unbound fraction), the amount of the label in either bound or unbound fraction is measured and may be correlated with the amount of kallikrein polypeptides, and optionally CA125, in the test sample in any conventional manner, e.g., by comparison to a standard curve.

In an aspect, a non-competitive method is used for the determination of a plurality of kallikrein polypeptides, and optionally CA125, with the most common method being the "sandwich" method. In this assay, two types of antibodies specific for each of a plurality of kallikrein polypeptides, and optionally CA125 are employed. One type of antibody is directly or indirectly labeled (sometimes referred to as the "detection antibody") and the other is immobilized or immobilizable (sometimes referred to as the "capture antibody"). The capture and detection antibodies can be contacted simultaneously or sequentially with a test sample. Sequential methods can be accomplished by incubating capture antibodies with the sample, and adding the detection antibodies at a predetermined time thereafter (sometimes referred to as the "forward" method); or the detection antibodies can be incubated with the sample first and then the capture antibodies added (sometimes referred to as the "reverse" method). After the necessary incubation(s) have occurred, to complete the assay, the capture antibodies are separated from the liquid test mixture, and labels are measured in at least a portion of the separated capture antibody phase or the remainder of the liquid test mixture. Generally the labels are measured in the capture antibody phase since it comprises kallikrein polypeptides, and optionally CA125, bound by ("sandwiched" between) the capture and detection antibodies. In an embodiment, the label may be measured without separating the capture antibodies and liquid test mixture.

In a typical two-site immunometric assay for a plurality of kallikrein polypeptides, and optionally CA125, one or both of the capture and detection antibodies are polyclonal antibodies or one or both of the capture and detection antibodies are monoclonal antibodies (i.e. polyclonal/polyclonal, monoclonal/monoclonal, or monoclonal/polyclonal). The labels used with the detection antibodies can be selected from any of those known conventionally in the art. The labels may be an enzyme or a chemiluminescent moiety, but it can also be a radioactive isotope, a fluorophor, a detectable ligand (e.g., detectable by a secondary binding by a labeled binding partner for the ligand), and the like. Preferably antibodies are labelled with enzymes which are detected by adding substrates that are selected so that a reaction product of the enzymes and substrates forms fluorescent complexes. Capture antibodies may be selected so that they provide a means for being separated from the remainder of the test mixture. Accordingly, the capture antibodies can be introduced to the assay in an already immobilized or insoluble form, or can be in an immobilizable form, that is, a form which enables immobilization to be accomplished subsequent to introduction of the capture antibodies to the assay. An immobilized capture antibody may comprise an antibody covalently or noncovalently attached to a solid phase such as a magnetic particle, a latex particle, a microtiter plate well, a bead, a cuvette, or other reaction vessel. An example of an immobilizable capture antibody is antibody which has been chemically modified with a ligand moiety, e.g., a hapten, biotin, or the like, and which can be subsequently immobilized by contact with an immobilized form of a binding partner for the ligand, e.g., an antibody, avidin, or the like. In an embodiment, a capture antibody may be immobilized using a species specific antibody for the capture antibody that is bound to the solid phase.

A particular sandwich immunoassay method of the invention employs two types of antibodies, first antibodies are reactive against each of a plurality of kallikrein polypeptides, and optionally CA125, and second antibodies having specificity against antibodies reactive against each of a plurality of kallikrein polypeptides, and optionally CA125, labelled with enzymatic labels, and fluorogenic substrates for the enzymes. An enzyme may be alkaline phosphatase (ALP) and the substrate is 5-fluorosalicyl phosphate. ALP cleaves phosphate out of the fluorogenic substrate, 5-fluorosalicyl phosphate, to produce 5-fluorosalicylic acid (FSA). 5-Fluorosalicylic acid can then form a highly fluorescent ternary complex of the form FSA-Tb(3+)-EDTA, which can be quantified by measuring the Tb3+ fluorescence in a time-resolved mode. Fluorescence intensity is measured using a time-resolved fluorometer as described herein.

The above-described immunoassay methods and formats are intended to be exemplary and are not limiting.

Computer Systems

Computer readable media comprising a plurality of kallikrein markers, and optionally CA125, is also provided. "Computer readable media" refers to any medium that can be read and accessed directly by a computer, including but not limited to magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media. Thus, the invention contemplates computer readable medium having recorded thereon markers identified for patients and controls.

"Recorded" refers to a process for storing information on computer readable medium. The skilled artisan can readily adopt any of the presently known methods for recording information on computer readable medium to generate manufactures comprising information on a plurality of kallikrein markers, and optionally CA125.

A variety of data processor programs and formats can be used to store information on a plurality of kallikrein markers, and optionally CA125, on computer readable medium. For example, the information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and MicroSoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. Any number of dataprocessor structuring formats (e.g., text file or database) may be adapted in order to obtain computer readable medium having recorded thereon the marker information.

By providing the marker information in computer readable form, one can routinely access the information for a variety of purposes. For example, one skilled in the art can use the information in computer readable form to compare marker information obtained during or following therapy with the information stored within the data storage means.

The invention provides a medium for holding instructions for performing a method for determining whether a patient has ovarian cancer or a pre-disposition to ovarian cancer, comprising determining the presence or absence of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, and based on the presence or absence of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, determining whether the patient has ovarian cancer or a pre-disposition to

ovarian cancer, and optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention also provides in an electronic system and/or in a network, a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a plurality of kallikrein markers, and optionally CA125, and/or polynucleotides encoding same, comprising determining the presence or absence of a plurality of kallikrein markers, and optionally CA125, and/or polynucleotides encoding same, and based on the presence or absence of the plurality of kallikrein markers, and optionally CA125, and/or polynucleotides encoding same, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer, and optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention further provides in a network, a method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a plurality of kallikrein markers, optionally CA125 and/or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on a plurality of kallikrein markers, optionally CA125 and/or polynucleotides encoding same associated with samples from the subject; (b) acquiring information from the network corresponding to the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same; and (c) based on the phenotypic information and information on the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer; and (d) optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

The invention still further provides a system for identifying selected records that identify an ovarian cancer cell. A system of the invention generally comprises a digital computer; a database server coupled to the computer; a database coupled to the database server having data stored therein, the data comprising records of data comprising a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, and a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records which match the desired selection criteria.

In an aspect of the invention a method is provided for detecting an ovarian cancer cell using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:

(a) creating records of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, isolated from a sample suspected of containing an ovarian cancer cell;

(b) providing a database comprising records of data comprising a plurality of kallikrein markers, optionally CA125, wherein the markers are kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and/or comprising polynucleotides encoding same; and

(c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of records of step (a) which provide a match of the desired selection criteria of the database of step (b) the presence of a match being a

positive indication that the markers of step (a) have been isolated from a cell that is an ovarian cancer cell.

The invention contemplates a business method for determining whether a subject has ovarian cancer or a pre-disposition to ovarian cancer associated with a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, comprising: (a) receiving phenotypic information on the subject and information on a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, associated with samples from the subject; (b) acquiring information from a network corresponding to the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same; and (c) based on the phenotypic information, information on a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, and acquired information, determining whether the subject has ovarian cancer or a pre-disposition to ovarian cancer; and (d) optionally recommending treatment for the ovarian cancer or pre-ovarian cancer condition.

Imaging Methods

Antibodies specific for each of a plurality of kallikrein polypeptides, and optionally CA125, may also be used in imaging methodologies in the management of ovarian cancer. The invention provides a method for imaging tumors associated with a plurality of kallikrein polypeptides, and optionally CA125.

In an embodiment the method is an *in vivo* method and a subject or patient is administered imaging agents that carry imaging labels and are capable of targeting or binding to each of a plurality of kallikrein polypeptides, and optionally CA125. In the method each imaging agent is labeled so that it can be distinguished during the imaging. The imaging agents are allowed to incubate *in vivo* and bind to the plurality of kallikrein polypeptides, and optionally CA125, associated with ovarian tumors. The presence of label is localized to the ovarian cancer, and the localized label is detected using imaging devices known to those skilled in the art.

The imaging agents may be antibodies or chemical entities that recognize the plurality of kallikrein polypeptides, and optionally CA125. In an aspect of the invention an imaging agent is a polyclonal antibody or monoclonal antibody, or fragments thereof, or constructs thereof including but not limited to, single chain antibodies, bifunctional antibodies, molecular recognition units, and peptides or entities that mimic peptides. The antibodies specific for kallikrein polypeptides and CA125 used in the methods of the invention may be obtained from scientific or commercial sources, or isolated native or recombinant kallikrein and CA125 polypeptides may be utilized to prepare antibodies etc as described herein.

An imaging agent may be a peptide that mimics the epitope for an antibody specific for kallikrein polypeptide or CA125 and binds to kallikrein polypeptide or CA125. The peptide may be produced on a commercial synthesizer using conventional solid phase chemistry. By way of example, a peptide may be prepared that includes either tyrosine, lysine, or phenylalanine to which N_2S_2 chelate is complexed (See U.S. Patent No. 4,897,255). The anti-kallikrein peptide conjugate is then combined with a radiolabel (e.g. sodium ^{99m}Tc pertechnetate or sodium ^{188}Re perrhenate) and it may be used to locate a tumor producing a plurality of kallikrein polypeptides, and optionally CA125.

Imaging agents carry labels to image the plurality of kallikrein polypeptides and CA125. Agents may be labelled for use in radionuclide imaging. In particular, agents may be directly or indirectly labelled

with a radioisotope. Examples of radioisotopes that may be used in the present invention are the following: ^{277}Ac, ^{211}At, ^{128}Ba, ^{131}Ba, ^{7}Be, ^{204}Bi, ^{205}Bi, ^{206}Bi, ^{76}Br, ^{77}Br, ^{82}Br, ^{109}Cd, ^{47}Ca, ^{11}C, ^{14}C, ^{36}Cl, ^{48}Cr, ^{51}Cr, ^{62}Cu, ^{64}Cu, ^{67}Cu, ^{165}Dy, ^{155}Eu, ^{18}F, ^{153}Gd, ^{66}Ga, ^{67}Ga, ^{68}Ga, ^{72}Ga, ^{198}Au, ^{3}H, ^{166}Ho, ^{111}In, ^{113m}In, ^{115m}In, ^{123}I, ^{125}I, ^{131}I, ^{189}Ir, ^{191m}Ir, ^{192}Ir, ^{194}Ir, ^{52}Fe, ^{55}Fe, ^{59}Fe, ^{177}Lu, ^{15}O, $^{191m-191}Os$, ^{109}Pd, ^{32}P, ^{33}P, ^{42}K, ^{226}Ra, ^{186}Re, ^{188}Re, ^{82m}Rb, ^{153}Sm, ^{46}Sc, ^{47}Sc, ^{72}Se, ^{75}Se, ^{105}Ag, ^{22}Na, ^{24}Na, ^{89}Sr, ^{35}S, ^{38}S, ^{177}Ta, ^{96}Tc, ^{99m}Tc, ^{201}Tl, ^{202}Tl, ^{113}Sn, ^{117m}Sn, ^{121}Sn, ^{166}Yb, ^{169}Yb, ^{175}Yb, ^{88}Y, ^{90}Y, ^{62}Zn and ^{65}Zn. Preferably the radioisotope is ^{131}I, ^{125}I, ^{123}I, ^{111}I, ^{99m}Tc, ^{90}Y, ^{186}Re, ^{188}Re, ^{32}P, ^{153}Sm, ^{67}Ga, ^{201}Tl ^{77}Br, or ^{18}F, and it is imaged with a photoscanning device.

Procedures for labeling biological agents with the radioactive isotopes are generally known in the art. U.S. Pat. No. 4,302,438 describes tritium labeling procedures. Procedures for iodinating, tritium labeling, and ^{35}S labeling especially adapted for murine monoclonal antibodies are described by Goding, J. W. (supra, pp 124-126) and the references cited therein. Other procedures for iodinating biological agents, such as antibodies, binding portions thereof, probes, or ligands, are described in the scientific literature (see Hunter and Greenwood, Nature 144:945 (1962), David et al., Biochemistry 13:1014-1021 (1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110). Iodinating procedures for agents are described by Greenwood, F. et al., Biochem. J. 89:114-123 (1963); Marchalonis, J., Biochem. J. 113:299-305 (1969); and Morrison, M. et al., Immunochemistry, 289-297 (1971). ^{99m} Tc-labeling procedures are described by Rhodes, B. et al. in Burchiel, S. et al. (eds.), Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Labelling of antibodies or fragments with technetium-99m are also described for example in U.S. Pat. No. 5,317,091, U.S. Pat. No. 4,478,815, U.S. Pat. No. 4,478,818, U.S. Pat. No. 4,472,371, U.S. Pat. No. Re 32,417, and U.S. Pat. No. 4,311,688. Procedures suitable for ^{111} In-labeling biological agents are described by Hnatowich, D. J. et al., J. Immul. Methods, 65:147-157 (1983), Hnatowich, D. et al., J. Applied Radiation, 35:554-557 (1984), and Buckley, R. G. et al., F.E.B.S. 166:202-204 (1984).

An imaging agent may also be labeled with a paramagnetic isotope for purposes of an *in vivo* method of the invention. Examples of elements that are useful in magnetic resonance imaging include gadolinium, terbium, tin, iron, or isotopes thereof. (See, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340; Wolf, G L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93-95; Wesbey et al., (1984) Physiol. Chem. Phys. Med. NMR 16, 145-155; Runge et al., (1984) Invest. Radiol. 19, 408-415 for discussions on *in vivo* nuclear magnetic resonance imaging.)

In the case of radiolabeled agents, the agents may be administered to the patient, localized to the tumor having a plurality of kallikrein polypeptides, and optionally CA125, with which the agents bind, and detected or "imaged" *in vivo* using known techniques such as radionuclear scanning using, for example, a gamma camera or emission tomography. [See for example, A. R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al., (eds.), pp. 65-85 (Academic Press 1985)]. A positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can also be used where the radiolabel emits positrons (e.g., ^{11} C, ^{18} F, ^{15} O, and ^{13} N).

Whole body imaging techniques using radioisotope labeled agents can be used for locating both primary tumors and tumors which have metastasized. Antibodies specific for a plurality of kallikrein

polypeptides, and optionally CA125, or fragments thereof having the same epitope specificity, are bound to a suitable radioisotope, or a combination thereof, and administered parenterally. For ovarian cancer, administration preferably is intravenous. The bio-distribution of the labels can be monitored by scintigraphy, and accumulations of the labels can be related to the presence of ovarian cancer cells. Whole body imaging techniques are described in U.S. Pat. Nos. 4,036,945 and 4,311,688. Other examples of agents useful for diagnosis and therapeutic use that can be coupled to antibodies and antibody fragments include metallothionein and fragments (see, U.S. Pat. No. 4,732,864). These agents are useful in diagnosis, staging and visualization of cancer, in particular ovarian cancer, so that surgical and/or radiation treatment protocols can be used more efficiently.

Screening Methods

The invention also contemplates methods for evaluating test agents or compounds for their ability to inhibit ovarian cancer or potentially contribute to ovarian cancer. Test agents and compounds include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)2, and Fab expression library fragments, and epitope-binding fragments thereof)], nucleic acids (e.g. antisense, interference RNA) and small organic or inorganic molecules. The agents or compounds may be endogenous physiological compounds or natural or synthetic compounds.

The invention also provides a method for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, the method comprising comparing:

(a) levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a first sample obtained from a patient and exposed to the test agent, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and

(b) levels of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting ovarian cancer in the patient.

The first and second samples may be portions of a single sample obtained from a patient or portions of pooled samples obtained from a patient.

In an aspect, the invention provides a method of selecting an agent for inhibiting ovarian cancer in a patient comprising:

(a) obtaining a sample comprising cancer cells from the patient;

(b) separately maintaining aliquots of the sample in the presence of a plurality of test agents;

(c) comparing a plurality of kallikrein markers, optionally CA125, and/or polynucleotides

encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and

(d) selecting one of the test agents which alters the levels of the kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot containing that test agent, relative to other test agents.

Still another aspect of the present invention provides a method of conducting a drug discovery business comprising:

(a) providing one or more methods or assay systems for identifying agents that inhibit ovarian cancer in a patient;

(b) conducting therapeutic profiling of agents identified in step (a), or further analogs thereof, for efficacy and toxicity in animals; and

(c) formulating a pharmaceutical preparation including one or more agents identified in step (b) as having an acceptable therapeutic profile.

In certain embodiments, the subject method can also include a step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

The invention also contemplates a method of assessing the ovarian carcinogenic potential of a test compound comprising:

(a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and

(b) comparing a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

A significant difference between the levels of the markers in the aliquot maintained in the presence of (or exposed to) the test compound relative to the aliquot maintained in the absence of the test compound, indicates that the test compound possesses ovarian carcinogenic potential.

Kits

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least a plurality of kallikrein nucleic acids or binding agents (e.g. antibodies) or CA125 nucleic acids or binding agents described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients, and to screen and identify those individuals afflicted with or exhibiting a predisposition to ovarian cancer.

Thus, the invention also contemplates kits for carrying out the methods of the invention. Such kits typically comprise two or more components required for performing a diagnostic assay. Components include but are not limited to compounds, reagents, containers, and/or equipment.

In an embodiment, a container with a kit comprises binding agents as described herein. By way of example, the kit may contain antibodies specific for a plurality of kallikrein polypeptides, and optionally

CA125, antibodies against the antibodies labelled with enzymes; and substrates for the enzymes. The kit may also contain microtiter plate wells, standards, assay diluent, wash buffer, adhesive plate covers, and/or instructions for carrying out a method of the invention using the kit.

In an aspect of the invention, the kit includes antibodies or antibody fragments which bind specifically to epitopes of each of a plurality of kallikrein polypeptides, and optionally CA125, and means for detecting binding of the antibodies to epitopes associated with tumor cells, either as concentrates (including lyophilized compositions), which may be further diluted prior to use or at the concentration of use, where the vials may include one or more dosages. Where the kits are intended for *in vivo* use, single dosages may be provided in sterilized containers, having the desired amount and concentration of agents. Containers that provide a formulation for direct use, usually do not require other reagents, as for example, where the kit contains radiolabelled antibody preparations for *in vivo* imaging.

A kit may be designed to detect the level of polynucleotides encoding kallikrein polypeptides, and optionally CA125 polynucleotides, in a sample. Such kits generally comprise oligonucleotide probes or primers, as described herein, that hybridize to a plurality of polynucleotides encoding kallikrein polypeptides and optionally CA125. Such oligonucleotides may be used, for example, within a PCR or hybridization procedure. Additional components that may be present within the kits include second oligonucleotides and/or diagnostic reagents to facilitate detection of a plurality polynucleotides encoding kallikrein polypeptides, and optionally CA125 polynucleotides.

The reagents suitable for applying the screening methods of the invention to evaluate compounds may be packaged into convenient kits described herein providing the necessary materials packaged into suitable containers.

Applications

Kallikrein polypeptides (in particular, kallikrein 5, 6, 10 and 11), optionally in combination with CA125, are targets for ovarian cancer immunotherapy. Such immunotherapeutic methods include the use of antibody therapy, *in vivo* vaccines, and *ex vivo* immunotherapy approaches.

In one aspect, the invention provides antibodies specific for a plurality of kallikrein polypeptides (for example, kallikreins 5, 6, 10 and 11) and optionally CA125, that may be used systemically to treat ovarian cancer. Preferably antibodies are used that target the tumor cells but not the surrounding non-tumor cells and tissue. Thus, the invention provides a method of treating a patient susceptible to, or having a cancer that expresses a plurality of kallikrein polypeptides, and optionally CA125, comprising administering to the patient an effective amount of antibodies that bind specifically to a plurality of kallikrein polypeptides, and optionally CA125. In another aspect, the invention provides a method of inhibiting the growth of tumor cells expressing a plurality of kallikrein polypeptides, and optionally CA125, comprising administering to a patient antibodies which bind specifically to the plurality of kallikrein polypeptides, and optionally CA125, in amounts effective to inhibit growth of the tumor cells. Antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, may also be used in a method for selectively inhibiting the growth of, or killing a cell expressing a plurality of kallikrein polypeptides, and optionally CA125, comprising reacting antibody immunoconjugates or immunotoxins with the cell in an amount sufficient to inhibit the growth of, or kill the cell.

By way of example, unconjugated antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, may be introduced into a patient such that the antibodies bind to cancer cells expressing a plurality of kallikrein polypeptides, and optionally CA125, and mediate growth inhibition of such cells (including the destruction thereof), and the tumor, by mechanisms which may include complement-mediated cytolysis, antibody-dependent cellular cytotoxicity, altering the physiologic function of a plurality of kallikrein polypeptides, and optionally CA125, and/or the inhibition of ligand binding or signal transduction pathways. In addition to unconjugated antibodies, antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, conjugated to therapeutic agents (e.g. immunoconjugates) may also be used therapeutically to deliver the agents directly to tumor cells expressing a plurality of kallikrein polypeptides, and optionally CA125, and thereby destroy the tumor. Examples of such agents include abrin, ricin A, *Pseudomonas* exotoxin, or diphtheria toxin, proteins such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, and biological response modifiers such as lymphokines, interleukin-1, interleukin-2, interleukin-6, granulocyte macrophage colony stimulating factor, granulocyte colony stimulating factor, or other growth factors.

Cancer immunotherapy using antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, may utilize the various approaches that have been successfully employed for cancers, including but not limited to colon cancer (Arlen et al., 1998, Crit Rev Immunol 18: 133-138), multiple myeloma (Ozaki et al., 1997, Blood 90: 3179-3186; Tsunenati et al., 1997, Blood 90: 2437-2444), gastric cancer (Kasprzyk et al., 1992, Cancer Res 52: 2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J Immunther Emphasis Tumor Immunol 19: 93-101), leukemia (Zhong et al., 1996, Leuk Res 20: 581-589), colorectal cancer (Moun et al., 1994, Cancer Res 54: 6160-6166); Velders et al., 1995, Cancer Res 55: 4398-4403), and breast cancer (Shepard et al., 1991, J Clin Immunol 11: 117-127).

In the practice of a method of the invention, antibodies specific for a plurality of kallikrein polypeptides, optionally in combination with antibodies specific for CA125, capable of inhibiting the growth of cancer cells expressing a plurality of kallikrein polypeptides, and optionally CA125, are administered in a therapeutically effective amount to cancer patients whose tumors express or overexpress a plurality of kallikrein polypeptides, and optionally CA125. The invention may provide a specific, effective and long-needed treatment for ovarian cancer. The antibody therapy methods of the invention may be combined with other therapies including chemotherapy and radiation.

Patients may be evaluated for the presence and levels of a plurality of kallikrein polypeptides, and optionally CA125, expression and overexpression in tumors, preferably using immunohistochemical assessments of tumor tissue, quantitative imaging as described herein, or other techniques capable of reliably indicating the presence and degree of expression of a plurality of kallikrein polypeptides, and optionally CA125. Immunohistochemical analysis of tumor biopsies or surgical specimens may be employed for this purpose.

Antibodies specific for a plurality of kallikrein polypeptides and CA125 useful in treating cancer include those that are capable of initiating a potent immune response against the tumor and those that are capable of direct cytotoxicity. In this regard, the antibodies may elicit tumor cell lysis by either complement-mediated or antibody-dependent cell cytotoxicity (ADCC) mechanisms, both of which require an intact Fc

portion of the immunoglobulin molecule for interaction with effector cell Fc receptor sites or complement proteins. In addition, antibodies specific for a plurality of kallikrein polypeptides and CA125 that exert a direct biological effect on tumor growth are useful in the practice of the invention. Such antibodies may not require the complete immunoglobulin to exert the effect. Potential mechanisms by which such directly cytotoxic antibodies may act include inhibition of cell growth, modulation of cellular differentiation, modulation of tumor angiogenesis factor profiles, and the induction of apoptosis. The mechanism by which a particular antibody exerts an anti-tumor effect may be evaluated using any number of *in vitro* assays designed to determine ADCC, antibody-dependent macrophage-mediated cytotoxicity (ADMMC), complement-mediated cell lysis, and others known in the art.

The anti-tumor activity of a combination of antibodies specific for a plurality of kallikrein polypeptides and optionally CA125, may be evaluated *in vivo* using a suitable animal model. Xenogenic cancer models, wherein human cancer explants or passaged xenograft tissues are introduced into immune compromised animals, such as nude or SCID mice, may be employed.

The methods of the invention contemplate the administration of combinations, or "cocktails" of different individual antibodies recognizing epitopes of a plurality of kallikrein polypeptides, and optionally CA125. Such cocktails may have certain advantages inasmuch as they contain antibodies that bind to different epitopes and/or exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects. In addition, the administration of the antibodies may be combined with other therapeutic agents, including but not limited to chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL2, GM-CSF). The antibodies may be administered in their "naked" or unconjugated form, or may have therapeutic agents conjugated to them.

The antibodies specific for a plurality of kallikrein polypeptides and optionally CA125, used in the practice of the method of the invention may be formulated into pharmaceutical compositions comprising a carrier suitable for the desired delivery method. Suitable carriers include any material which when combined with the antibodies retains the anti-tumor function of the antibodies and is non-reactive with the subject's immune systems. Examples include any of a number of standard pharmaceutical carriers such as sterile phosphate buffered saline solutions, bacteriostatic water, and the like (see, generally, Remington's Pharmaceutical Sciences 16.sup.th Edition, A. Osal., Ed., 1980).

Antibody formulations may be administered via any route capable of delivering the antibodies to the tumor site. Routes of administration include, but are not limited to, intravenous, intraperitoneal, intramuscular, intratumor, intradermal, and the like. Preferably, the route of administration is by intravenous injection. Antibody preparations may be lyophilized and stored as a sterile powder, preferably under vacuum, and then reconstituted in bacteriostatic water containing, for example, benzyl alcohol preservative, or in sterile water prior to injection.

Treatment will generally involve the repeated administration of the antibody preparation via an acceptable route of administration such as intravenous injection (IV), at an effective dose. Dosages will depend upon various factors generally appreciated by those of skill in the art, including the type of cancer and the severity, grade, or stage of the cancer, the binding affinity and half life of the antibodies used, the

degree of expression of a plurality of kallikrein polypeptides, and optionally CA125, in the patient, the extent of circulating kallikrein polypeptide antigens, and optionally CA125 antigens, the desired steady-state antibody concentration level, frequency of treatment, and the influence of any chemotherapeutic agents used in combination with a treatment method of the invention.

Daily doses may range from about 0.1 to 100 mg/kg. Doses in the range of 10-500 mg antibodies per week may be effective and well tolerated, although even higher weekly doses may be appropriate and/or well tolerated. A determining factor in defining the appropriate dose is the amount of antibodies necessary to be therapeutically effective in a particular context. Repeated administrations may be required to achieve tumor inhibition or regression. Direct administration of antibodies specific for a plurality of kallikrein polypeptides and optionally CA125 is also possible and may have advantages in certain situations.

Patients may be evaluated for a plurality of kallikrein polypeptides and optionally CA125, preferably in serum, in order to assist in the determination of the most effective dosing regimen and related factors. The assay methods described herein, or similar assays, may be used for quantitating circulating kallikrein polypeptide and optionally CA125 levels in patients prior to treatment. Such assays may also be used for monitoring throughout therapy, and may be useful to gauge therapeutic success in combination with evaluating other parameters, such as serum kallikrein polypeptides, and optionally CA125, levels.

The invention further provides vaccines formulated to contain a plurality of kallikrein polypeptides, and optionally CA125, or fragments thereof. The use in anti-cancer therapy of tumor antigens in a vaccine for generating humoral and cell-mediated immunity is well known and, for example, has been employed in prostate cancer using human PSMA and rodent PAP immunogens (Hodge et al., 1995, Int. J. Cancer 63: 231-237; Fong et al., 1997, J. Immunol. 159: 3113-3117). These methods can be practiced by employing a plurality of kallikrein polypeptides, and optionally CA125, or fragments thereof, or nucleic acids and recombinant vectors capable of expressing and appropriately presenting the kallikrein and optionally CA125, immunogens.

By way of example, viral gene delivery systems may be used to deliver nucleic acids encoding a plurality of kallikrein polypeptides, and optionally CA125. Various viral gene delivery systems which can be used in the practice of this aspect of the invention include, but are not limited to, vaccinia, fowlpox, canarypox, adenovirus, influenza, poliovirus, adeno-associated virus, lentivirus, and sindbus virus (Restifo, 1996, Curr. Opin. Immunol. 8: 658-663). Non-viral delivery systems may also be employed by using naked DNA encoding a plurality of kallikrein polypeptides, and optionally CA125, or fragments thereof introduced into the patient (e.g., intramuscularly) to induce an anti-tumor response.

Various *ex vivo* strategies may also be employed. One approach involves the use of cells to present kallikrein and optionally CA125 antigens to a patient's immune system. For example, autologous dendritic cells which express MHC class I and II, may be pulsed with a plurality of kallikrein polypeptides, and optionally CA125, or peptides thereof that are capable of binding to MHC molecules, to thereby stimulate ovarian cancer patients' immune systems (See, for example, Tjoa et al., 1996, Prostate 28: 65-69; Murphy et al., 1996, Prostate 29: 371-380).

Anti-idiotypic antibodies specific for a plurality of kallikrein polypeptides, and optionally CA125, can also be used in anti-cancer therapy as a vaccine for inducing an immune response to cells expressing the

polypeptides. The generation of anti-idiotypic antibodies is well known in the art and can readily be adapted to generate anti-idiotypic antibodies that mimic an epitope on a kallikrein polypeptide or CA125 (see, for example, Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J Clin Invest 96: 334-342; Herlyn et al., 1996, Cancer Immunol Immunother 43: 65-76). Such antibodies can be used in anti-idiotypic therapy as presently practiced with other anti-idiotypic antibodies directed against tumor antigens.

Genetic immunization methods may be utilized to generate prophylactic or therapeutic humoral and cellular immune responses directed against cancer cells expressing a plurality of kallikrein polypeptides, and optionally CA125. Constructs comprising DNA encoding kallikrein and optionally CA125 polypeptides/immunogens and appropriate regulatory sequences may be injected directly into muscle or skin of an individual, such that the cells of the muscle or skin take-up the construct and express the encoded kallikrein or CA125 polypeptides/immunogens. The polypeptides/immunogens may be expressed as cell surface proteins or be secreted. Expression of the polypeptides/immunogens results in the generation of prophylactic or therapeutic humoral and cellular immunity against the cancer. Various prophylactic and therapeutic genetic immunization techniques known in the art may be used.

The invention further provides methods for inhibiting cellular activity (e.g., cell proliferation, activation, or propagation) of a cell expressing a plurality of kallikrein polypeptides, and optionally CA125. This method comprises reacting immunoconjugates of the invention (e.g., a heterogeneous or homogenous mixture) with the cell so that the kallikrein polypeptides, and optionally CA125, form complexes with the immunoconjugates. A subject with a neoplastic or preneoplastic condition can be treated when the inhibition of cellular activity results in cell death.

In another aspect, the invention provides methods for selectively inhibiting a cell expressing a plurality of kallikrein polypeptides, and optionally CA125, by reacting a combination of immunoconjugates of the invention with the cell in an amount sufficient to inhibit the cell. Amounts include those that are sufficient to kill the cell or sufficient to inhibit cell growth or proliferation.

Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver nucleic acids encoding a plurality of kallikrein polypeptides, and optionally CA125, to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct recombinant vectors that will express antisense nucleic acid molecules for kallikrein polypeptides and CA125. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

Genes encoding a plurality of kallikrein polypeptides, and optionally CA125, can be turned off by transfecting a cell or tissue with vectors that express high levels of a desired kallikrein or CA125 polypeptide-encoding fragments. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of genes encoding kallikrein polypeptides, and optionally CA125, i.e., the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed

so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding a plurality of kallikrein polypeptides, and optionally CA125.

Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

Kallikrein polypeptides, optionally CA125 polypeptide, and/or polynucleotides encoding the polypeptides, and fragments thereof, antibodies and/or agents identified using a method of the invention, or combinations thereof, may be used in the treatment of ovarian cancer or diseases, conditions or syndromes associated with ovarian cancer, in a subject. A combination of kallikrein polypeptides and/or polynucleotides encoding the kallikreins (e.g. kallikreins 7 and 8) and inhibitors (antisense, antibodies, or agents) of other kallikreins (e.g. kallikreins 5, 6, 10 and 11) and/or CA125 may be used in a prognostic or therapeutic method of the invention. The polypeptides, polynucleotides, and agents may be formulated into compositions for administration to subjects suffering from ovarian cancer. Therefore, the present invention also relates to a composition comprising a plurality of kallikrein polypeptides and optionally CA125, or nucleic acids encoding the polypeptides, or a fragment thereof, or an agent identified using a method of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing ovarian cancer in a subject is also provided comprising administering to a patient in need thereof, a plurality of kallikrein polypeptides and optionally CA125, or nucleic acids encoding the polypeptides, an agent identified in accordance with a method of the invention, and/or a composition of the invention.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to

protect the substance from the action of enzymes, acids and other natural conditions that may inactivate the substance.

The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The compositions are indicated as therapeutic agents either alone or in conjunction with other therapeutic agents or other forms of treatment (e.g. chemotherapy or radiotherapy). The compositions of the invention may be administered concurrently, separately, or sequentially with other therapeutic agents or therapies.

The following non-limiting examples are illustrative of the present invention:

Example 1

To investigate the additional discriminatory value of the kallikreins to CA125 a logistic regression model was developed. Included in the study were serum samples from 39 ovarian cancer patients and 194 non-cancer females. The age of the patients was as follows: median = 59, range 32-82. The age of the controls was as follows: median = 46; range = 22-77. The model was adjusted for the following variables: f(x) = -0.29 hK5* +0.12* hK6-0.65*hK7-0.6*hK8+1.09*hK10+0.98*hK11+0.057*CA125-0.62. For these data, the crude odds ratio and the 95% confidence interval were found to be 2.71 and 1.91-3.84 ($p<0.001$). The log likelihood scores for this multivariate logistic regression model, which incorporated the combined variables for each patient was calculated. From these data, by picking different thresholds for the regression function values, a ROC curve was devised which shows the added value of using kallikreins and CA125 together in a multivariate function.(AUC, 0.99;95%CI,0.96-1.00). (See Figure 8.) Statistically significant correlations between age and other studied variables were not observed.

Example 2

Statistically significant differences in serum kallikrein concentration was found between patient and control subjects for kallikreins hK5 ($p<0.0001$), hK7 ($p=0.007$), hK8 ($p=0.005$), hK10 ($p=0.0003$) and CA125 ($p<0.0001$) by the Mann-Whitney test. The diagnostic sensitivity (SENS) and specificity (SPEC) for each one of these markers were as follows (SENS/SPEC; both as %): 31/95 (hK5); 62/71 (hK7); 62/70 (hK10); 54/54 (hK11); 89/94 (CA125). When these data were combined in a logistic regression model, kallikreins 5 and 10 did not contribute to a great extent to the sensitivity and specificity of CA125. The area under the curve of CA125 alone (93%) improved by a further 1% when adding hK6, by 2% when adding hK11, 3% when adding hK7 and 5% when adding hK8. The combination of CA125 and hK8 resulted in an AUC of 98%.

Below is a summary of each marker and its ability to separate the cases and controls.

hK5: high values associated with cancer
test+ is hK5>0.10, test- is hK5<=0.10
sensitivity=31%, specificity=95%,
AUC=.62, p(AUC)=.02
Wilcoxon rank sum test has p<.0001.
Of the 233 persons analyzed, 207 have value zero for hK5 (27 cases, 180 controls).
Possible good marker

hK6: high values associated with cancer
test+ is hK6>6.3, test- is hK6<=6.3
sensitivity=69%, specificity=40%,
AUC=.50, p(AUC)=1.00
Wilcoxon rank sum test has p=.91.
Not a good marker

hK7: low values associated with cancer
test+ is hK7<2.05, test- is hK7>=2.05
sensitivity=62%, specificity=71%,
AUC=.64, p(AUC)=.006
Wilcoxon rank sum test has p=.007.
Possible good marker

hK8: low values associated with cancer
test+ is hK8<13.0, test- is hK8>=13.0
sensitivity=72%, specificity=42%,
AUC=.64, p(AUC)=.006
Wilcoxon rank sum test has p=.005
Possible good marker

hK10: high values associated with cancer
test+ is hK10>1.42, test- is hK10<=1.42
sensitivity=62%, specificity=70%,
AUC=.68, p(AUC)=.0004
Wilcoxon rank sum test has p=.0003.
Best single kallikrein marker

hK11: high values associated with cancer
test+ is hK11>0.14, test- is hK11<=0.14
sensitivity=54%, specificity=54%,
AUC=.58, p(AUC)=.12
Wilcoxon rank sum test has p=.11.
Not a good marker

CA125: high values associated with cancer
test+ is Ca125>34, test- is Ca125<=34
sensitivity=89%, specificity=94%,
AUC=.933, p(AUC)=<.0001
Wilcoxon rank sum test has p<.0001.
Good marker

After some further multivariate analysis of only the kallikrein markers, the combination of hK 7, 8, 10 and 11 was a preferred set. This combination was arrived at by looking at the incremental AUC as markers were combined. Below is a summary of all the models tried:

hK10 alone, AUC=.68
hK10+hK7: AUC=.88

hK10+hK7+hK8: AUC=.90
hK10+hK7+hK8+hK11: AUC=.925
Multivariate model of hK7, hK8, hK10, hK11, call it hK7_8_10_11

hK7_8_110_11:
Calculate SA=2.00-1.49(hK7)-.34(hK8)+1.16(hK10)+3.50(hK11)
high values associated with cancer
test+ is SA>-1.15, test- is SA<=-1.15
sensitivity=87%, specificity=89%,
AUC=.93, p(AUC)=<.0001
Wilcoxon rank sum test has p<.0001.
Good marker

The hK marker that added the most to CA125 was also investigated.

CA125 alone, AUC=.933

CA125+hK8: AUC=.978

Multivariate model of Ca125, hK8, call it Ca125_hK8

Ca125_hK8:
SC=-1.71+.086(Ca125)-.47(hK8).
high values associated with cancer
test+ is SC>-2.52, test- is SC<-2.52
sensitivity=97%, specificity=90%,
AUC=.978, p(AUC)=<.0001
Wilcoxon rank sum test has p<.0001.
Good marker

Below is a summary of the above analyses:

a) The preferred kallikrien marker alone is hK10, AUC=.68

b) CA125 has an AUC of .933

c) The preferred combination of kallikrein markers increases the AUC up to .925, which is close to the CA125 AUC of .933

d) Adding a kallikrein marker to CA125 can increase the AUC up to .978

How does CA125 alone compare with the multivariate kallikrein model hK7_8_10_11?

(based on 39 cases and 186 controls evaluated with CA125)

	Sensitivity	Specificity	misclassification
CA125	90%	94%	12FP, 4FN, total 16 pts misclassified
hK7_8_10_11	85%	89%	31FP, 4FN, total 35 pts misclassified
both positive	77%	100%	0FP, 9FN, total 9 pts misclassified
either positive	97%	82%	33FP, 1FN, total 34 pts misclassified

How does CA125 alone compare with the multivariate model of CA125 plus hK8?

(based on 39 cases and 186 controls evaluated with CA125)

	Sensitivity	Specificity	misclassification
CA125	90%	94%	12FP, 4FN, total 16 pts misclassified
CA125_hK8	95%	91%	17FP, 2FN, total 19 pts misclassified

Kallikrein markers approach CA125 in terms of AUC and sensitivity, but their specificity is not as high. Adding hK8 to CA125 improves sensitivity but specificity is lower than CA125 alone.

Summary

a) The best kallikrein marker alone is hK10, area under the ROC curve (AUC) =.68.

b) CA125 has an AUC of .933. Adding a single kallikrein marker to CA125 can get the AUC up to .978. Adding hK8 to CA125 improves sensitivity but specificity is lower compared with CA125 alone.

c) The best combination of kallikrein markers gets the AUC up to .925, which is close to the CA125 AUC of .933. Kallikrein markers approach CA125 in terms of AUC and sensitivity, but their specificity is lower.

The present invention is not to be limited in scope by the specific embodiments described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety. All publications, patents and patent applications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the domains, cell lines, vectors, methodologies etc. which are reported therein which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Below full citations are set out for the references referred to in the specification.

Table 1

Kallikrein Polypeptide	Kallikrein Nucleic Acid Designation	GenBank Accession No.
Kallikrein 5	KLK5	AAD26429, AF135028, AF168768
Kallikrein 6	KLK6	AAB66483, AF013988 (CDS 174..881), AF149289 (CDS join 3567..3606, 4346..4502, 8122..8369, 9791..9927,11805..11957) U62801 (CDS 246..980)
Kallikrein 7	KLK7	AAC37551, L33404 (CDS 16..777), AF166330 (CDS join 3237..3309, 3722..3869, 4566..4813, 5129..5265, 7362..7517) (mRNA join(1756..1785, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..8265) /product="stratum corneum chymotryptic enzyme" /note="alternatively spliced" ; mRNA join (1756..1785, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..7991) /note="alternatively spliced"; mRNA join (1821..1864, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..8265) /product="stratum corneum chymotryptic enzyme" /note="alternatively spliced"; mRNA join (1821..1864, 3179..3309, 3722..3869, 4566..4813, 5129..5265, 7362..7991) /note="alternatively spliced"
Kallikrein 8	KLK8	BAA28673, AB009849 (CDS 35..817), AF095743 (CDS join 1035..1104, 1619..1778, 1944..2206, 4304..4437, 5974..6129, mRNA 500..670, 1027..1104, 1619..1778, 1944..2206, 4304..4437, 5974..6174), AB010780 (CDS join 1..39, 418..712, 878..>946), AF055982
Kallikrein 10	KLK10	AAC14266, AF055481 (CDS join 614..701, 2455..2635, 3589..3863, 4195..4328, 4793..4945, mRNA join 48..120, 605..701, 2455..2635, 3589..3863, 4195..4328, 4793..5474), NM_002776 (CDS 220..1050)
Kallikrein 11	KLK11	BAA33404, AAD47815, AB012917 (CDS 26..874), AF164623 (CDS 4224..4263, 5061..5217, 5545..5810, 6627..6763, 7158..7310) (mRNA join (2313..2398, 4189..4263, 5061..5217,5545..5810, 6627..6763,7158..7622)

Table 2

Descriptive statistics for hk5, hk6, hk7, hk8, hk10 and hk11 serum protein levels in controls and patients with ovarian cancer

	Mean	Standard Error	Median	Range	p value*
hk5 (ng/ml)					
Non cancer (N=194)	0.063	0.029	0.00	0.00-4.50	
Cancer (N=39)	0.48	0.18	0.00	0.00-5.70	
% Increase**	661%	--	--	--	<0.001
hk6(ng/ml)					
Non cancer (N=194)	6.96	0.18	6.60	1.60-15.30	
Cancer (N=39)	9.88	2.20	6.60	1.50-70.80	
% Increase**	42%	--	--	--	0.91
hk7(ng/ml)					
Non cancer (N=194)	2.60	0.071	2.67	0.30-6.00	
Cancer (N=39)	2.49	0.41	1.80	0.00-10.80	
% Decrease**	4%	--	33%	--	0.007
hk8(ng/ml)					
Non cancer (N=194)	11.74	0.27	11.70	2.40-22.20	
Cancer (N=39)	11.91	1.88	6.90	0.00-46.20	
% Decrease**	--	--	41%	--	0.005
hK10(ng/ml)					
Non cancer (N=194)	1.16	0.051	1.08	0.00-4.20	
Cancer (N=39)	6.51	2.46	1.59	0.27-90.0	
% Increase**	461%	--	40%	--	<0.001
hK11(ng/ml)					
Non cancer (N=194)	0.21	0.018	0.12	00-1.30	
Cancer (N=39)	0.79	0.21	0.18	0.00-5.52	
% Increase**	276%	--	50%		0.011

* Calculated by the Mann Whitney test

** Calculated by assuming that value in non-cancerouos tissue is 100%

Table 3

Correlations between the studied variables in 194 non-cancer cases

variable		hK5	hK6	hK7	hK8	hK10	hK11	CA125
hK5	r_s	1.000	0.034	-0.053	0.066	0.134	0.150	0.101
	p	.	*0.642*	*0.462*	*0.359*	*0.062*	*0.037*	*0.172*
hK6	r_s	0.034	1.000	0.114	0.298	0.191	0.120	-0.160
	p	*0.642*	.	*0.115*	*0.000*	*0.008*	*0.097*	*0.029*
hK7	r_s	-0.053	0.114	1.000	0.497	0.321	0.399	0.135
	p	*0.462*	*0.115*	.	*0.000*	*0.000*	*0.000*	*0.066*
hK8	r_s	0.066	0.298	0.497	1.000	0.263	0.396	0.048
	p	*0.359*	*0.000*	*0.000*	.	*0.000*	*0.000*	*0.519*
hK10	r_s	0.134	0.191	0.321	0.263	1.000	0.176	0.035
	p	*0.062*	*0.008*	*0.000*	*0.000*	.	*0.014*	*0.638*
hK11	r_s	0.150	0.120	0.399	0.396	0.176	1.000	0.125
	p	*0.037*	*0.097*	*0.000*	*0.000*	*0.014*	.	*0.090*
CA125	r_s	0.101	-0.160	0.135	0.048	0.035	0.125	1.000
	p	*0.172*	*0.029*	*0.066*	*0.519*	*0.638*	*0.090*	.

Table 4

Correlations between the studied variables in 39 ovarian cancer cases

variable		hK5	hK6	hK7	hK8	hK10	hK11	CA125
hK5	r_s	1.000	0.475	0.553	0.554	0.618	0.584	0.507
	p	.	*0.002*	*0.000*	*0.000*	*0.000*	*0.000*	*0.001*
hK6	r_s	0.475	1.000	0.327	0.513	0.470	0.661	0.530
	p	*0.002*	.	*0.042*	*0.001*	*0.003*	*0.000*	*0.001*
hK7	r_s	0.553	0.327	1.000	0.695	0.690	0.748	0.262
	p	*0.000*	*0.042*	.	*0.000*	*0.000*	*0.000*	*0.107*
hK8	r_s	0.554	0.513	0.695	1.000	0.602	0.783	0.443
	p	*0.000*	*0.001*	*0.000*	.	*0.000*	*0.000*	*0.005*
hK10	r_s	0.618	0.470	0.690	0.602	1.000	0.706	0.548
	p	*0.000*	*0.003*	*0.000*	*0.000*	.	*0.000*	*0.000*
hK11	r_s	0.584	0.661	0.748	0.783	0.706	1.000	0.556
	p	*0.000*	*0.000*	*0.000*	*0.000*	*0.000*	.	*0.000*
CA125	r_s	0.507	0.530	0.262	0.443	0.548	0.556	1.000
	p	*0.001*	*0.001*	*0.107*	*0.005*	*0.000*	*0.000*	.

Table 5

	CANCER						CONTROL						Wilcoxon								
	n	mean	median	sd	min	max	n	mean	median	sd	min	max	p(mean)	p(median)	p(logistic)	AUC (se)	p(AUC)	CUTPOINT	SENSITIVITY	SPECIFICITY	
hK5	39	0.48	0.00	1.14	0.00	5.70	194	0.06	0.00	0.40	0.00	4.50	0.03	<.0001	0.005	0.62 (.05)	0.0200	>0.10	31%	95%	hK5
hK6	39	9.88	6.60	13.77	1.50	70.80	194	6.97	6.60	2.60	1.60	15.30	0.20	0.9100	0.0570	0.50 (.05)	1.0000	>6.30	69%	40%	hK6
hK7	39	2.49	1.80	2.54	0.00	10.80	194	2.60	2.67	0.99	0.30	6.00	0.79	0.0070	0.6500	0.64 (.05)	0.0060	<2.05	62%	71%	hK7
hK8	39	11.91	6.90	11.80	0.00	46.20	194	11.74	11.70	3.80	2.40	22.20	0.93	0.0050	0.8700	0.64 (.05)	0.0060	<13.0	72%	42%	hK8
hK10	39	6.52	1.59	15.40	0.27	90.00	194	1.17	1.08	0.72	0.00	4.20	0.04	0.0003	0.0002	0.68 (.05)	0.0004	>1.42	62%	70%	hK10
hK11	39	0.80	0.18	1.36	0.00	5.52	194	0.21	0.12	0.26	0.00	1.30	0.01	0.1100	0.0008	0.58 (.05)	0.1200	>0.14	54%	54%	hK11
CA125	39	649	277	971	20	4494	186	24	21	9	0	84	0.00	<.0001	<.0001	0.933 (.028)	<.0001	>34	90%	94%	CA125
hK7_8_10_11	39	4.51	0.50	15.8	-4.74	92.26	194	-3.84	-3.68	2.07	-10.05	1.07	0.002	<.0001	<.001	0.925 (.030)	<.0001	>-1.32	85%	88%	hK7_8_10_11
CA125_hK8	39	48.64	15.02	82.86	-5.86	382.85	186	-5.07	-4.92	1.91	-9.49	0.50	0.0002	<.0001	<.001	0.978 (.017)	<.0001	>-2.52	97%	90%	CA125_hK8

We Claim:

1. A method for detecting a plurality of kallikrein markers associated with ovarian cancer in a patient comprising:
   (a) obtaining a sample from a patient;
   (b) detecting in the sample a plurality of kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
   (c) comparing the detected amounts with amounts detected for a standard.
2. A method for diagnosing and monitoring ovarian cancer in a subject comprising detecting in a sample from the subject a plurality of kallikrein markers, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein.
3. A method as claimed in claim 1 or 2 wherein the plurality of kallikrein markers are detected using antibodies that bind to each of the plurality of kallikrein markers or parts thereof
4. A method as claimed in claim 1, 2, 3 which further comprises detecting CA125.
5. A method of detecting ovarian cancer in a patient, the method comprising comparing:
   (a) levels of a plurality of kallikrein markers, and optionally CA125, in a sample from the patient, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and
   (b) normal levels of expression of the plurality of kallikrein markers, and optionally CA125, in a control sample, wherein a significant difference in levels of kallikrein markers and optionally CA125, relative to the corresponding normal levels, is indicative of ovarian cancer.
6. A method for monitoring the progression of ovarian cancer in a patient, the method comprising: (a) detecting in a sample from the patient at a first time point, a plurality of kallikrein markers, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of ovarian cancer.
7. A method for determining in a patient whether ovarian cancer has metastasized or is likely to metastasize in the future, the method comprising comparing (a) levels of a plurality of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (b) normal levels or non-metastatic levels of the kallikrein markers and optionally CA125, in a control sample wherein a significant difference between the levels of expression in the patient sample and the normal levels or non-metastatic levels is an indication that the ovarian cancer has metastasized.
8. A method for assessing the aggressiveness or indolence of ovarian cancer comprising comparing:

(a) levels of expression of a plurality of kallikrein markers, and optionally CA125, in a patient sample, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (b) normal levels of expression of the plurality of markers and optionally CA125, in a control sample, wherein a significant difference between the levels in the patient sample and normal levels is an indication that the cancer is aggressive or indolent.

9. A method for diagnosing and monitoring ovarian cancer in a sample from a subject comprising isolating nucleic acids from the sample; and detecting in the sample polynucleotides encoding a plurality of kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein.

10. A method as claimed in claim 9 wherein significant differences in the levels of the polynucleotides in the sample compared to a control is indicative of disease, disease stage, and/or prognosis.

11. A method for determining the presence or absence of ovarian cancer in a subject comprising: (a) contacting a sample obtained from the subject with oligonucleotides that hybridize to polynucleotides encoding kallikrein markers, and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (b) detecting in the sample a level of nucleic acids in the sample that hybridize to the polynucleotides relative to a predetermined cut-off value, and therefrom determining the presence or absence of ovarian cancer in the subject.

12. A method as claimed in claim 11, wherein the nucleic acids are mRNA and the levels of nucleic acids are detected by polymerase chain reaction.

13. A method as claimed in claim 11 wherein the nucleic acids are mRNA and the amounts of mRNA are detected using a hybridization technique, employing oligonucleotide probes that hybridize to kallikrein markers, and optionally CA125.

14. A method for assessing the potential efficacy of a test agent for inhibiting ovarian cancer in a patient, the method comprising comparing: (a) levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a first sample obtained from a patient and exposed to the test agent, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and (b) levels of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a second sample obtained from the patient, wherein the sample is not exposed to the test agent, wherein a significant difference in the levels of expression of the plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the first sample, relative to the second sample, is an indication that the test agent is potentially efficacious for inhibiting ovarian cancer in the patient.

15. A method of claim 14 wherein the first and second samples are portions of a single sample obtained from the patient.

16. A method of claim 14 wherein the first and second samples are portions of pooled samples obtained

from the patient.

17. A method of assessing the efficacy of a therapy for inhibiting ovarian cancer in a patient, the method comprising comparing: (a) levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a first sample obtained from the patient, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and (b) levels of the kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in a second sample obtained from the patient following therapy, wherein a significant difference in the levels of expression of the kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting ovarian cancer in the patient.

18. A method of selecting an agent for inhibiting ovarian cancer in a patient the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately exposing aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (d) selecting one of the test agents which alters the levels of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot containing that test agent, relative to other test agents.

19. A method of inhibiting ovarian cancer in a patient, the method comprising (a) obtaining a sample comprising cancer cells from the patient; (b) separately maintaining aliquots of the sample in the presence of a plurality of test agents; (c) comparing levels of a plurality of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; and (d) administering to the patient at least one of the test agents which alters the levels of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot containing that test agent, relative to other test agents.

20. A method of assessing the ovarian cell carcinogenic potential of a test compound, the method comprising: (a) maintaining separate aliquots of ovarian cells in the presence and absence of the test compound; and (b) comparing expression of a plurality of markers, optionally CA125, and/or polynucleotides encoding same, in each of the aliquots, wherein the markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11, and wherein a significant difference in levels of kallikrein markers, optionally CA125, and/or polynucleotides encoding same, in the aliquot maintained in the presence of the test compound, relative to the aliquot maintained in the absence of the test compound, is an indication that the test compound possesses ovarian cell carcinogenic potential.

21. A method of inhibiting ovarian cancer in a patient at risk for developing ovarian cancer, the method comprising inhibiting expression of genes encoding kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5,

kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

22. A method of any preceding claim wherein the plurality comprises at least three of the markers.

23. A method of any preceding claim wherein the plurality comprises at least five of the markers.

24. A method of any preceding claim wherein the plurality of kallikrein markers is selected from the group consisting of kallikrein 5, kallikrein 7, and kallikrein 8; kallikrein 5, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 5, kallikrein 7, kallikrein 8, and kallikrein 10; kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; kallikrein 5, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11; or kallilkrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10 and kallikrein 11.

25. A method of any proceeding claims wherein the kallikrein markers are kallikrein 7, kallikrein 8, kallikrein 10 and kallirkein 11.

26. A method of any preceding claim wherein the patient sample comprises serum obtained from the patient.

27. A kit for carrying out a method as claimed in any preceding claim.

28. A kit for assessing whether a patient is afflicted with ovarian cancer, the kit comprising reagents that specifically bind with a plurality of kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

29. A kit for assessing the suitability of each of a plurality of agents for inhibiting ovarian cancer in a patient, the kit comprising: (a) the plurality of agents; and (b) reagents for detecting a plurality of kallikrein markers and optionally CA125, wherein the kallikrein markers comprise or are selected from the group consisting of kallikrein 5, kallikrein 6, kallikrein 7, kallikrein 8, kallikrein 10, and kallikrein 11.

30. A kit as claimed in claim 28 or 29 wherein the reagents are antibodies that specifically bind with protein or protein fragments corresponding to kallikrein markers and optionally CA125.

Figure 1



Figure 2



Figure 3



Figure 4



Figure 5



Figure 6


hk11
2.0
1.5
1.0
0.5
0.0
hk11
0
50
100
150
200
250
VialNUM
hK11c
hk11n

Figure 7


Ca125
1000
900
800
700
600
500
400
300
200
100
0
Ca125
0
50
100
150
200
250
VialNUM
Ca125c
Ca125n
missing

Figure 8


Sensitivity (true positives)
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0
0.2
0.4
0.6
0.8
1
1 - Specificity (false positives)
No discrimination
CA125
Kallikrein & CA125 Combination
AUC (CA125) = 0.93
95%CI=0.86-0.99
AUC (Kallikrein & CA125 Combination) = 0.99
95%CI=0.96-1.00

Sequence Listing

SEQ ID NO. 1

CA125 amino acid

```
       1 mlkpsglpgs ssptrslmtg srstkatpem dsgltgatls pktstgaivv tehtlpftsp
      61 dktlasptss vvgrttqslg vmssalpest srgmthseqr tspslspqvn gtpsrnypat
     121 smvsglsspr trtsstegnf tkeastytlt vettsgpvte kytvptetst tegdstetpw
     181 dtryipvkit spmktfadst askenapvsm tpaettvtds htpgrtnpsf gtlyssfldl
     241 spkgtpnsrg etslelilst tgypfsspep gsaghsrist saplsssasv ldnkisetsi
     301 fsgqsltspl spgvpearas tmpnsaipfs mtlsnaetsa ervrstissl gtpsistkqt
     361 aetiltfhaf aetmdipsth iaktlasewl gspgtlggts tsaltttsps ttlvseetnt
     421 hhstsgkete gtlntsmtpl etsapgeese mtatlvptlg fttldskirs psqvssshpt
     481 relrttgsts grqssstaah gssdilratt sstskasswt sestaqqfse pqhtqwvets
     541 psmkterppa stsvaapitt svpsvvsgft tlktsstkgi wleetsadtl igestagptt
     601 hqfavptgis mtggsstrgs qgtthlltra tassetsadl tlatngvpvs vspavsktaa
     661 gssppggtkp sytmvssvip etsslqssaf regtslgltp lntrhpfssp epdsaghtki
     721 stsipllssa svledkvsat stfshhkats sittgtpeis tktkpssavl ssmtlsnaat
     781 spervrnats plthpspsge etagsvltls tsaettdspn ihptgtltse ssespstlsl
     841 psvsgvkttf ssstpsthlf tsgeeteets npsvsqpets vsrvrttlas tsvptpvfpt
     901 mdtwptrsaq fssshlvsel ratsstsvtn stgsalpkis hltgtatmsq tnrdtfndsa
     961 apqsttwpet sprfktglps atttvstsat slsatvmvsk ftspatssme atsirepstt
    1021 ilttettngp gsmavastni pigkgyiteg rldtshlpig ttassetsmd ftmakesvsm
    1081 svspsqsmda agsstpgrts qfvdtfsddv yhltsreiti prdgtssalt pqmtathpps
    1141 pdpgsarstw lgilssspss ptpkvtmsst fstqrvttsm imdtvetsrw nmpnlpstts
    1201 ltpsniptsg aigkstlvpl dtpspatsle asegglptls typestntps ihlgahasse
    1261 spstikltma svvkpgsytp ltfpsiethi hvstarmays sgsspemtap getntgstwd
    1321 pttyitttdp kdtssaqvst phsvrtlrtt enhpktesat paaysgspki ssspnltspa
    1381 tkawtitdtt ehstqlhytk laekssgfet qsapgpvsvv iptsptigss tleltsdvpg
    1441 eplvlapseq ttitlpmatw lstslteema stdldissps spmstfaifp pmstpshels
    1501 kseadtsair ntdsttldqh lgirslgrtg dlttvpitpl tttwtsvieh stqaqdtlsa
    1561 tmspthvtqs lkdqtsipas aspshltevy pelgtqgrss seattfwkps tdtlsreiet
    1621 gptniqstpp mdntttgsss sgvtlgiahl pigtsspaet stnmalerrs statvsmagt
    1681 mgllvtsapg rsisqslgrv ssvlsestte gvtdsskgss prlntqgnta lsssslepsya
    1741 egsqmstsip ltsspttpdv efiggstfwt kevttvmtsd iskssartes ssatlmstal
    1801 gstentgkek lrtasmdlps ptpsmevtpw isltlsnapn ttdsldlshg vhtssagtla
    1861 tdrslntgvt rasrlengsd tsskslsmgn sthtsmtdte ksevsssihp rpetsapgae
    1921 ttltstpgnr aisltlpfss ipveevistg itsgpdinsa pmthspitpp tivwtstgti
    1981 eqstqplhav ssekvsvqtq stpyvnsvav saspthensv ssgsstsspy ssaslesslds
    2041 tisrrnaits wlwdlttslp tttwpstsls ealssghsgv snpsstttef plfsaastsa
    2101 akqrnpetet hgpqntaast lntdassvtg lsetpvgasi ssevplpmai tsrsdvsglt
    2161 sestanpslg tassagtklt rtislptses lvsfrmnkdp wtvsiplgsh pttntetsip
    2221 vnsagppgls tvasdvidtp sdgaesiptv sfspspdtev ttishfpekt thsfrtissl
    2281 theltsrvtp ipgdwmssam stkptgasps itlgerrtit saapttspiv ltasftetst
    2341 vsldnettvk tsdildarkt nelpsdssss sdlintsias stmdvtktas isptsisgmt
    2401 assspslfss drpqvptstt etntatspsv ssntysldgg snvggtpstl ppftithpve
    2461 tssallawsr pvrtfstmvs tdtasgenpt ssnsvvtsvp apgtwasvgs ttdlpamgfl
    2521 ktspageahs llastiepat aftphlsaav vtgssatsea sllttseska ihsspqtptt
    2581 ptsganwets atpesllvvt etsdttltsk ilvtdtilfs tvstppskfp stgtlsgasf
    2641 ptllpdtpai pltateptss latsfdstpl vtiasdslgt vpettltmse tsngdalvlk
    2701 tvsnpdrsip gitiqgvtes plhpsstsps kivaprntty egsitvalst lpagttgslv
    2761 fsqssenset talvdssagl erasvmpltt gsqgmassgg irsgsthstg tktfsslplt
    2821 mnpgevtams eittnrltat qstapkgipv kptsaesgll tpvsasssps kafaslttap
    2881 pstwgipqst ltfefsevps ldtksaslpt pgqslntipd sdastasssl skspeknpra
    2941 rmmtstkais assfqstgft etpegsasps magheprvpt sgtgdpryas esmsypdpsk
    3001 assamtstsl askl ttlfst gqaarsgsss spislsteke tsflsptast srktslflgp
    3061 smarqpnilv hlqtsaltls ptstlnmsqe eppeltssqt iaeeegttae tqtltftpse
    3121 tptsllpvss pteptarrks spetwassis vpaktslvet tdgtlvttik mssqaaqgns
    3181 twpapaeetg tspagtspgs pevsttlkim sskepsispe irstvrnspw ktpettvpme
    3241 ttvepvtlqs talgsgstsi shlptgttsp tksptenmla tervslspsp peawtnlysg
```

3301 tpggtrqsla tmssvslesp tarsitgtgq qsspelvskt tgmefsmwhg stggttgdth
3361 vslstssnil edpvtspnsv ssltdkskhk tetwvsttai pstvlnnkim aaeqqtsrsv
3421 deaysstssw sdqtsgsdit lgaspdvtnt lyitstaqtt slvslpsgdq gitsltnpsg
3481 gktssassvt spsigletlr anvsavksdi aptaghlsqt sspaevsild vttaptpgis
3541 ttittmgtns istttpnpev gmstmdstpa terrttsteh pstwsstaas dswtvtdmts
3601 nlkvarspgt istmhttsfl assteldsms tphgritvig tslvtpssda savktetsts
3661 ertlspsdtt astpistfsr vqrmsisvpd ilstswtpss teaedvpvsm vstdhastkt
3721 dpntplstfl fdslstldwd tgrslssata ttsapqgatt pqeltletmi spatsqlpfs
3781 ighitsavtp aamarssgvt fsrpdptskk aeqtstqlpt ttsahpgqvp rsaattldvi
3841 phtaktpdat fqrqgqtalt tearatsdsw nekekstpsa pwitemmnsv sedtikevts
3901 sssvlkdpey aghklgiwdd fipkfgkaah mrelpllspp qdkeaihpst ntvettgwvt
3961 ssehashsti pahsassklt spvvttstre qaivsmsttt wpestrarte pnsfltielr
4021 dvspymdtss ttqtsiissp gstaitkgpr teitsskris ssflaqsmrs sdspseaitr
4081 lsnfpamtes ggmilamqts ppgatslsap tldtsatasw tgtplattqr ftysekttlf
4141 skgpedtsqp sppsveetss ssslvpihat tspsnillts qghspsstpp vtsvflsets
4201 glgkttdmsr islepgtslp pnlsstagea lstyeasrdt kaihhsadta vtnmeatsse
4261 yspipghtkp skatsplvts himgditsst svfgssette ietvssvnqg lqerstsqva
4321 ssatetstvi thvssgdatt hvtktqatfs sgtsissphq fitstntftd vstnpstsli
4381 mtessgvtit tqtgptgaat qgpylldtst mpyltetpla vtpdfmqsek ttliskgpkd
4441 vtwtsppsva etsypssltp flvttippat stlqgqhtss pvsatsvlts glvkttdmln
4501 tsmepvtnsp qnlnnpsnei latlaattdi etihpsinka vtnmgtassa hvlhstlpvs
4561 sepstatspm vpassmgdal asisipgset tdiegeptss ltagrkenst lqemnsttes
4621 niilsnvsvg aiteatkmev psfdatfipt paqstkfpdi fsvassrlsn sppmtisthm
4681 tttqtgssga tskiplaldt stletsagtp svvtegfahs kittamnndv kdvsqtnppf
4741 qdeasspssq apvlvttlps svaftpqwhs tsspvsmssv ltsslvktag kvdtsletvt
4801 sspqsmsntl ddisvtsaat tdietthpsi ntvvtnvgtt gsafeshstv saypepskvt
4861 spnvtttstme dttisrsipk sskttrtete ttssltpklr etsisqeits stetstvpyk
4921 eltgattevs rtdvtsssst sfpgpdqstv sldistetnt rlstspimte saeitittqt
4981 gphgatsqdt ftmdpsnttp qagihsamth gfsqldvttl msripqdvsw tsppsvdkts
5041 spssflsspa mttpslisst lpedklsspm tslltsglvk itdilrtrle pvtsslpnfs
5101 stsdkilats kdskdtkeif psinteetnv kannsghesh spaladsetp kattqmvitt
5161 tvgdpapsts mpvhgssett nikreptyfl tprlretsts qessfptdts fllskvptgt
5221 itevsstgvn ssskistpdh dkstvppdtf tgeiprvfts siktksaemt ittqasppes
5281 ashstlpldt sttlsqggth stvtqgfpys evttlmgmgp gnvswmttpp veetssvssl
5341 msspamtsps pvsstspqsi pssplpvtal ptsvlvtttd vlgttspesv tssppnlssi
5401 therpatykd tahteaamhh stntavtnvg tsgsghksqs svladsetsk atplmsttst
5461 lgdtsvstst pnisqtnqiq teptaslspr lresstsekt ssttetntaf syvptgaitq
5521 asrteisssr tsisdldrpt iapdistgmi trlftspimt ksaemtvttq tttpgatsqg
5581 ilpwdtsttl fqggthstvs qgfphseitt lrsrtpgdvs wmttppveet ssgfslmsps
5641 mtspspvsst spesipsspl pvtalltsvl vtttnvlgtt spetvtsspp nlssptqerl
5701 ttykdtahte amhasmhtnt avanvgtsis ghesqssvpa dshtskatsp mgitfamgdt
5761 svststpaff etriqtests slipglrdtr tseeintvte tstvlsevpt ttttevsrte
5821 vitssrttis gpdhskmspy istetitrls tfpfvtgste maitnqtgpi gtisqatltl
5881 dtsstasweg thspvtqrfp hseetttmsr stkgvswqsp psveetssps spvplpaits
5941 hsslysavsg ssptsalpvt slltsgrrkt idmldthsel vtsslpsass fsgeiltsea
6001 stntetihfs entaetnmgt tnsmhklhss vsihsqpsgh tppkvtgsmm edaivststp
6061 gspetknvdr dstspltpel kedstalvmn sttesntvfs svsldaatev sraevtyydp
6121 tfmpasaqst kspdispeas sshsnspplt isthktiatq tgpsgvtslg qltldtstia
6181 tsagtpsart qdfvdsetts vmnndlndvl ktspfsaeea nslssqapll vttspspvts
6241 tlqehsstssl vsvtsvptpt lakitdmdtn lepvtrspqn lrntlatsea ttdthtmhps
6301 intamanvgt tsspnefyft vspdsdpyka tsavvitsts gdsivstsmp rssamkkies
6361 ettfslifrl retstsqkig sssdtstvfd kaftaattev srteltsssr tsiqgtekpt
6421 mspdtstrsv tmlstfaglt kseertiatq tgphratsqg tltwdtsitt sqagthsamt
6481 hgfsqldlst ltsrvpeyis gtsppsvekt sssssllslp aitspspvpt tlpesrpssp
6541 vhltslptsg lvkttdmlas vaslppnlgs tshkipttse dikdtekmyp stniavtnvg
6601 tttsekesys svpayseppk vtspmvtsfn irdtivstsm pgsseitrie mestfsvahg
6661 lkgtstsqdp ivsteksavl hklttgatet srtevassrr tsipgpdhst espdistevi
6721 pslpislgit essnmtiitr tgpplgstsq gtftldtptt ssragthsma tqefphsemt
6781 tvmnkdpeil swtippsiek tsfssslmps pamtsppvss tlpktihttp spmtslltps
6841 lvmttdtlgt spepttsspp nlsstshvil ttdedttaie amhpststaa tnvettcsgh
6901 gsqssvltds ektkatapmd ttstmghttv stsmsvsset tkikrestys ltpglretsi

```
 6961 sqnasfstdt sivlsevptg ttaevsrtev tssgrtsipg psqstvlpei strtmtrlfa
 7021 sptmtesaem tiptqtgpsg stsqdtltld tsttksqakt hstltqrfph semttlmsrg
 7081 pgdmswqssp slenpsslps llslpattsp ppisstlpvt isssplpvts lltsspvttt
 7141 dmlhtspelv tssppklsht sderlttgkd ttnteavhps tntaasnvei psfghespss
 7201 aladsetska tspmfitstq edttvaistp hfletsriqk esisslspkl retgssvets
 7261 saietsavls evsigattei srtevtsssr tsisgsaest mlpeisttrk iikfptspil
 7321 aessemtikt qtsppgstse stftldtstt pslvithstm tqrlphseit tlvsrgagdv
 7381 prpsslpvee tsppssqlsl samispspvs stlpasshss sasvtspltp gqvkttevld
 7441 asaepetssp pslsstsvei latsevttdt ekihpfpnta vtkvgtsssg hespssvlpd
 7501 settkatsam gtisimgdts vstltpalsn trkiqsepas slttrlrets tseetslate
 7561 antvlskvst gattevsrte aisfsrtsms gpeqstmsqd isigtipris assvltesak
 7621 mtittqtgps estlestlnl ntattpswve thsiviqgfp hpemttsmgr gpggvswpsp
 7681 pfvketspps splslpavts phpvsttfla hippsplpvt slltsgpatt tdilgtstep
 7741 gtsssssist tsherlttyk dtahteavhp stntggtnva ttssgyksqs svladsspmc
 7801 ttstmgdtsv ltstpaflet rriqtelass ltpglressg segtssgtkm stvlskvptg
 7861 atteiskedv tsipgpaqst ispdistrtv swfstspvmt esaeitmnth tsplgattqg
 7921 tstlatsstt sltmthstis qgfshsqmst lmrrgpedvs wmsppllekt rpsfslmssp
 7981 attspspvss tlpesisssp lpvtslltsg lakttdmlhk ssepvtnspa nlsstsveil
 8041 atsevttdte kthpssnrtv tdvgtsssgh estsfvlads qtskvtspmv itstmedtsv
 8101 ststpgffet sriqteptss ltlglrktss segtslatem stvlsgvptg ataevsrtev
 8161 tsssrtsisg faqltvspet stetitrlpt ssimtesaem miktqtdppg stpesthtvd
 8221 isttpnwvet hstvtqrfsh semttlvsrs pgdmlwpsqs sveetssass llslpattsp
 8281 spvsstlved fpsaslpvts lltpglvitt drmgisrepg tsstsnlsst sherlttled
 8341 tvdtedmqps thtavtnvrt sisghesqss vlsdsetpka tspmgttytm getsvsists
 8401 dffetsriqi eptssltsgl retssseris sategstvls evpsgattev srtevissrg
 8461 tsmsgpdqft ispdisteai trlstspimt esaesaitie tgspgatseg tltldtsttt
 8521 fwsgthstas pgfshsemtt lmsrtpgdvp wpslpsveea ssvssslssp amtstsffsa
 8581 lpesisssph pvtalltlgp vkttdmlrts sepetssppn lsstsaeila tsevtkdrek
 8641 ihpssntpvv nvgtviykhl spssvladlv ttkptspmat tstlgntsvs tstpafpetm
 8701 mtqptsslts glreistsqe tssatersas lsgmptgatt kvsrtealsl grtstpgpaq
 8761 stispeiste titristplt ttgsaemtit pktghsgass qgtftldtss raswpgthsa
 8821 athrsphsgm ttpmsrgped vswpsrpsve ktsppsslvs lsavtspspl ystpsesshs
 8881 splrvtslft pvmmkttdml dtslepvtts ppsmnitsde slatskatme teaiqlsent
 8941 avtqmgtisa rqefyssypg lpepskvtsp vvtsstikdi vsttipasse itriemests
 9001 tltptprets tsqeihsatk pstvpykalt satiedsmtq vmsssrgpsp dqstmsqdis
 9061 sevitrlsts pikaestemt ittqtgspga tsrgtltldt sttfmsgths tasqgfshsq
 9121 mtalmsrtpg dvpwlshpsv eeassasfsl sspvmtsssp vsstlpdsih ssslpvtsll
 9181 tsglvkttel lgtssepets sppnlsstsa eilattevtt dteklemtnv vtsgythesp
 9241 ssvladsvtt katssmgity ptgdtnvlts tpafsdtsri qtkskls1tp glmetsisee
 9301 tssatekstv lssvptgatt evsrteaiss srtsipgpaq stmssdtsme titristplt
 9361 rkestdmait pktgpsgats qgtftldsss taswpgthsa ttqrfpqsvv ttpmsrgped
 9421 vswpsplsve knsppsslvs sssvtspspl ystpsgsshs spvpvtslft simmkatdml
 9481 daslepetts apnmnitsde slatskatte teaihvfent aashvettsa teelyssspg
 9541 fseptkvisp vvtsssirdn mvsttmpgss gitrieiesm ssltpglret rtsqditsst
 9601 etstvlykms sgatpevsrt evmpssrtsi pgpaqstmsl disdevvtrl stspimtesa
 9661 eititqtgy slatsqvtlp lgtsmtflsg thstmsqgls hsemtnlmsr gpeslswtsp
 9721 rfvettrsss sltslpltts lspvsstlld sspssplpvt slilpglvkt tevldtssep
 9781 ktssspnlss tsveipatse imtdtekihp ssntavakvr tsssvheshs svladsetti
 9841 tipsmgitsa vddttvftsn pafsetrrip teptfsltpg fretstseet tsitetsavl
 9901 ygvptsatte vsmteimssn rthipdsdqs tmspdiitev itrlssssmm sestqmtitt
 9961 qksspgataq stltlattta plarthstvp prflhsemtt lmsrspenps wksspfvekt
10021 sssssllslp vttspsvsst lpqsipsssf svtslltpgm vkttdtstep gtslspnlsg
10081 tsveilaase vttdtekihp sssmavtnvg ttssghelys svsihsepsk atypvgtpss
10141 maetsistsm panfettgfe aepfshltsg frktnmsldt ssvtptntps spgsthllqs
10201 sktdftssak tsspdwppas qyteipvdii tpfnaspsit estgitsfpe srftmsvtes
10261 thhlstdllp saetistgtv mpslseamts fattgvprai sgsgspfsrt esgpgdatls
10321 tiaeslpsst pvpfssstft ttdsstipal heitsssatp yrvdtslgte ssttegrlvm
10381 vstldtssqp grtsstpild trmtesvelg tvtsayqvps lstrltrtdg imehitkipn
10441 eaahrgtirp vkgpqtstsp aspkglhtgg tkrmetttta lkttttalkt tsratlttsv
10501 ytptlgtltp lnasrqmast iltemmittp yvfpdvpett sslatslgae tstalprttp
10561 svlnresett aslvsrsgae rspviqtldv sssepdttas wvihpaetip tvskttpnff
```

```
10621 hseldtvsst atshgadvss aiptnispse ldaltplvti sgtdtsttfp tltksphete
10681 trttwlthpa etsstiprti pnfshhesda tpsiatspga etssaipimt vspgaedlvt
10741 sqvtssgtdr nmtiptltls pgepktiasl vthpeaqtss aiptstispa vsrlvtsmvt
10801 slaaktsttn raltnspgep attvslvthp aqtsptvpwt tsiffhsksd ttpsmttshg
10861 aesssavptp tvstevpgvv tplvtssrav isttipiltl spgepettps matshgeeas
10921 saiptptvsp gvpgvvtslv tssravtstt ipiltfslge pettpsmats hgteagsavp
10981 tvlpevpgmv tslvassrav tsttlptltl spgepettps matshgaeas stvptvspev
11041 pgvvtslvts ssgvnstsip tlilspgele ttpsmatshg aeassavptp tvspgvsgvv
11101 tplvtssrav tsttipiltl sssepettps matshgveas savltvspev pgmvtslvts
11161 sravtsttip tltissdepe tttslvthse akmisaiptl avsptvqglv tslvtssgse
11221 tsafsnltva ssqpetidsw vahpgteass vvptltvstg epftnislvt hpaessstlp
11281 rttsrfshse ldtmpstvts peaesssais ttispgipgv ltslvtssgr disatfptvp
11341 espheseata swvthpavts ttvprttpny shsepdttps iatspgaeat sdfptitvsp
11401 dvpdmvtsqv tssgtdtsit iptltlssge petttsfity sethtssaip tlpvspgask
11461 mltslvissg tdstttfptl tetpyepett aiqlihpaet ntmvpkttpk fshsksdttl
11521 pvaitspgpe assavsttti spdmsdlvts lvpssgtdts ttfptlsetp yepettvtwl
11581 thpaetsttv sgtipnfshr gsdtapsmvt spgvdtrsgv ptttippsip gvvtsqvtss
11641 atdtstaipt ltpspgepet tassathpgt qtgftvpirt vpssepdtma swvthppqts
11701 tpvsrttssf shsspdatpv matsprteas savlttispg apemvtsqit ssgaatsttv
11761 ptlthspgmp ettallsthp rtgtsktfpa stvfpqvset tasltirpga etstalptqt
11821 tsslftllvt gtsrvdlspt aspgvsakta plsthpgtet stmiptstls lgllettgll
11881 atsssaetst stltltvspa vsglssasit tdkpqtvtsw ntetspsvts vgppefsrtv
11941 tgttmtlips emptppktsh gegvspttil rttmveatnl attgssptva kttttfntla
12001 gslftplttp gmstlasesv tsrtsynhrs wisttssynr rywtpatstp vtstfspgis
12061 tssipsstaa tvpfmvpftl nftitnlqye edmrhpgsrk fnaterelqg llkplfrnss
12121 leylysgcrl aslrpekdss amavdaicth rpdpedlgld rerlywelsn ltngiqelgp
12181 ytldrnslyv ngfthrssmp ttstpgtstv dvgtsgtpss spsptaagpl lmpftlnfti
12241 tnlqyeedmr rtgsrkfntm esvlqgllkp lfkntsvgpl ysgcrltllr pekdgaatgv
12301 daicthrldp kspglnreql ywelskltnd ieelgpytld rnslyvngft hqssvsttst
12361 pgtstvdlrt sgtpsslssp timaagpllv pftlnftitn lqygedmghp gsrkfntter
12421 vlqgllgpif kntsvgplys gcrltslrse kdgaatgvda icihhldpks pglnrerlyw
12481 elsqltngik elgpytldrn slyvngfthr tsvpttstpg tstvdlgtsg tpfslpspat
12541 agpllvlftl nftitnlkye edmhrpgsrk fnttervlqt llgpmfknts vgllysgcrl
12601 tllrsekdga atgvdaicth rldpkspgld reqlywelsq ltngikelgp ytldrnslyv
12661 ngfthwipvp tsstpgtstv dlgsgtpssl psptaagpll vpftlnftit nlqyeedmhh
12721 pgsrkfntte rvlqgllgpm fkntsvglly sgcrltllrs ekdgaatgvd aicthrldpk
12781 spgvdreqly welsqltngi kelgpytldr nslyvngfth qtsapntstp gtstvdlgts
12841 gtpsslpspt sagpllvpft lnftitnlqy eedmrhpgsr kfnttervlq gllkplfkst
12901 svgplysgcr ltllrsekdg aatgvdaict hrldpkspgv dreqlywels qltngikelg
12961 pytldrnsly vngfthqtsa pntstpgtst vdlgtsgtps slpsptsagp llvpftlnft
13021 itnlqyeedm hhpgsrkfnt tervlqgllg pmfkntsvgl lysgcrltll rpekngaatg
13081 mdaicshrld pkspglnreq lywelsqlth gikelgpytl drnslyvngf thrssvapts
13141 tpgtstvdlg tsgtpsslps pttavpllvp ftlnftitnl qygedmrhpg srkfntterv
13201 lqgllgplfk nssvgplysg crlislrsek dgaatgvdai cthhlnpqsp gldreqlywq
13261 lsqmtngike lgpytldrns lyvngfthrs sglttstpwt stvdlgtsgt pspvpsptta
13321 gpllvpftln ftitnlqyee dmhrpgsrkf nttervlqgl lspifknssv gplysgcrlt
13381 slrpekdgaa tgmdavclyh pnpkrpgldr eqlywelsql thnitelgpy sldrdslyvn
13441 gfthqnsvpt tstpgtstvy wattgtpssf pghtepgpll ipftfnftit nlhyeenmqh
13501 pgsrkfntte rvlqgllkpl fkntsvgply sgcrltslrp ekdgaatgmd avclyhpnpk
13561 rpgldreqly welsqlthni telgpysldr dslyvngfth qnsvpttstp gtstvywatt
13621 gtpssfpght epgpllipft fnftitnlhy eenmqhpgsr kfnttervlq gllkplfknt
13681 svgplysgcr ltllrpekhe aatgvdtict hrvdpigpgl drerlywels qltnsitelg
13741 pytldrdsly vngfnprssv pttstpgtst vhlatsgtps slpghtapvp llipftlnft
13801 itnlhyeenm qhpgsrkfnt tervlqgllk plfkntsvgp lysgcrltll rpekheaatg
13861 vdticthrvd pigpglxxex lywelsxltx xixelgpytl drxslyvngf thxxsxptts
13921 tpgtstvxxg tsgtpssxpx xtsagpllvp ftlnftitnl qyeedmhhpg srkfntterv
13981 lqgllgpmfk ntsvgllysg crltllrpek ngaatgmdai cshrldpksp gldreqlywe
14041 lsqlthgike lgpytldrns lyvngfthrs svaptstpgt stvdlgtsgt psslpsptta
14101 vpllvpftln ftitnlqyge dmrhpgsrkf nttervlqgl lgplfknssv gplysgcrli
14161 slrsekdgaa tgvdaicthh lnpqspgldr eqlywqlsqm tngikelgpy tldrnslyvn
14221 gfthrssglt tstpwtstvd lgtsgtpspv pspttagpll vpftlnftit nlqyeedmhr
```

14281 pgsrkfnate rvlqgllspi fknssvgply sgcrltslrp ekdgaatgmd avclyhpnpk
14341 rpgldreqly welsqlthni telgpysldr dslyvngfth qssmtttrtp dtstmhlats
14401 rtpaslsgpt taspllvlft inctitnlqy eedmrrtgsr kfntmesvlq gllkplfknt
14461 svgplysgcr ltllrpkkdg aatgvdaict hrldpkspgl nreqlywels kltndieelg
14521 pytldrnsly vngfthqssv sttstpgtst vdlrtsgtps slssptimxx xpllxpftxn
14581 xtitnlxxxx xmxxpgsrkf nttervlqgl lrplfkntsv sslysgcrlt llrpekdgaa
14641 trvdaactyr pdpkspgldr eqlywelsql thsitelgpy tldrvslyvn gfnprssvpt
14701 tstpgtstvh latsgtpssl pghtxxxpll xpftxnxtit nlxxxxxmxx pgsrkfntte
14761 rvlqgllkpl frnssleyly sgcrlaslrp ekdssamavd aicthrpdpe dlgldrerly
14821 welsnltngi qelgpytldr nslyvngfth rssglttstp wtstvdlgts gtpspvpspt
14881 tagpllvpft lnftitnlqy eedmhrpgsr rfnttervlq glltplfknt svgplysgcr
14941 ltllrpekqe aatgvdtict hrvdpigpgl drerlywels qltnsitelg pytldrdsly
15001 vngfnpwssv pttstpgtst vhlatsgtps slpghtapvp llipftlnft itdlhyeenm
15061 qhpgsrkfnt tervlqgllk plfkstsvgp lysgcrltll rpekhgaatg vdaictlrld
15121 ptgpgldrer lywelsqltn svtelgpytl drdslyvngf thrssvptts ipgtsavhle
15181 tsgtpaslpg htapgpllvp ftlnftitnl qyeedmrhpg srkfstterv lqgllkplfk
15241 ntsvsslysg crltllrpek dgaatrvdav cthrpdpksp gldrerlywk lsqlthgite
15301 lgpytldrhs lyvngfthqs smtttrtpdt stmhlatsrt paslsgptta spllvlftin
15361 ftitnlryee nmhhpgsrkf nttervlqgl lrpvfkntsv gplysgcrlt tlrpkkdgaa
15421 tkvdaictyr pdpkspgldr eqlywelsql thsitelgpy tqdrdslyvn gfthrssvpt
15481 tsipgtsavh letsgtpasl pghtapgpll vpftlnftit nlqyeedmrh pgsrkfntte
15541 rvlqgllkpl fkstsvgply sgcrltllrp ekrgaatgvd ticthrldpl npgldreqly
15601 welskltrgi ielgpylldr gslyvngfth rtsvpttstp gtstvdlgts gtpfslpspa
15661 xxxpllxpft xnxtitnlxx xxxmxxpgsr kfnttervlq tllgpmfknt svgllysgcr
15721 ltllrsekdg aatgvdaict hrldpkspgv dreqlywels qltngikelg pytldrnsly
15781 vngfthwipv ptsstpgtst vdlgsgtpss lpspttagpl lvpftlnfti tnlkyeedmh
15841 cpgsrkfntt ervlqslgp mfkntsvgpl ysgcrltllr sekdgaatgv daicthrldp
15901 kspgvdreql ywelsqltng ikelgpytld rnslyvngft hqtsapntst pgtstvdlgt
15961 sgtpsslpsp txxxpllxpf txnxtitnlx xxxxmxxpgs rkfnttexvl qgllxpxfkn
16021 xsvgxlysgc rltxlrxekx gaatgxdaic xhxxxpkxpg lxxexlywel sxltxxixel
16081 gpytldrxsl yvngfthwip vptsstpgts tvdlgsgtps slpspttagp llvpftlnft
16141 itnlkyeedm hcpgsrkfnt tervlqslg pmfkntsvgp lysgcrltsl rsekdgaatg
16201 vdaicthrvd pkspgvdreq lywelsqltn gikelgpytl drnslyvngf thqtsapnts
16261 tpgtstvxxg tsgtpssxpx xtsagpllvp ftlnftitnl qyeedmhhpg srkfntterv
16321 lqgllgpmfk ntsvgllysg crltllrpek ngattgmdai cthrldpksp glxxexlywe
16381 lsxltxxixe lgpytldrxs lyvngfthxx sxpttstpgt stvxxgtsgt pssxpxxtxx
16441 xpllxpftxn xtitnlxxxx xmxxpgsrkf nttervlqgl lkplfrnssl eylysgcrla
16501 slrpekdssa mavdaicthr pdpedlgldr erlywelsnl tngiqelgpy tldrnslyvn
16561 gfthrssmpt tstpgtstvd vgtsgtpsss pspttagpll ipftlnftit nlqygedmgh
16621 pgsrkfntte rvlqgllgpi fkntsvgply sgcrltslrs ekdgaatgvd aicihhldpk
16681 spglnrerly welsqltngi kelgpytldr nslyvngfth rtsvpttstp gtstvdlgts
16741 gtpfslpspa tagpllvlft lnftitnlky eedmhrpgsr kfnttervlq tllgpmfknt
16801 svgllysgcr ltllrsekdg aatgvdaict hrldpkspgl xxexlywels xltxxixelg
16861 pytldrxsly vngfthxxsx pttstpgtst vxxgtsgtps sxpxxtxxxp llxpftxnxt
16921 itnlxxxxxm xxpgsrkfnt tervlqgllr pvfkntsvgp lysgcrltll rpkkdgaatk
16981 vdaictyrpd pkspgldreq lywelsqlth sitelgpytq drdslyvngf thrssvptts
17041 ipgtsavhle ttgtpssfpg htepgpllip ftfnftitnl ryeenmqhpg srkfntterv
17101 lqglltplfk ntsvgplysg crltllrpek qeaatgvdti cthrvdpigp gldrerlywe
17161 lsqltnsite lgpytldrds lyvdgfnpws svpttstpgt stvhlatsgt psplpghtap
17221 vpllipftln ftitdlhyee nmqhpgsrkf nttervlqgl lkplfkstsv gplysgcrlt
17281 llrpekhgaa tgvdaictlr ldptgpgldr erlywelsql tnsitelgpy tldrdslyvn
17341 gfnpwssvpt tstpgtstvh latsgtpssl pghttagpll vpftlnftit nlkyeedmhc
17401 pgsrkfntte rvlqslhgpm fkntsvgply sgcrltllrs ekdgaatgvd aicthrldpk
17461 spglxxexly welsxltxxi xelgpytldr xslyvngfth xxsxpttstp gtstvxxgts
17521 gtpssxpxxt xxxpllxpft xnxtitnlxx xxxmxxpgsr kfnttexvlq gllxpxfknx
17581 svgxlysgcr ltxlrxekxg aatgxdaicx hxxxpkxpgl xxexlywels xltnsitelg
17641 pytldrdsly vngfthrssm pttsipgtsa vhletsgtpa slpghtapgp llvpftlnft
17701 itnlqyeedm rhpgsrkfnt tervlqgllk plfkstsvgp lysgcrltll rpekrgaatg
17761 vdticthrld plnpglxxex lywelsxltx xixelgpytl drxslyvngf thxxsxptts
17821 tpgtstvxxg tsgtpssxpx xtxxxpllxp ftxnxtitnl xxxxxmxxpg srkfnttexv
17881 lqgllxpxfk nxsvgxlysg crltxlrxek xgaatgxdai cxhxxxpkxp glxxexlywe

17941 lsxltxxixe lgpytldrxs lyvngfhprs svpttstpgt stvhlatsgt psslpghtap
18001 vpllipftln ftitnlhyee nmqhpgsrkf nttervlqgl lgpmfkntsv gllysgcrlt
18061 llrpekngaa tgmdaicshr ldpkspglxx exlywelsxl txxixelgpy tldrxslyvn
18121 gfthxxsxpt tstpgtstvx xgtsgtpssx pxxtxxxpll xpftxnxtit nlxxxxxmxx
18181 pgsrkfntte xvlqgllxpx fknxsvgxly sgcrltxlrx ekxgaatgxd aicxhxxxpk
18241 xpglxxexly welsxltxxi xelgpytldr xslyvngfth qnsvpttstp gtstvywatt
18301 gtpssfpght epgpllipft fnftitnlhy eenmqhpgsr kfnttervlq glltplfknt
18361 svgplysgcr ltllrpekqe aatgvdtict hrvdpigpgl xxexlywels xltxxixelg
18421 pytldrxsly vngfthxxsx pttstpgtst vxxgtsgtps sxpxxtxxxp llxpftxnxt
18481 itnlxxxxxm xxpgsrkfnt texvlqgllx pxfknxsvgx lysgcrltxl rxekxgaatg
18541 xdaicxhxxx pkxpglxxex lywelsxltx xixelgpytl drxslyvngf thrssvptts
18601 spgtstvhla tsgtpsslpg htapvpllip ftlnftitnl hyeenmqhpg srkfntterv
18661 lqgllkplfk stsvgplysg crltllrpek hgaatgvdai ctlrldptgp glxxexlywe
18721 lsxltxxixe lgpytldrxs lyvngfthxx sxpttstpgt stvxxgtsgt pssxpxxtxx
18781 xpllxpftxn xtitnlxxxx xmxxpgsrkf nttexvlqgl lxpxfknxsv gxlysgcrlt
18841 xlrxekxgaa tgxdaicxhx xxpkxpglxx exlywelsxl txxixelgpy tldrxslyvn
18901 gfthrtsvpt tstpgtstvh latsgtpssl pghtapvpll ipftlnftit nlqyeedmhr
18961 pgsrkfntte rvlqgllspi fknssvgply sgcrltslrp ekdgaatgmd avclyhpnpk
19021 rpgldreqly celsqlthni telgpysldr dslyvngfth qnsvpttstp gtstvywatt
19081 gtpssfpght xxxpllxpft xnxtitnlxx xxxmxxpgsr kfnttexvlq gllxpxfknx
19141 svgxlysgcr ltxlrxekxg aatgxdaicx hxxxpkxpgl xxexlywels xltxxixelg
19201 pytldrxsly vngfthwssg lttstpwtst vdlgtsgtps pvpspttagp llvpftlnft
19261 itnlqyeedm hrpgsrkfna tervlqglls pifkntsvgp lysgcrltll rpekqeaatg
19321 vdticthrvd pigpglxxex lywelsxltx xixelgpytl drxslyvngf thxxsxptts
19381 tpgtstvxxg tsgtpssxpx xtxxxpllxp ftxnxtitnl xxxxxmxxpg srkfnttexv
19441 lqgllxpxfk nxsvgxlysg crltxlrxek xgaatgxdai cxhxxxpkxp glxxexlywe
19501 lsxltxxixe lgpytldrxs lyvngfthrs fglttstpwt stvdlgtsgt pspvpsptta
19561 gpllvpftln ftitnlqyee dmhrpgsrkf nttervlqgl ltplfrntsv sslysgcrlt
19621 llrpekdgaa trvdavcthr pdpkspglxx exlywelsxl txxixelgpy tldrxslyvn
19681 gfthxxsxpt tstpgtstvx xgtsgtpssx pxxtxxxpll xpftxnxtit nlxxxxxmxx
19741 pgsrkfntte xvlqgllxpx fknxsvgxly sgcrltxlrx ekxgaatgxd aicxhxxxpk
19801 xpglxxexly welsxltxxi xelgpytldr xslyvngfth wipvptsstp gtstvdlgsg
19861 tpsslpsptt agpllvpftl nftitnlqyg edmghpgsrk fnttervlqg llgpifknts
19921 vgplysgcrl tslrsekdga atgvdaicih hldpkspglx xexlywelsx ltxxixelgp
19981 ytldrxslyv ngfthxxsxp ttstpgtstv xxgtsgtpss xpxxtxxxpl lxpftxnxti
20041 tnlxxxxxmx xpgsrkfntt exvlqgllxp xfknxsvgxl ysgcrltxlr xekxgaatgx
20101 daicxhxxxp kxpglxxexl ywelsxltxx ixelgpytld rxslyvngft hqtfapntst
20161 pgtstvdlgt sgtpsslpsp tsagpllvpf tlnftitnlq yeedmhhpgs rkfnttervl
20221 qgllgpmfkn tsvgllysgc rltllrpekn gaatrvdavc thrpdpkspg lxxexlywel
20281 sxltxxixel gpytldrxsl yvngfthxxs xpttstpgts tvxxgtsgtp ssxpxxtapv
20341 pllipftlnf titnlhyeen mqhpgsrkfn ttervlqgll kplfkstsvg plysgcrltl
20401 lrpekhgaat gvdaictlrl dptgpgldre rlywelsqlt nsvtelgpyt ldrdslyvng
20461 ftqrssvptt sipgtsavhl etsgtpaslp ghtapgpllv pftlnftitn lqyevdmrhp
20521 gsrkfntter vlqgllkplf kstsvgplys gcrltllrpe krgaatgvdt icthrldpln
20581 pgldreqlyw elskltrgii elgpylldrg slyvngfthr nfvpitstpg tstvhlgtse
20641 tpsslprpiv pgpllvpftl nftitnlqye eamrhpgsrk fnttervlqg llrplfknts
20701 igplysscrl tllrpekdka atrvdaicth hpdpqspgln reqlywelsq lthgitelgp
20761 ytldrdslyv dgfthwspip ttstpgtsiv nlgtsgipps lpettxxxpl lxpftxnxti
20821 tnlxxxxxmx xpgsrkfntt ervlqgllkp lfkstsvgpl ysgcrltllr pekdgvatrv
20881 daicthrpdp kipgldrqql ywelsqlths itelgpytld rdslyvngft qrssvpttst
20941 pgtftvqpet setpsslpgp tatgpvllpf tlnftitnlq yeedmhrpgs rkfnttervl
21001 qgllmplfkn tsvsslysgc rltllrpekd gaatrvdavc thrpdpkspg ldrerlywkl
21061 sqlthgitel gpytldrhsl yvngfthqss mtttrtpdts tmhlatsrtp aslsgpttas
21121 pllvlftinf titnlryeen mhhpgsrkfn ttervlqgll rpvfkntsvg plysgcrltl
21181 lrpkkdgaat kvdaictyrp dpkspgldre qlywelsqlt hsitelgpyt ldrdslyvng
21241 ftqrssvptt sipgtptvdl gtsgtpvskp gpsaaspllv lftlnftitn lryeenmqhp
21301 gsrkfntter vlqgllrslf kstsvgplys gcrltllrpe kdgtatgvda icthhpdpks
21361 prldreqlyw elsqlthnit elghyaldnd slfvngfthr ssvsttstpg tptvylgask
21421 tpasifgpsa ashllilftl nftitnlrye enmwpgsrkf nttervlqgl lrplfkntsv
21481 gplysgsrlt llrpekdgea tgvdaicthr pdptgpgldr eqlylelsql thsitelgpy
21541 tldrdslyvn gfthrssvpt tstgvvseep ftlnftinnl rymadmgqpg slkfnitdnv

```
21601 mkhllsplfq rsslgarytg crvialrsvk ngaetrvdll ctylqplsgp glpikqvfhe
21661 lsqqthgitr lgpysldkds lylngynepg ldeppttpkp attflpplse attamgyhlk
21721 tltlnftisn lqyspdmgkg satfnstegv lqhllrplfq kssmgpfylg cqlislrpek
21781 dgaatgvdtt ctyhpdpvgp gldiqqlywe lsqlthgvtq lgfyvldrds lfingyapqn
21841 lsirgeyqin fhivnwnlsn pdptsseyit llrdiqdkvt tlykgsqlhd tfrfclvtnl
21901 tmdsvlvtvk alfssnldps lveqvfldkt lnasfhwlgs tyqlvdihvt emessvyqpt
21961 sssstqhfyl nftitnlpys qdkaqpgttn yqrnkrnied alnqlfrnss iksyfsdcqv
22021 stfrsvpnrh htgvdslcnf splarrvdrv aiyeeflrmt rngtqlqnft ldrssvlvdg
22081 yspnrneplt gnsdlpfwav iliglagllg litclicgvl vttrrrkkeg eynvqqqcpg
22141 yyqshldled lq
```

SEQ ID NO. 2

CA125 nucleic acid Genbank No. AF414442

CDS 205..66663

```
    1 aagcgttgca caattccccc aacctccata catacggcag ctcttctaga cacaggtttt
   61 cccaggtcaa atgcggggac cccagccata tctcccaccc tgagaaattt tggagtttca
  121 gggagctcag aagctctgca gaggccaccc tctctgaggg gattcttctt agacctccat
  181 ccagaggcaa atgttgacct gtccatgctg aaaccctcag gccttcctgg gtcatcttct
  241 cccacccgct ccttgatgac agggagcagg agcactaaag ccacaccaga aatggattca
  301 ggactgacag gagccacctt gtcacctaag acatctacag gtgcaatcgt ggtgacagaa
  361 catactctgc cctttacttc cccagataag accttggcca gtcctacatc ttcggttgtg
  421 ggaagaacca cccagtcttt gggggtgatg tcctctgctc tccctgagtc aacctctaga
  481 ggaatgacac actccgagca aagaaccagc ccatcgctga gtccccaggt caatggaact
  541 ccctctagga actaccctgc tacaagcatg gtttcaggat tgagttcccc aaggaccagg
  601 accagttcca cagaaggaaa ttttaccaaa gaagcatcta catacacact cactgtagag
  661 accacaagtg gcccagtcac tgagaagtac acagtcccca ctgagacctc aacaactgaa
  721 ggtgacagca cagagacccc ctgggacaca agatatattc ctgtaaaaat cacatctcca
  781 atgaaaacat ttgcagattc aactgcatcc aaggaaaatg ccccagtgtc tatgactcca
  841 gctgagacca cagttactga ctcacatact ccaggaagga caaacccatc atttgggaca
  901 ctttattctt ccttccttga cctatcacct aaagggaccc caaattccag aggtgaaaca
  961 agcctggaac tgattctatc aaccactgga tatcccttct cctctcctga acctggctct
 1021 gcaggacaca gcagaataag taccagtgcg cctttgtcat catctgcttc agttctcgat
 1081 aataaaatat cagagaccag catattctca ggccagagtc tcacctcccc tctgtctcct
 1141 ggggtgcccg aggccagagc cagcacaatg cccaactcag ctatcccttt ttccatgaca
 1201 ctaagcaatg cagaaacaag tgccgaaagg gtcagaagca caatttcctc tctggggact
 1261 ccatcaatat ccacaaagca gacagcagag actatcctta ccttccatgc cttcgctgag
 1321 accatggata tacccagcac ccacatagcc aagactttgg cttcagaatg gttgggaagt
 1381 ccaggtaccc ttggtggcac cagcacttca gcgctgacaa ccacatctcc atctaccact
 1441 ttagtctcag aggagaccaa cacccatcac tccacgagtg gaaaggaaac agaaggaact
 1501 ttgaatacat ctatgactcc acttgagacc tctgctcctg gagaagagtc cgaaatgact
 1561 gccaccttgg tccccactct aggttttaca actcttgaca gcaagatcag aagtccatct
 1621 caggtctctt catcccaccc aacaagagag ctcagaacca caggcagcac ctctgggagg
 1681 cagagttcca gcacagctgc ccacgggagc tctgacatcc tgagggcaac cacttccagc
 1741 acctcaaaag catcatcatg gaccagtgaa agcacagctc agcaatttag tgaaccccag
 1801 cacacacagt gggtggagac aagtcctagc atgaaaacag agagacccca agcatcaacc
 1861 agtgtggcag cccctatcac cacttctgtt ccctcagtgg tctctggctt caccaccctg
 1921 aagaccagct ccacaaaagg gatttggctt gaagaaacat ctgcagacac actcatcgga
 1981 gaatccacag ctggcccaac cacccatcag tttgctgttc ccactgggat ttcaatgaca
 2041 ggaggcagca gcaccagggg aagccagggc acaacccacc tactcaccag agccacagca
 2101 tcatctgaga catccgcaga tttgactctg gccacgaacg gtgtcccagt ctccgtgtct
 2161 ccagcagtga gcaagacggc tgctggctca agtcctccag gagggacaaa gccatcatat
 2221 acaatggttt cttctgtcat ccctgagaca tcatctctac agtcctcagc tttcagggaa
 2281 ggaaccagcc tgggactgac tccattaaac actagacatc ccttctcttc ccctgaacca
 2341 gactctgcag gacacaccaa gataagcacc agcattcctc tgttgtcatc tgcttcagtt
 2401 cttgaggata aagtgtcagc gaccagcaca ttctcacacc acaaagccac ctcatctatt
 2461 accacaggga ctcctgaaat ctcaacaaag acaaagccca gctcagccgt tctttcctcc
 2521 atgaccctaa gcaatgcagc aacaagtcct gaaagagtca gaaatgcaac ttccccctctg
```

```
2581 actcatccat ctccatcagg ggaagagaca gcagggagtg tcctcactct cagcacctct
2641 gctgagacta cagactcacc taacatccac ccaactggga cactgacttc agaatcgtca
2701 gagagtccta gcactctcag cctcccaagt gtctctggag tcaaaaccac attttcttca
2761 tctactcctt ccactcatct atttactagt ggagaagaaa cagaggaaac ttcgaatcca
2821 tctgtgtctc aacctgagac ttctgtttcc agagtaagga ccaccttggc cagcacctct
2881 gtccctaccc cagtattccc caccatggac acctggccta cacgttcagc tcagttctct
2941 tcatcccacc tagtgagtga gctcagagct acgagcagta cctcagttac aaactcaact
3001 ggttcagctc ttcctaaaat atctcacctc actgggacgg caacaatgtc acagaccaat
3061 agagacacgt ttaatgactc tgctgcaccc caaagcacaa cttggccaga gactagtccc
3121 agattcaaga cagggttacc ttcagcaaca accactgttt caacctctgc cacttctctc
3181 tctgctactg taatggtctc taaattcact tctccagcaa ctagttccat ggaagcaact
3241 tctatcaggg aaccatcaac aaccatcctc acaacagaga ccacgaatgg cccaggctct
3301 atggctgtgg cttctaccaa catcccaatt ggaaagggct acattactga aggaagattg
3361 gacacaagcc atctgcccat tggaaccaca gcttcctctg agacatctat ggattttacc
3421 atggccaaag aaagtgtctc aatgtcagta tctccatctc agtccatgga tgctgctggc
3481 tcaagcactc caggaaggac aagccaattc gttgacacat tttctgatga tgtctatcat
3541 ttaacatcca gagaaattac aatacctaga gatggaacaa gctcagctct gactccacaa
3601 atgactgcaa ctcaccctcc atctcctgat cctggctctg ctagaagcac ctggcttggc
3661 atcttgtcct catctccttc ttctcctact cccaaagtca caatgagctc cacattttca
3721 actcagagag tcaccacaag catgataatg gacacagttg aaactagtcg gtggaacatg
3781 cccaacttac cttccacgac ttccctgaca ccaagtaata ttccaacaag tggtgccata
3841 ggaaaaagca ccctggttcc cttggacact ccatctccag ccacatcatt ggaggcatca
3901 gaaggggggac ttccaaccct cagcacctac cctgaatcaa caaacacacc cagcatccac
3961 ctcggagcac acgctagttc agaaagtcca agcaccatca aacttaccat ggcttcagta
4021 gtaaaacctg gctcttacac acctctcacc ttcccctcaa tagagaccca cattcatgta
4081 tcaacagcca gaatggctta ctcttctggg tcttcacctg agatgacagc tcctggagag
4141 actaacactg gtagtacctg ggaccccacc acctacatca ccactacgga tcctaaggat
4201 acaagttcag ctcaggtctc tacaccccac tcagtgagga cactcagaac cacagaaaac
4261 catccaaaga cagagtccgc caccccagct gcttactctg gaagtcctaa aatctcaagt
4321 tcacccaatc tcaccagtcc ggccacaaaa gcatggacca tcacagacac aactgaacac
4381 tccactcaat tacattacac aaaattggca gaaaaatcat ctggatttga gacacagtca
4441 gctccaggac ctgtctctgt agtaatccct acctccccta ccattggaag cagcacattg
4501 gaactaactt ctgatgtccc aggggaaccc ctggtccttg ctcccagtga gcagaccaca
4561 atcactctcc ccatggcaac atggctgagt accagtttga cagaggaaat ggcttcaaca
4621 gaccttgata tttcaagtcc aagttcaccc atgagtacat ttgctatttt tccacctatg
4681 tccacacctt ctcatgaact ttcaaagtca gaggcagata ccagtgccat tagaaataca
4741 gattcaacaa cgttggatca gcacctagga atcaggagtt tgggcagaac tggggactta
4801 acaactgttc ctatcacccc actgacaacc acgtggacca gtgtgattga acactcaaca
4861 caagcacagg acacccttc tgcaacgatg agtcctactc acgtgacaca gtcactcaaa
4921 gatcaaacat ctataccagc ctcagcatcc ccttcccatc ttactgaagt ctaccctgag
4981 ctcgggacac aagggagaag ctcctctgag gcaaccactt tttggaaacc atctacagac
5041 acactgtcca gagagattga gactggccca acaaacattc aatccactcc acccatggac
5101 aacacaacaa cagggagcag tagtagtgga gtcaccctgg gcatagccca ccttcccata
5161 ggaacatcct ccccagctga gacatccaca aacatggcac tggaaagaag aagttctaca
5221 gccactgtct ctatggctgg gacaatggga ctccttgtta ctagtgctcc aggaagaagc
5281 atcagccagt cattaggaag agtttcctct gtcctttctg agtcaactac tgaaggagtc
5341 acagattcta gtaagggaag cagcccaagg ctgaacacac agggaaatac agctctctcc
5401 tcctctcttg aacccagcta tgctgaagga agccagatga gcacaagcat ccctctaacc
5461 tcatctccta caactcctga tgtggaattc atagggggca gcacattttg gaccaaggag
5521 gtcaccacag ttatgacctc agacatctcc aagtcttcag caaggacaga gtccagctca
5581 gctacccttа tgtccacagc tttgggaagc actgaaaata caggaaaaga aaaactcaga
5641 actgcctcta tggatcttcc atctccaact ccatcaatgg aggtgacacc atggatttct
5701 ctcactctca gtaatgcccc caataccaca gattcacttg acctcagcca tggggtgcac
5761 accagctctg cagggacttt ggccactgac aggtcattga atactggtgt cactagagcc
5821 tccagattgg aaaacggctc tgatacctct tctaagtccc tgtctatggg aaacagcact
5881 cacacttcca tgactgacac agagaagagt gaagtgtctt cttcaatcca tccccgacct
5941 gagacctcag ctcctggagc agagaccact ttgacttcca ctcctggaaa cagggccata
6001 agcttaacat tgccttttтc atccattcca gtggaagaag tcatttctac aggcataacc
6061 tcaggaccag acatcaactc agcacccatg acacattctc ccatcacccc accaacaatt
6121 gtatggacca gtacaggcac aattgaacag tccactcaac cactacatgc agtttcttca
6181 gaaaaagttt ctgtgcagac acagtcaact ccatatgtca actctgtggc agtgtctgct
```

```
6241 tcccctaccc atgagaattc agtctcttct ggaagcagca catcctctcc atattcctca
6301 gcctcacttg aatccttgga ttccacaatc agtaggagga atgcaatcac ttcctggcta
6361 tgggacctca ctacatctct ccccactaca acttggccaa gtactagttt atctgaggca
6421 ctgtcctcag gccattctgg ggtttcaaac ccaagttcaa ctacgactga atttccactc
6481 ttttcagctg catccacatc tgctgctaag caaagaaatc cagaaacaga gacccatggt
6541 ccccagaata cagccgcgag tactttgaac actgatgcat cctcggtcac aggtctttct
6601 gagactcctg tgggggcaag tatcagctct gaagtccctc ttccaatggc cataacttct
6661 agatcagatg tttctggcct tacatctgag agtactgcta acccgagttt aggcacagcc
6721 tcttcagcag ggaccaaatt aactaggaca atatccctgc ccacttcaga gtctttggtt
6781 tcctttagaa tgaacaagga tccatggaca gtgtcaatcc ctttggggtc ccatccaact
6841 actaatacag aaacaagcat cccagtaaac agcgcaggtc cacctggctt gtccacagta
6901 gcatcagatg taattgacac accttcagat ggggctgaga gtattcccac tgtctccttt
6961 tccccctccc ctgatactga agtgacaact atctcacatt tcccagaaaa gacaactcat
7021 tcatttagaa ccatttcatc tctcactcat gagttgactt caagagtgac acctattcct
7081 ggggattgga tgagttcagc tatgtctaca aagcccacag gagccagtcc ctccattaca
7141 ctgggagaga gaaggacaat cacctctgct gctccaacca cttcccccat agttctcact
7201 gctagtttca cagagaccag cacagtttca ctggataatg aaactacagt aaaaacctca
7261 gatatccttg acgcacggaa aacaaatgag ctcccctcag atagcagttc ttcttctgat
7321 ctgatcaaca cctccatagc ttcttcaact atggatgtca ctaaaacagc ctccatcagt
7381 cccactagca tctcaggaat gacagcaagt tcctccccat ctctcttctc ttcagataga
7441 ccccaggttc ccacatctac aacagagaca aatacagcca cctctccatc tgtttccagt
7501 aacacctatt ctcttgatgg gggctccaat gtgggtggca ctccatccac tttaccaccc
7561 tttacaatca cccaccctgt cgagacaagc tcggccctat tagcctggtc tagaccagta
7621 agaactttca gcaccatggt cagcactgac actgcctccg gagaaaatcc tacctctagc
7681 aattctgtgg tgacttctgt tccagcacca ggtacatggg ccagtgtagg cagtactact
7741 gacttacctg ccatgggctt tctcaagaca agtcctgcag gagaggcaca ctcacttcta
7801 gcatcaacta ttgaaccagc cactgccttc actccccatc tctcagcagc agtggtcact
7861 ggatccagtg ctacatcaga agccagtctt ctcactacga gtgaaagcaa agccattcat
7921 tcttcaccac agaccccaac tacacccacc tctggagcaa actgggaaac ttcagctact
7981 cctgagagcc ttttggtagt cactgagact tcagacacaa cacttacctc aaagattttg
8041 gtcacagata ccatcttgtt ttcaactgtg tccacgccac cttctaaatt tccaagtacg
8101 gggactctgt ctggagcttc cttccctact ttactcccgg acactccagc catccctctc
8161 actgccactg agccaacaag ttcattagct acatcctttg attccacccc actggtgact
8221 atagcttcgg atagtcttgg cacagtccca gagactaccc tgaccatgtc agagacctca
8281 aatggtgatg cactggttct taagacagta agtaacccag ataggagcat ccctggaatc
8341 actatccaag gagtaacaga aagtccactc catccttctt ccacttcccc ctctaagatt
8401 gttgctccac ggaatacaac ctatgaaggt tcgatcacag tggcactttc tactttgcct
8461 gcgggaacta ctggttccct tgtattcagt cagagttctg aaaactcaga gacaacggct
8521 ttggtagact catcagctgg gcttgagagg gcatctgtga tgccactaac cacaggaagc
8581 cagggtatgg ctagctctgg aggaatcaga agtgggtcca ctcactcaac tggaaccaaa
8641 acattttctt ctctccctct gaccatgaac ccaggtgagg ttacagccat gtctgaaatc
8701 accacgaaca gactgacagc tactcaatca acagcaccca aagggatacc tgtgaagccc
8761 accagtgctg agtcaggcct cctaacacct gtctctgcct cctcaagccc atcaaaggcc
8821 tttgcctcac tgactacagc tcccccatca acttgggggа tcccacagtc taccttgaca
8881 tttgagtttt ctgaggtccc aagtttggat actaagtccg cttctttacc aactcctgga
8941 cagtccctga acaccattcc agactcagat gcaagcacag catcttcctc actgtccaag
9001 tctccagaaa aaaacccaag ggcaaggatg atgacttcca caaaggccat aagtgcaagc
9061 tcatttcaat caacaggttt tactgaaacc cctgagggat ctgcctcccc ttctatggca
9121 gggcatgaac ccagagtccc cacttcagga acaggggacc ctagatatgc ctcagagagc
9181 atgtcttatc cagacccaag caaggcatca tcagctatga catcgacctc tcttgcatca
9241 aaactcacaa ctctcttcag cacaggtcaa gcagcaaggt ctggttctag ttcctctccc
9301 ataagcctat ccactgagaa agaaacaagc ttcctttccc ccactgcatc cacctccaga
9361 aagacttcac tatttcttgg gccttccatg gcaaggcagc ccaacatatt ggtgcatctt
9421 cagacttcag ctctgacact ttctccaaca tccactctaa atatgtccca ggaggagcct
9481 cctgagttaa cctcaagcca gaccattgca gaagaagagg gaacaacagc tgaaacacag
9541 acgttaacct tcacaccatc tgagacccca acatccttgt tacctgtctc ttctcccaca
9601 gaacccacag ccagaagaaa gagttctcca gaaacatggg caagctctat ttcagttcct
9661 gccaagacct ccttggttga aacaactgat ggaacgctag tgaccaccat aaagatgtca
9721 agccaggcag cacaaggaaa ttccacgtgg cctgccccag cagaggagac ggggaccagt
9781 ccagcaggca catccccagg aagcccagaa gtgtctacca ctctcaaaat catgagctcc
9841 aaggaaccca gcatcagccc agagatcagg tccactgtgc gaaattctcc ttggaagact
```

```
 9901 ccagaaacaa ctgttcccat ggagaccaca gtggaaccag tcacccttca gtccacagcc
 9961 ctaggaagtg gcagcaccag catctctcac ctgcccacag gaaccacatc accaaccaag
10021 tcaccaacag aaaatatgtt ggctacagaa agggtctccc tctccccatc cccacctgag
10081 gcttggacca acctttattc tggaactcca ggagggacca ggcagtcact ggccacaatg
10141 tcctctgtct ccctagagtc accaactgct agaagcatca cagggactgg tcagcaaagc
10201 agtccagaac tggtttcaaa gacaactgga atggaattct ctatgtggca tggctctact
10261 ggagggacca caggggacac acatgtctct ctgagcacat cttccaatat ccttgaagac
10321 cctgtaacca gcccaaactc tgtgagctca ttgacagata aatccaaaca taaaaccgag
10381 acatgggtaa gcaccacagc cattccctcc actgtcctga ataataagat aatggcagct
10441 gaacaacaga caagtcgatc tgtggatgag gcttattcat caactagttc ttggtcagat
10501 cagacatctg ggagtgacat cacccttggt gcatctcctg atgtcacaaa cacattatac
10561 atcacctcca cagcacaaac cacctcacta gtgtctctgc cctctggaga ccaaggcatt
10621 acaagcctca ccaatccctc aggaggaaaa acaagctctg cgtcatctgt cacatctcct
10681 tcaatagggc ttgagactct gagggccaat gtaagtgcag tgaaaagtga cattgccact
10741 actgctgggc atctatctca gacttcatct cctgcggaag tgagcatcct ggacgtaacc
10801 acagctccta ctccaggtat ctccaccacc atcaccacca tgggaaccaa ctcaatctca
10861 actaccacac ccaacccaga agtgggtatg agtaccatgg acagcacccc ggccacagag
10921 aggcgcacaa cttctacaga acacccttcc acctggtctt ccacagctgc atcagattcc
10981 tggactgtca cagacatgac ttcaaacttg aaagttgcaa gatctcctgg aacaatttcc
11041 acaatgcata caacttcatt cttagcctca agcactgaat tagactccat gtctactccc
11101 catggccgta taactgtcat tggaaccagc ctggtcactc catcctctga tgcttcagct
11161 gtaaagacag agaccagtac aagtgaaaga acattgagtc cttcagacac aactgcatct
11221 actcccatct caacttttc tcgtgtccag aggatgagca tctcagttcc tgacatttta
11281 agtacaagtt ggactcccag tagtacagaa gcagaagatg tgcctgtttc aatggtttct
11341 acagatcatg ctagtacaaa gactgaccca aatacgcccc tgtccacttt tctgtttgat
11401 tctctgtcca ctcttgactg ggacactggg agatctctgt catcagccac agccactacc
11461 tcagctcctc agggggccac aactccccag gaactcactt tggaaaccat gatcagccca
11521 gctacctcac agttgccctt ctctataggg cacattacaa gtgcagtcac accagctgca
11581 atggcaagga gctctggagt tacttttca agaccagatc ccacaagcaa aaaggcagag
11641 cagacttcca ctcagcttcc caccaccact tctgcacatc cagggcaggt gcccagatca
11701 gcagcaacaa ctctggatgt gatcccacac acagcaaaaa ctccagatgc aacttttcag
11761 agacaagggc agacagctct tacaacagag gcaagagcta catctgactc ctggaatgag
11821 aaagaaaaat caaccccaag tgcaccttgg atcactgaga tgatgaattc tgtctcagaa
11881 gataccatca aggaggttac cagctcctcc agtgtattaa aggaccctga atacgctgga
11941 cataaacttg gaatctggga cgacttcatc cccaagtttg gaaaagcagc ccatatgaga
12001 gagttgcccc ttctgagtcc accacaggac aaagaggcaa ttcacccttc tacaaacaca
12061 gtagagacca caggctgggt cacaagttcc gaacatgctt ctcattccac tatcccagcc
12121 cactcagcgt catccaaact cacatctcca gtggttacaa cctccaccag ggaacaagca
12181 atagtttcta tgtcaacaac cacatggcca gagtctacaa gggctagaac agagcctaat
12241 tccttcttga ctattgaact gagggacgtc agcccttaca tggacaccag ctcaaccaca
12301 caaacaagta ttatctcttc cccaggttcc actgcgatca ccaaggggcc tagaacagaa
12361 attacctcct ctaagagaat atccagctca ttccttgccc agtctatgag gtcgtcagac
12421 agcccctcag aagccatcac caggctgtct aactttcctg ccatgacaga atctggagga
12481 atgatccttg ctatgcaaac aagtccacct ggcgctacat cactaagtgc acctactttg
12541 gatacatcag ccacagcctc ctggacaggg actccactgg ctacgactca gagatttaca
12601 tactcagaga agaccactct ctttagcaaa ggtcctgagg atacatcaca gccaagccct
12661 ccctctgtgg aagaaaccag ctcttcctct tccctggtac ctatccatgc tacaacctcg
12721 ccttccaata ttttgttgac atcacaaggg cacagtccct cctctactcc acctgtgacc
12781 tcagttttct tgtctgagac ctctggcctg gggaagacca cagacatgtc gaggataagc
12841 ttggaacctg gcacaagttt acctcccaat ttgagcagta cagcaggtga ggcgttatcc
12901 acttatgaag cctccagaga tacaaaggca attcatcatt ctgcagacac agcagtgacg
12961 aatatggagg caaccagttc tgaatattct cctatcccag gccatacaaa gccatccaaa
13021 gccacatctc cattggttac ctcccacatc atgggggaca tcacttcttc cacatcagta
13081 tttggctcct ccgagaccac agagattgag acagtgtcct ctgtgaacca gggacttcag
13141 gagagaagca catcccaggt ggccagctct gctacagaga caagcactgt cattacccat
13201 gtgtctagtg gtgatgctac tactcatgtc accaagacac aagccacttt ctctagcgga
13261 acatccatct caagccctca tcagtttata acttctacca acacatttac agatgtgagc
13321 accaaccctt ccacctctct gataatgaca gaatcttcag gagtgaccat caccacccaa
13381 acaggtccta ctggagctgc aacacagggt ccatatctct tggacacatc aaccatgcct
13441 tacttgacag agactccatt agctgtgact ccagatttta tgcaatcaga gaagaccact
13501 ctcataagca aaggtcccaa ggatgtgacc tggacaagcc ctccctctgt ggcagaaacc
```

```
13561 agctatccct cttccctgac acctttcttg gtcacaacca tacctcctgc cacttccacg
13621 ttacaagggc aacatacatc ctctcctgtt tctgcgactt cagttcttac ctctggactg
13681 gtgaagacca cagatatgtt gaacacaagc atggaacctg tgaccaattc acctcaaaat
13741 ttgaacaatc catcaaatga gatactggcc actttggcag ccaccacaga tatagagact
13801 attcatcctt ccataaacaa agcagtgacc aatatgggga ctgccagttc agcacatgta
13861 ctgcattcca ctctcccagt cagctcagaa ccatctacag ccacatctcc aatggttcct
13921 gcctccagca tgggggacgc tcttgcttct atatcaatac ctggttctga gaccacagac
13981 attgagggag agccaacatc ctccctgact gctggacgaa aagagaacag caccctccag
14041 gagatgaact caactacaga gtcaaacatc atcctctcca atgtgtctgt gggggctatt
14101 actgaagcca caaaaatgga agtcccctct tttgatgcaa cattcatacc aactcctgct
14161 cagtcaacaa agttcccaga tattttctca gtagccagca gtagactttc aaactctcct
14221 cccatgacaa tatctaccca catgaccacc acccagacag ggtcttctgg agctacatca
14281 aagattccac ttgccttaga cacatcaacc ttggaaacct cagcagggac tccatcagtg
14341 gtgactgagg ggtttgccca ctcaaaaata accactgcaa tgaacaatga tgtcaaggac
14401 gtgtcacaga caaaccctcc ctttcaggat gaagccagct ctccctcttc tcaagcacct
14461 gtccttgtca caaccttacc ttcttctgtt gctttcacac cgcaatggca cagtacctcc
14521 tctcctgttt ctatgtcctc agttcttact tcttcactgg taaagaccgc aggcaaggtg
14581 gatacaagct tagaaacagt gaccagttca cctcaaagta tgagcaacac tttggatgac
14641 atatcggtca cttcagcagc caccacagat atagagacaa cgcatccttc cataaacaca
14701 gtagttacca atgtggggac caccggttca gcatttgaat cacattctac tgtctcagct
14761 tacccagagc catctaaagt cacatctcca aatgttacca cctccaccat ggaagacacc
14821 acaatttccc gatcaatacc taaatcctct aagactacaa gaactgagac tgagacaact
14881 tcctccctga ctcctaaact gagggagacc agcatctccc aggagatcac ctcgtccaca
14941 gagacaagca ctgttcctta caaagagctc actggtgcca ctaccgaggt atccaggaca
15001 gatgtcactt cctctagcag tacatccttc cctggccctg atcagtccac agtgtcacta
15061 gacatctcca cagaaaccaa caccaggctg tctacctccc caataatgac agaatctgca
15121 gaaataacca tcaccaccca aacaggtcct catggggcta catcacagga tacttttacc
15181 atggacccat caaatacaac cccccaggca gggatccact cagctatgac tcatggattt
15241 tcacaattgg atgtgaccac tcttatgagc agaattccac aggatgtatc atggacaagt
15301 cctccctctg tggataaaac cagctccccc tcttcctttc tgtcctcacc tgcaatgacc
15361 acaccttccc tgatttcttc taccttacca gaggataagc tctcctctcc tatgacttca
15421 cttctcacct ctggcctagt gaagattaca gacatattac gtacacgctt ggaacctgtg
15481 accagctcac ttccaaattt cagcagcacc tcagataaga tactggccac ttctaaagac
15541 agtaaagaca caaaggaaat ttttccttct ataaacacag aagagaccaa tgtgaaagcc
15601 aacaactctg gacatgaatc ccattcccct gcactggctg actcagagac acccaaagcc
15661 acaactcaaa tggttatcac caccactgtg ggagatccag ctccttccac atcaatgcca
15721 gtgcatggtt cctctgagac tacaaacatt aagagagagc caacatattt cttgactcct
15781 agactgagag agaccagtac ctctcaggag tccagctttc ccacggacac aagttttcta
15841 ctttccaaag tccccactgg tactattact gaggtctcca gtacaggggt caactcttct
15901 agcaaaattt ccaccccaga ccatgataag tccacagtgc cacctgacac cttcacagga
15961 gagatcccca gggtcttcac ctcctctatt aagacaaaat ctgcagaaat gacgatcacc
16021 acccaagcaa gtcctcctga gtctgcatcg cacagtaccc ttcccttgga cacatcaacc
16081 acactttccc agggagggac tcattcaact gtgactcagg gattcccata ctcagaggtg
16141 accactctca tgggcatggg tcctgggaat gtgtcatgga tgacaactcc ccctgtggaa
16201 gaaaccagct ctgtgtcttc cctgatgtct tcacctgcca tgacatcccc ttctcctgtt
16261 tcctccacat caccacagag catcccctcc tctcctcttc ctgtgactgc acttcctact
16321 tctgttctgg tgacaaccac agatgtgttg ggcacaacaa gcccagagtc tgtaaccagt
16381 tcacctccaa atttgagcag catcactcat gagagaccgg ccacttacaa agacactgca
16441 cacacagaag ccgccatgca tcattccaca aacaccgcag tgaccaatgt agggacttcc
16501 gggtctggac ataaatcaca atcctctgtc ctagctgact cagagacatc gaaagccaca
16561 cctctgatga gtaccacctc caccctgggg gacacaagtg tttccacatc aactcctaat
16621 atctctcaga ctaaccaaat tcaaacagag ccaacagcat ccctgagccc tagactgagg
16681 gagagcagca cgtctgagaa gaccagctca acaacagaga caaatactgc cttttcttat
16741 gtgcccacag gtgctattac tcaggcctcc agaacagaaa tctcctctag cagaacatcc
16801 atctcagacc ttgatcggcc cacaatagca cccgacatct ccacaggaat gatcaccagg
16861 ctcttcacct cccccatcat gacaaaatct gcagaaatga ccgtcaccac tcaaacaact
16921 actcctgggg ctacatcaca gggtatcctt ccttgggaca catcaaccac acttttccag
16981 ggagggactc attcaaccgt gtctcaggga ttcccacact cagagataac cactcttcgg
17041 agcagaaccc ctggagatgt gtcatggatg acaactcccc ctgtggaaga aaccagctct
17101 gggttttccc tgatgtcacc ttccatgaca tccccttctc ctgtttcctc cacatcacca
17161 gagagcatcc cctcctctcc tctccctgtg actgcacttc ttacttctgt tctggtgaca
```

17221 accaccaatg tattgggcac aacaagccca gagaccgtaa cgagttcacc tccaaattta
17281 agcagcccca cacaggagag actgaccact tacaaagaca ctgcgcacac agaagccatg
17341 catgcttcca tgcatacaaa cactgcagtg gccaacgtcg ggacctccat ttctggacat
17401 gaatcacaat cttctgtccc agctgattca cacacatcca aagccacatc tccaatgggt
17461 atcaccttcg ccatggggga tacaagtgtt tctacatcaa ctcctgcctt ctttgagact
17521 agaattcaga ctgaatcaac atcctctttg attcctggat taagggacac caggacgtct
17581 gaggagatca acactgtgac agagaccagc actgtccttt cagaagtgcc cactactact
17641 actactgagg tctccaggac agaagttatc acttccagca gaacaaccat ctcagggcct
17701 gatcattcca aaatgtcacc ctacatctcc acagaaacca tcaccaggct ctccactttt
17761 ccttttgtaa caggatccac agaaatggcc atcaccaacc aaacaggtcc tatagggact
17821 atctcacagg ctacccttac cctggacaca tcaagcacag cttcctggga agggactcac
17881 tcacctgtga ctcagagatt tccacactca gaggagacca ctactatgag cagaagtact
17941 aagggcgtgt catggcaaag ccctccctct gtggaagaaa ccagttctcc ttcttcccca
18001 gtgcctttac ctgcaataac ctcacattca tctctttatt ccgcagtatc aggaagtagc
18061 cccacttctg ctctccctgt gacttccctt ctcacctctg gcaggaggaa gaccatagac
18121 atgttggaca cacactcaga acttgtgacc agctccttac caagtgcaag tagcttctca
18181 ggtgagatac tcacttctga agcctccaca aatacagaga caattcactt ttcagagaac
18241 acagcagaaa ccaatatggg gaccaccaat tctatgcata aactacattc ctctgtctca
18301 atccactccc agccatccgg acacacacct ccaaaggtta ctggatctat gatggaggac
18361 gctattgttt ccacatcaac acctggttct cctgagacta aaaatgttga cagagactca
18421 acatcccctc tgactcctga actgaaagag gacagcaccg ccctggtgat gaactcaact
18481 acagagtcaa acactgtttt ctccagtgtg tccctggatg ctgctactga ggtctccagg
18541 gcagaagtca cctactatga tcctacattc atgccagctt ctgctcagtc aacaaagtcc
18601 ccagacattt cacctgaagc cagcagcagt cattctaact ctcctccctt gacaatatct
18661 acacacaaga ccatcgccac acaaacaggt ccttctgggg tgacatctct tggccaactg
18721 accctggaca catcaaccat agccacctca gcaggaactc catcagccag aactcaggat
18781 tttgtagatt cagaaacaac cagtgtcatg aacaatgatc tcaatgatgt gttgaagaca
18841 agccctttct ctgcagaaga agccaactct ctctcttctc aggcacctct ccttgtgaca
18901 acctcacctt ctcctgtaac ttccacattg caagagcaca gtacctcctc tcttgtttct
18961 gtgacctcag tacccacccc tacactggcg aagatcacag acatggacac aaacttagaa
19021 cctgtgactc gttcacctca aaatttaagg aacaccttgg ccacttcaga agccaccaca
19081 gatacacaca caatgcatcc ttctataaac acagcaatgg ccaatgtggg gaccaccagt
19141 tcaccaaatg aattctattt tactgtctca cctgactcag acccatataa agccacatcc
19201 gcagtagtta tcacttccac ctcgggggac tcaatagttt ccacatcaat gcctagatcc
19261 tctgcgatga aaaagattga gtctgagaca actttctccc tgatatttag actgagggag
19321 actagcacct cccagaaaat tggctcatcc tcagacacaa gcacggtctt tgacaaagca
19381 ttcactgctg ctactactga ggtctccaga acagaactca cctcctctag cagaacatcc
19441 atccaaggca ctgaaaagcc cacaatgtca ccggacacct ccacaagatc tgtcaccatg
19501 ctttctactt ttgctggcct gacaaaatcc gaagaaagga ccattgccac ccaaacaggt
19561 cctcataggg cgacatcaca gggtaccctt acctgggaca catcaatcac aacctcacag
19621 gcagggaccc actcagctat gactcatgga ttttcacaat tagatttgtc cactcttacg
19681 agtagagttc ctgagtacat atcagggaca agcccaccct ctgtggaaaa aaccagctct
19741 tcctcttccc ttctgtcttt accagcaata acctcaccgt cccctgtacc tactacatta
19801 ccagaaagta ggccgtcttc tcctgttcat ctgacttcac tccccacctc tggcctagtg
19861 aagaccacag atatgctggc atctgtggcc agtttacctc caaacttggg cagcacctca
19921 cataagatac cgactacttc agaagacatt aaagatacag agaaaatgta tccttccaca
19981 aacatagcag taaccaatgt ggggaccacc acttctgaaa aggaatctta ttcgtctgtc
20041 ccagcctact cagaaccacc caaagtcacc tctccaatgg ttacctcttt caacataagg
20101 gacaccattg tttccacatc catgcctggc tcctctgaga ttacaaggat tgagatggag
20161 tcaacattct ccgtggctca tgggctgaag ggaaccagca cctcccagga ccccatcgta
20221 tccacagaga aaagtgctgt ccttcacaag ttgaccactg gtgctactga gacctctagg
20281 acagaagttg cctcttctag aagaacatcc attccaggcc ctgatcattc cacagagtca
20341 ccagacatct ccactgaagt gatccccagc ctgcctatct cccttggcat tacagaatct
20401 tcaaatatga ccatcatcac tcgaacaggt cctcctcttg gctctacatc acagggcaca
20461 tttaccttgg acacaccaac tacatcctcc agggcaggaa cacactcgat ggcgactcag
20521 gaatttccac actcagaaat gaccactgtc atgaacaagg accctgagat tctatcatgg
20581 acaatccctc cttctataga gaaaaccagc ttctcctctt ccctgatgcc ttcaccagcc
20641 atgacttcac ctcctgtttc ctcaacatta ccaaagacca ttcacaccac tccttctcct
20701 atgacctcac tgctcacccc tagcctagtg atgaccacag acacattggg cacaagccca
20761 gaacctacaa ccagttcacc tccaaatttg agcagtacct cacatgtgat actgacaaca
20821 gatgaagaca ccacagctat agaagccatg catccttcca caagcacagc agcgactaat

```
20881 gtggaaacca cctgttctgg acatgggtca caatcctctg tcctaactga ctcagaaaaa
20941 accaaggcca cagctccaat ggataccacc tccaccatgg ggcatacaac tgtttccaca
21001 tcaatgtctg tttcctctga gactacaaaa attaagagag agtcaacata ttccttgact
21061 cctggactga gagagaccag catttcccaa aatgccagct tttccactga cacaagtatt
21121 gttctttcag aagtccccac tggtactact gctgaggtct ccaggacaga agtcacctcc
21181 tctggtagaa catccatccc tggcccttct cagtccacag ttttgccaga aatatccaca
21241 agaacaatga caaggctctt tgcctcgccc accatgacag aatcagcaga aatgaccatc
21301 cccactcaaa caggtccttc tgggtctacc tcacaggata cccttacctt ggacacatcc
21361 accacaaagt cccaggcaaa gactcattca actttgactc agagatttcc acactcagag
21421 atgaccactc tcatgagcag aggtcctgga gatatgtcat ggcaaagctc tccctctctg
21481 gaaaatccca gctctctccc ttccctgctg tctttacctg ccacaacctc acctcctccc
21541 atttcctcca cattaccagt gactatctcc tcctctcctc ttcctgtgac ttcacttctc
21601 acctctagcc cggtaacgac cacagacatg ttacacacaa gcccagaact tgtaaccagt
21661 tcacctccaa agctgagcca cacttcagat gagagactga ccactggcaa ggacaccaca
21721 aatacagaag ctgtgcatcc ttccacaaac acagcagcgt ccaatgtgga gattcccagc
21781 tttggacatg aatccccttc ctctgcctta gctgactcag agacatccaa agccacatca
21841 ccaatgttta ttacctccac ccaggaggat acaactgttg ccatatcaac ccctcacttc
21901 ttggagacta gcagaattca gaaagagtca atttcctccc tgagccctaa attgagggag
21961 acaggcagtt ctgtggagac aagctcagcc atagagacaa gtgctgtcct ttctgaagtg
22021 tccattggtg ctactactga gatctccagg acagaagtca cctcctctag cagaacatcc
22081 atctctggtt ctgctgagtc cacaatgttg ccagaaatat ccaccacaag aaaaatcatt
22141 aagttcccta cttcccccat cctggcagaa tcatcagaaa tgaccatcaa gacccaaaca
22201 agtcctcctg ggtctacatc agagagtacc tttacattag acacatcaac cactccctcc
22261 ttggtaataa cccattcgac tatgactcag agattgccac actcagagat aaccactctt
22321 gtgagtagag gtgctgggga tgtgccacgg cccagctctc tccctgtgga agaaacaagc
22381 cctccatctt cccagctgtc tttatctgcc atgatctcac cttctcctgt ttcttccaca
22441 ttaccagcaa gtagccactc ctctttctgct tctgtgactt cacctctcac accaggccaa
22501 gtgaagacta ctgaggtgtt ggacgcaagt gcagaacctg aaaccagttc acctccaagt
22561 ttgagcagca cctcagttga aatactggcc acctctgaag tcaccacaga tacggagaaa
22621 attcatcctt tcccaaacac ggcagtaacc aaagttggaa cttccagttc tggacatgaa
22681 tcccccttcct ctgtcctacc tgactcagag acaaccaaag ccacatcggc aatgggtacc
22741 atctccatta tgggggatac aagtgtttct acattaactc ctgccttatc taacactagg
22801 aaaattcagt cagagccagc ttcctcactg accaccagat tgagggagac cagcacctct
22861 gaagagacca gcttagccac agaagcaaac actgttcttt ctaaagtgtc cactggtgct
22921 actactgagg tctccaggac agaagccatc tcctttagca gaacatccat gtcaggccct
22981 gagcagtcca caatgtcaca agacatctcc ataggaacca tccccaggat ttctgcctcc
23041 tctgtcctga cagaatctgc aaaaatgacc atcacaaccc aaacaggtcc ttcggagtct
23101 acactagaaa gtacccttaa tttgaacaca gcaaccacac cctcttgggt ggaaacccac
23161 tctatagtaa ttcagggatt tccacaccca gagatgacca cttccatggg cagaggtcct
23221 ggaggtgtgt catggcctag ccctcccttt gtgaaagaaa ccagccctcc atcctccccg
23281 ctgtctttac ctgccgtgac ctcacctcat cctgtttcca ccacattcct agcacatatc
23341 ccccctctc ccttcctgt gacttcactt ctcacctctg gcccggcgac aaccacagat
23401 atcttgggta caagcacaga acctggaacc agttcatctt caagtttgag caccacctcc
23461 catgagagac tgaccactta caaagacact gcacatacag aagccgtgca tccttccaca
23521 aacacaggag ggaccaatgt ggcaaccacc agctctggat ataaatcaca gtcctctgtc
23581 ctagctgact catctccaat gtgtaccacc tccaccatgg gggatacaag tgttctcaca
23641 tcaactcctg ccttccttga gactaggagg attcagacag agctagcttc ctccctgacc
23701 cctggattga gggagtccag tggctctgaa gggaccagct caggcaccaa gatgagcact
23761 gtcctctcta aagtgcccac tggtgctact actgagatct ccaaggaaga cgtcacctcc
23821 atcccaggtc ccgctcaatc cacaatatca ccagacatct ccacaagaac cgtcagctgg
23881 ttctctacat cccctgtcat gacagaatca gcagaaataa ccatgaacac ccatacaagt
23941 cctttagggg ccacaacaca aggcaccagt actttggcca cgtcaagcac aacctctttg
24001 acaatgacac actcaactat atctcaagga ttttcacact cacagatgag cactcttatg
24061 aggaggggtc ctgaggatgt atcatggatg agccctcccc ttctggaaaa aactagacct
24121 tccttttctc tgatgtcttc accagccaca acttcacctt ctcctgtttc ctccacatta
24181 ccagagagca tctcttcctc tcctcttcct gtgacttcac tcctcacgtc tggcttggca
24241 aaaactacag atatgttgca caaaagctca gaacctgtaa ccaactcacc tgcaaatttg
24301 agcagcacct cagttgaaat actggccacc tctgaagtca ccacagatac agagaaaact
24361 catccttctt caaacagaac agtgaccgat gtggggacct ccagttctgg acatgaatcc
24421 acttcctttg tcctagctga ctcacagaca tccaaagtca catctccaat ggttattacc
24481 tccaccatgg aggatacgag tgtctccaca tcaactcctg gcttttttga gactagcaga
```

```
24541 attcagacag aaccaacatc ctccctgacc cttggactga gaaagaccag cagctctgag
24601 gggaccagct tagccacaga gatgagcact gtcctttctg gagtgcccac tggtgccact
24661 gctgaagtct ccaggacaga agtcacctcc tctagcagaa catccatctc aggctttgct
24721 cagctcacag tgtcaccaga gacttccaca gaaaccatca ccagactccc tacctccagc
24781 ataatgacag aatcagcaga aatgatgatc aagacacaaa cagatcctcc tgggtctaca
24841 ccagagagta ctcatactgt ggacatatca acaacaccca actgggtaga aacccactcg
24901 actgtgactc agagattttc acactcagag atgaccactc ttgtgagcag aagccctggt
24961 gatatgttat ggcctagtca atcctctgtg gaagaaacca gctctgcctc ttccctgctg
25021 tctctgcctg ccacgacctc accttctcct gtttcctcta cattagtaga ggatttccct
25081 tccgcttctc ttcctgtgac ttctcttctc acccctggcc tggtgataac cacagacagg
25141 atgggcataa gcagagaacc tggaaccagt tccacttcaa atttgagcag cacctcccat
25201 gagagactga ccactttgga agacactgta gatacagaag acatgcagcc ttccacacac
25261 acagcagtga ccaacgtgag gacctccatt tctggacatg aatcacaatc ttctgtccta
25321 tctgactcag agacacccaa agccacatct ccaatgggta ccacctacac catgggggaa
25381 acgagtgttt ccatatccac ttctgacttc tttgagacca gcagaattca gatagaacca
25441 acatcctccc tgacttctgg attgagggag accagcagct ctgagaggat cagctcagcc
25501 acagagggaa gcactgtcct ttctgaagtg cccagtggtg ctaccactga ggtctccagg
25561 acagaagtga tatcctctag gggaacatcc atgtcagggc ctgatcagtt caccatatca
25621 ccagacatct ctactgaagc gatcaccagg ctttctactt cccccattat gacagaatca
25681 gcagaaagtg ccatcactat tgagacaggt tctcctgggg ctacatcaga gggtaccctc
25741 accttggaca cctcaacaac aacctttggg tcagggaccc actcaactgc atctccagga
25801 ttttcacact cagagatgac cactcttatg agtagaactc ctggagatgt gccatggccg
25861 agccttccct ctgtggaaga agccagctct gtctcttcct cactgtcttc acctgccatg
25921 acctcaactt ctttttttctc cgcattacca gagagcatct cctcctctcc tcatcctgtg
25981 actgcacttc tcacccttgg cccagtgaag accacagaca tgttgcgcac aagctcagaa
26041 cctgaaacca gttcacctcc aaatttgagc agcacctcag ctgaaatatt agccacgtct
26101 gaagtcacca aagatagaga gaaaattcat ccctcctcaa acacacctgt agtcaatgta
26161 gggactgtga tttataaaca tctatcccct tcctctgttt tggctgactt agtgacaaca
26221 aaacccacat ctccaatggc taccacctcc actctgggga atacaagtgt ttccacatca
26281 actcctgcct tcccagaaac tatgatgaca cagccaactt cctccctgac ttctggatta
26341 agggagatca gtacctctca agagaccagc tcagcaacag agagaagtgc ttctctttct
26401 ggaatgccca ctggtgctac tactaaggtc tccagaacag aagccctctc cttaggcaga
26461 acatccaccc caggtcctgc tcaatccaca atatcaccag aaatctccac ggaaaccatc
26521 actagaattt ctactccccc caccacgaca ggatcagcag aaatgaccat caccccaaa
26581 acaggtcatt ctggggcatc ctcacaaggt acctttacct tggacacatc aagcagagcc
26641 tcctggccag gaactcactc agctgcaact cacagatctc cacactcagg gatgaccact
26701 cctatgagca gaggtcctga ggatgtgtca tggccaagcc gcccatcagt ggaaaaaact
26761 agccctccat cttccctggt gtctttatct gcagtaacct caccttcgcc actttattcc
26821 acaccatctg agagtagcca ctcatctcct ctccgggtga cttctctttt caccctgtc
26881 atgatgaaga ccacagacat gttggacaca agcttggaac ctgtgaccac ttcacctccc
26941 agtatgaata tcacctcaga tgagagtctg gccacttcta aagccaccat ggagacagag
27001 gcaattcagc tttcagaaaa cacagctgtg actcagatgg gcaccatcag cgctagacaa
27061 gaattctatt cctcttatcc aggcctccca gagccatcca aagtgacatc tccagtggtc
27121 acctcttcca ccataaaaga cattgtttct acaaccatac ctgcttcctc tgagataaca
27181 agaattgaga tggagtcaac atccaccctg acccccacac caagggagac cagcacctcc
27241 caggagatcc actcagccac aaagccaagc actgttcctt acaaggcact cactagtgcc
27301 acgattgagg actccatgac acaagtcatg tcctctagca gaggacctag ccctgatcag
27361 tccacaatgt cacaagacat atccagtgaa gtgatcacca ggctctctac ctcccccatc
27421 aaggcagaat ctacagaaat gaccattacc acccaaacag gttctcctgg ggctacatca
27481 aggggtaccc ttaccttgga cacttcaaca actttatgt cagggaccca ctcaactgca
27541 tctcaaggat tttcacactc acagatgacc gctcttatga gtagaactcc tggagatgtg
27601 ccatggctaa gccatccctc tgtggaagaa gccagctctg cctctttctc actgtcttca
27661 cctgtcatga cctcatcttc tcccgtttct tccacattac cagacagcat ccactcttct
27721 tcgcttcctg tgacatcact tctcacctca gggctggtga agaccacaga gctgttgggc
27781 acaagctcag aacctgaaac cagttcaccc ccaaatttga gcagcacctc agctgaaata
27841 ctggccacca ctgaagtcac tacagataca gagaaactgg agatgaccaa tgtggtaacc
27901 tcaggttata cacatgaatc tccttcctct gtcctagctg actcagtgac aacaaaggcc
27961 acatcttcaa tgggtatcac ctaccccaca ggagatacaa atgttctcac atcaacccct
28021 gccttctctg acaccagtag gattcaaaca aagtcaaagc tctcactgac tcctgggttg
28081 atggagacca gcatctctga agagaccagc tctgccacag aaaaaagcac tgtcctttct
28141 agtgtgccca ctggtgctac tactgaggtc tccaggacag aagccatctc ttctagcaga
```

```
28201 acatccatcc caggccctgc tcaatccaca atgtcatcag acacctccat ggaaaccatc
28261 actagaattt ctacccccct cacaaggaaa gaatcaacag acatggccat caccccaaa
28321 acaggtcctt ctggggctac ctcgcagggt acctttacct tggactcatc aagcacagcc
28381 tcctggccag gaactcactc agctacaact cagagatttc cacagtcagt ggtgacaact
28441 cctatgagca gaggtcctga ggatgtgtca tggccaagcc cgctgtctgt ggaaaaaaac
28501 agccctccat cttccctggt atcttcatct tcagtaacct caccttcgcc actttattcc
28561 acaccatctg ggagtagcca ctcctctcct gtccctgtca cttctctttt cacctctatc
28621 atgatgaagg ccacagacat gttggatgca agtttggaac ctgagaccac ttcagctccc
28681 aatatgaata tcacctcaga tgagagtctg gccacttcta aagccaccac ggagacagag
28741 gcaattcacg tttttgaaaa tacagcagcg tcccatgtgg aaaccaccag tgctacagag
28801 gaactctatt cctcttcccc aggcttctca gagccaacaa aagtgatatc tccagtggtc
28861 acctcttcct ctataagaga caacatggtt tccacaacaa tgcctggctc ctctggcatt
28921 acaaggattg agatagagtc aatgtcatct ctgacccctg gactgaggga gaccagaacc
28981 tcccaggaca tcacctcatc cacagagaca agcactgtcc tttacaagat gtcctctggt
29041 gccactcctg aggtctccag gacagaagtt atgccctcta gcagaacatc cattcctggc
29101 cctgctcagt ccacaatgtc actagacatc tccgatgaag ttgtcaccag gctgtctacc
29161 tctcccatca tgacagaatc tgcagaaata accatcacca cccaaacagg ttattctctg
29221 gctacatccc aggttaccct tcccttgggc acctcaatga ccttttttgtc agggacccac
29281 tcaactatgt ctcaaggact ttcacactca gagatgacca atcttatgag caggggtcct
29341 gaaagtctgt catggacgag ccctcgcttt gtggaaacaa ctagatcttc ctcttctctg
29401 acatcattac ctctcacgac ctcactttct cctgtgtcct ccacattact agacagtagc
29461 ccctcctctc ctcttcctgt gacttcactt atcctcccag gcctggtgaa gactacagaa
29521 gtgttggata caagctcaga gcctaaaacc agttcatctc caaatttgag cagcacctca
29581 gttgaaatac cggccacctc tgaaatcatg acagatacag agaaaattca tccttcctca
29641 aacacagcgg tggccaaagt gaggacctcc agttctgttc atgaatctca ttcctctgtc
29701 ctagctgact cagaaacaac cataaccata ccttcaatgg gtatcacctc cgctgtggac
29761 gataccactg ttttcacatc aaatcctgcc ttctctgaga ctaggaggat tccgacagag
29821 ccaacattct cattgactcc tggattcagg gagactagca cctctgaaga gaccacctca
29881 atcacagaaa caagtgcagt cctttatgga gtgcccacta gtgctactac tgaagtctcc
29941 atgacagaaa tcatgtcctc taatagaaca cacatccctg actctgatca gtccacgatg
30001 tctccagaca tcatcactga agtgatcacc aggctctctt cctcatccat gatgtcagaa
30061 tcaacacaaa tgaccatcac cacccaaaaa agttctcctg gggctacagc acagagtact
30121 cttaccttgg ccacaacaac agccccctg gcaaggaccc actcaactgt tcctcctaga
30181 tttttacact cagagatgac aactcttatg agtaggagtc ctgaaaatcc atcatggaag
30241 agctctccct ttgtggaaaa aactagctct tcatcttctc tgttgtcctt acctgtcacg
30301 acctcacctt ctgtttcttc cacattaccg cagagtatcc cttcctcctc tttttctgtg
30361 acttcactcc tcaccccagg catggtgaag actacagaca caagcacaga acctggaacc
30421 agtttatctc caaatctgag tggcacctca gttgaaatac tggctgcctc tgaagtcacc
30481 acagatacag agaaaattca tccttcttca agcatggcag tgaccaatgt gggaaccacc
30541 agttctggac atgaactata ttcctctgtt tcaatccact cggagccatc caaggctaca
30601 tacccagtgg gtactccctc ttccatggct gaaacctcta tttccacatc aatgcctgct
30661 aattttgaga ccacaggatt tgaggctgag ccatttttctc atttgacttc tggatttagg
30721 aagacaaaca tgtccctgga caccagctca gtcacaccaa caaatacacc ttcttctcct
30781 gggtccactc acctttttaca gagttccaag actgatttca cctcttctgc aaaaacatca
30841 tccccagact ggcctccagc ctcacagtat actgaaattc cagtggacat aatcacccc
30901 tttaatgctt ctccatctat tacggagtcc actgggataa cctccttccc agaatccagg
30961 tttactatgt ctgtaacaga aagtactcat catctgagta cagatttgct gccttcagct
31021 gagactattt ccactggcac agtgatgcct tctctatcag aggccatgac ttcatttgcc
31081 accactggag ttccacgagc catctcaggt tcaggtagtc cattctctag gacagagtca
31141 ggccctgggg atgctactct gtccaccatt gcagagagcc tgccttcatc cactcctgtg
31201 ccattctcct cttcaacctt cactaccact gattcttcaa gcatcccagc cctccatgag
31261 ataacttcct cttcagctac cccatataga gtggacacca gtcttgggac agagagcagc
31321 actactgaag gacgcttggt tatggtcagt actttggaca cttcaagcca accaggcagg
31381 acatcttcaa cacccatttt ggataccaga atgacagaga gcgttgagct gggaacagtg
31441 acaagtgctt atcaagttcc ttcactctca acacggttga caagaactga tggcattatg
31501 gaacacatca caaaaatacc caatgaagca gcacacagag gtaccataag accagtcaaa
31561 ggccctcaga catccacttc gcctgccagt cctaaaggac tacacacagg agggacaaaa
31621 agaatggaga ccaccaccac agctttgaag accaccacca cagctttgaa gaccacttcc
31681 agagccacct tgaccaccag tgtctatact cccactttgg gaacactgac tcccctcaat
31741 gcatcaaggc aaatggccag cacaatcctc acagaaatga tgatcacaac cccatatgtt
31801 ttccctgatg ttccagaaac gacatcctca ttggctacca gcctgggagc agaaaccagc
```

```
31861 acagctcttc ccaggacaac cccatctgtt ctcaatagag aatcagagac cacagcctca
31921 ctggtctctc gttctggggc agagagaagt ccggttattc aaactctaga tgtttcttct
31981 agtgagccag atacaacagc ttcatgggtt atccatcctg cagagaccat cccaactgtt
32041 tccaagacaa cccccaattt tttccacagt gaattagaca ctgtatcttc cacagccacc
32101 agtcatgggg cagacgtcag ctcagccatt ccaacaaata tctcacctag tgaactagat
32161 gcactgaccc cactggtcac tatttcgggg acagatacta gtacaacatt cccaacactg
32221 actaagtccc cacatgaaac agagacaaga accacatggc tcactcatcc tgcagagacc
32281 agctcaacta ttcccagaac aatccccaat ttttctcatc atgaatcaga tgccacacct
32341 tcaatagcca ccagtcctgg ggcagaaacc agttcagcta ttccaattat gactgtctca
32401 cctggtgcag aagatctggt gacctcacag gtcactagtt ctgggacaga cagaaatatg
32461 actattccaa ctttgactct ttctcctggt gaaccaaaga cgatagcctc attagtcacc
32521 catcctgaag cacagacaag ttcggccatt ccaacttcaa ctatctcgcc tgctgtatca
32581 cggttggtga cctcaatggt caccagtttg gcggcaaaga caagtacaac taatcgagct
32641 ctgacaaact cccctggtga accagctaca acagtttcat tggtcacgca tcctgcacag
32701 accagcccaa cagttccctg gacaacttcc attttttttcc atagtaaatc agacaccaca
32761 ccttcaatga ccaccagtca tggggcagaa tccagttcag ctgttccaac tccaactgtt
32821 tcaactgagg taccaggagt agtgacccct ttggtcacca gttctagggc agtgatcagt
32881 acaactattc caattctgac tctttctcct ggtgaaccag agaccacacc ttcaatggcc
32941 accagtcatg gggaagaagc cagttctgct attccaactc caactgtttc acctggggta
33001 ccaggagtgg tgacctctct ggtcactagt tctagggcag tgactagtac aactattcca
33061 attctgactt tttctcttgg tgaaccagag accacacctt caatggccac cagtcatggg
33121 acagaagctg gctcagctgt tccaactgtt ttacctgagg taccaggaat ggtgacctct
33181 ctggttgcta gttctagggc agtaaccagt acaactcttc caactctgac tctttctcct
33241 ggtgaaccag agaccacacc ttcaatggcc accagtcatg gggcagaagc cagctcaact
33301 gttccaactg tttcacctga ggtaccagga gtggtgacct ctctggtcac tagttctagt
33361 ggagtaaaca gtacaagtat tccaactctg attctttctc ctggtgaact agaaaccaca
33421 ccttcaatgg ccaccagtca tggggcagaa gccagctcag ctgttccaac tccaactgtt
33481 tcacctgggg tatcaggagt ggtgacccct ctggtcacta gttccagggc agtgaccagt
33541 acaactattc caattctaac tctttcttct agtgagccag agaccacacc ttcaatggcc
33601 accagtcatg gggtagaagc cagctcagct gttctaactg tttcacctga ggtaccagga
33661 atggtgacct ctctggtcac tagttctaga gcagtaacca gtacaactat tccaactctg
33721 actatttctt ctgatgaacc agagaccaca acttcattgg tcacccattc tgaggcaaag
33781 atgatttcag ccattccaac tttagctgtc tcccctactg tacaagggct ggtgacttca
33841 ctggtcacta gttctgggtc agagaccagt gcgttttcaa atctaactgt tgcctcaagt
33901 caaccagaga ccatagactc atgggtcgct catcctggga cagaagcaag ttctgttgtt
33961 ccaactttga ctgtctccac tggtgagccg tttacaaata tctcattggt cacccatcct
34021 gcagagagta gctcaactct tcccaggaca acctcaaggt tttcccacag tgaattagac
34081 actatgcctt ctacagtcac cagtcctgag gcagaatcca gctcagccat ttcaactact
34141 atttcacctg gtataccagg tgtgctgaca tcactggtca ctagctctgg gagagacatc
34201 agtgcaactt ttccaacagt gcctgagtcc ccacatgaat cagaggcaac agcctcatgg
34261 gttactcatc ctgcagtcac cagcacaaca gttcccagga caacccctaa ttattctcat
34321 agtgaaccag acaccacacc atcaatagcc accagtcctg gggcagaagc cacttcagat
34381 tttccaacaa taactgtctc acctgatgta ccagatatgg taacctcaca ggtcactagt
34441 tctgggacag acaccagtat aactattcca actctgactc tttcttctgg tgagccagag
34501 accacaacct catttatcac ctattctgag acacacacaa gttcagccat tccaactctc
34561 cctgtctccc ctggtgcatc aaagatgctg acctcactgg tcatcagttc tgggacagac
34621 agcactacaa ctttcccaac actgacggag accccatatg aaccagagac aacagccata
34681 cagctcattc atcctgcaga gaccaacaca atggttccca agacaactcc caagttttcc
34741 catagtaagt cagacaccac actcccagta gccatcacca gtcctgggcc agaagccagt
34801 tcagctgttt caacgacaac tatctcacct gatatgtcag atctggtgac ctcactggtc
34861 cctagttctg ggacagacac cagtacaacc ttcccaacat tgagtgagac cccatatgaa
34921 ccagagacta cagtcacgtg gctcactcat cctgcagaaa ccagcacaac ggtttctggg
34981 acaattccca acttttccca taggggatca gacactgcac cctcaatggt caccagtcct
35041 ggagtagaca cgaggtcagg tgttccaact acaaccatcc cacccagtat accaggggta
35101 gtgacctcac aggtcactag ttctgcaaca gacactagta cagctattcc aactttgact
35161 ccttctcctg gtgaaccaga gaccacagcc tcatcagcta cccatcctgg gacacagact
35221 ggcttcactg ttccaattcg gactgttccc tctagtgagc cagatacaat ggcttcctgg
35281 gtcactcatc ctccacagac cagcacacct gtttccagaa caacctccag tttttcccat
35341 agtagtccag atgccacacc tgtaatggcc accagtccta ggacagaagc cagttcagct
35401 gtactgacaa caatctcacc tggtgcacca gagatggtga cttcacagat cactagttct
35461 ggggcagcaa ccagtacaac tgttccaact ttgactcatt ctcctggtat gccagagacc
```

35521 acagccttat tgagcaccca tcccagaaca gggacaagta aaacatttcc tgcttcaact
35581 gtgtttcctc aagtatcaga gaccacagcc tcactcacca ttagacctgg tgcagagact
35641 agcacagctc tcccaactca gacaacatcc tctctcttca ccctacttgt aactggaacc
35701 agcagagttg atctaagtcc aactgcttca cctggtgttt ctgcaaaaac agccccactt
35761 tccacccatc cagggacaga gaccagcaca atgattccaa cttcaactct ttcccttggt
35821 ttactagaga ctacaggctt actggccacc agctcttcag cagagaccag cacgagtact
35881 ctaactctga ctgtttcccc tgctgtctct gggctttcca gtgcctctat aacaactgat
35941 aagccccaaa ctgtgacctc ctggaacaca gaaacctcac catctgtaac ttcagttgga
36001 cccccagaat tttccaggac tgtcacaggc accactatga ccttgatacc atcagagatg
36061 ccaacaccac ctaaaaccag tcatggagaa ggagtgagtc caaccactat cttgagaact
36121 acaatggttg aagccactaa tttagctacc acaggttcca gtcccactgt ggccaagaca
36181 acaaccacct tcaatacact ggctggaagc ctctttactc ctctgaccac acctgggatg
36241 tccaccttgg cctctgagag tgtgacctca agaacaagtt ataaccatcg gtcctggatc
36301 tccaccacca gcagttataa ccgtcggtac tggacccctg ccaccagcac tccagtgact
36361 tctacattct ccccagggat ttccacatcc tccatcccca gctccacagc agccacagtc
36421 ccattcatgg tgccattcac cctcaacttc accatcacca acctgcagta cgaggaggac
36481 atgcggcacc ctggttccag gaagttcaac gccacagaga gagaactgca gggtctgctc
36541 aaacccttgt tcaggaatag cagtctggaa tacctctatt caggctgcag actagcctca
36601 ctcaggccag agaaggatag ctcagccatg gcagtggatg ccatctgcac acatcgccct
36661 gaccctgaag acctcggact ggacagagag cgactgtact gggagctgag caatctgaca
36721 aatggcatcc aggagctggg cccctacacc ctggaccgga acagtctcta tgtcaatggt
36781 ttcacccatc gaagctctat gcccaccacc agcactcctg ggacctccac agtggatgtg
36841 ggaacctcag ggactccatc ctccagcccc agccccacgg ctgctggccc tctcctgatg
36901 ccgttcaccc tcaacttcac catcaccaac ctgcagtacg aggaggacat gcgtcgcact
36961 ggctccagga agttcaacac catggagagt gtcctgcagg gtctgctcaa gcccttgttc
37021 aagaacacca gtgttggccc tctgtactct ggctgcagat tgaccttgct caggcccgag
37081 aaagatgggg cagccactgg agtggatgcc atctgcaccc accgccttga ccccaaaagc
37141 cctggactca acagggagca gctgtactgg gagctaagca aactgaccaa tgacattgaa
37201 gagctgggcc cctacaccct ggacaggaac agtctctatg tcaatggttt cacccatcag
37261 agctctgtgt ccaccaccag cactcctggg acctccacag tggatctcag aacctcaggg
37321 actccatcct ccctctccag ccccacaatt atggctgctg gccctctcct ggtaccattc
37381 accctcaact tcaccatcac caacctgcag tatggggagg acatgggtca ccctggctcc
37441 aggaagttca acaccacaga gagggtcctg cagggtctgc ttggtcccat attcaagaac
37501 accagtgttg gccctctgta ctctggctgc agactgacct ctctcaggtc tgagaaggat
37561 ggagcagcca ctggagtgga tgccatctgc atccatcatc ttgaccccaa aagccctgga
37621 ctcaacagag agcggctgta ctgggagctg agccaactga ccaatggcat caaagagctg
37681 ggcccctaca ccctggacag gaacagtctc tatgtcaatg gtttcaccca tcggacctct
37741 gtgcccacca ccagcactcc tgggacctcc acagtggacc ttggaacctc agggactcca
37801 ttctccctcc caagccccgc aactgctggc cctctcctgg tgctgttcac cctcaacttc
37861 accatcacca acctgaagta tgaggaggac atgcatcgcc ctggctccag gaagttcaac
37921 accactgaga gggtcctgca gactctgctt ggtcctatgt tcaagaacac cagtgttggc
37981 cttctgtact ctggctgcag actgaccttg ctcaggtccg agaaggatgg agcagccact
38041 ggagtggatg ccatctgcac ccaccgtctt gaccccaaaa gccctggact ggacagagag
38101 cagctatact gggagctgag ccagctgacc aatggcatca aagagctggg cccctacacc
38161 ctggacagga acagtctcta tgtcaatggt ttcacccatt ggatccctgt gcccaccagc
38221 agcactcctg ggacctccac agtggacctt gggtcaggga ctccatcctc cctccccagc
38281 cccacagctg ctggccctct cctggtgcca ttcaccctca acttcaccat caccaacctg
38341 cagtacgagg aggacatgca tcacccaggc tccaggaagt tcaacaccac ggagcgggtc
38401 ctgcagggtc tgcttggtcc catgttcaag aacaccagtg tcggccttct gtactctggc
38461 tgcagactga ccttgctcag gtccgagaag gatggagcag ccactggagt ggatgccatc
38521 tgcacccacc gtcttgaccc caaaagccct ggagtggaca gggagcagct atactgggag
38581 ctgagccagc tgaccaatgg catcaaagag ctgggtccct acaccctgga cagaaacagt
38641 ctctatgtca atggtttcac ccatcagacc tctgcgccca acaccagcac tcctgggacc
38701 tccacagtgg accttgggac ctcagggact ccatcctccc tccccagccc tacatcngct
38761 ggccctctcc tggtnccntt caccctcaac ttcaccatca ccaacctgca gtacgaggag
38821 gacatgcggc acccnggntc caggaagttc aacaccacng agagggtnct gcagggtctg
38881 ctnaagcccc tnttcaagag caccagtgtt ggccctctgt actctggctg cagactgacc
38941 ttgctcaggt ccgagaagga tggagcagcc actggagtgg atgccatctg cacccaccgt
39001 cttgacccca aaagccctgg agtggacagg gagcagctat actgggagct gagccagctg
39061 accaatggca tcaaagagct gggtccctac accctggaca gaaacagtct ctatgtcaat
39121 ggtttcaccc atcagacctc tgcgcccaac accagcactc ctgggacctc cacagtggac

39181 cttgggacct cagggactcc atcctccctc cccagcccta catctgctgg ccctctcctg
39241 gtgccattca ccctcaactt caccatcacc aacctgcagt acgaggagga catgcatcac
39301 ccaggctcca ggaagttcaa caccacggag cgggtcctgc agggtctgct tggtcccatg
39361 ttcaagaaca ccagtgtcgg ccttctgtac tctggctgca gactgacctt gctcaggcct
39421 gagaagaatg gggcagccac tggaatggat gccatctgca gccaccgtct tgaccccaaa
39481 agccctggac tcaacagaga gcagctgtac tgggagctga gccagctgac ccatggcatc
39541 aaagagctgg gcccctacac cctggacagg aacagtctct atgtcaatgg tttcacccat
39601 cggagctctg tggcccccac cagcactcct gggacctcca cagtggacct tgggacctca
39661 gggactccat cctccctccc cagccccaca acagctgttc ctctcctggt gccgttcacc
39721 ctcaacttta ccatcaccaa tctgcagtat ggggaggaca tgcgtcaccc tggctccagg
39781 aagttcaaca ccacagagag ggtcctgcag ggtctgcttg gtcccttgtt caagaactcc
39841 agtgtcggcc ctctgtactc tggctgcaga ctgatctctc tcaggtctga gaaggatggg
39901 gcagccactg gagtggatgc catctgcacc caccacctta accctcaaag ccctggactg
39961 gacagggagc agctgtactg gcagctgagc cagatgacca atggcatcaa agagctgggc
40021 ccctacaccc tggaccggaa cagtctctac gtcaatggtt tcacccatcg gagctctggg
40081 ctcaccacca gcactccttg gacttccaca gttgaccttg gaacctcagg gactccatcc
40141 cccgtcccca gccccacaac tgctggccct ctcctggtgc cattcaccct caacttcacc
40201 atcaccaacc tgcagtatga ggaggacatg catcgccctg gatctaggaa gttcaacacc
40261 acagagaggg tcctgcaggg tctgcttagt cccattttca agaactccag tgttggccct
40321 ctgtactctg gctgcagact gacctctctc aggcccgaga aggatggggc agcaactgga
40381 atggatgctg tctgcctcta ccaccctaat cccaaaagac ctggactgga cagagagcag
40441 ctgtactggg agctaagcca gctgacccac aacatcactg agctgggccc ctacagcctg
40501 gacagggaca gtctctatgt caatggtttc acccatcaga actctgtgcc caccaccagt
40561 actcctggga cctccacagt gtactgggca accactggga ctccatcctc cttccccggc
40621 cacacagagc ctggccctct cctgatacca ttcactttca actttaccat caccaacctg
40681 cattatgagg aaaacatgca acaccctggt tccaggaagt tcaacaccac ggagagggtt
40741 ctgcagggtc tgctcaagcc cttgttcaag aacaccagtg ttggccctct gtactctggc
40801 tgcagactga cctctctcag gcccgagaag gatggggcag caactggaat ggatgctgtc
40861 tgcctctacc accctaatcc caaaagacct gggctggaca gagagcagct gtactgggag
40921 ctaagccagc tgacccacaa catcactgag ctgggccct acagcctgga cagggacagt
40981 ctctatgtca atggtttcac ccatcagaac tctgtgccca ccaccagtac tcctgggacc
41041 tccacagtgt actgggcaac cactgggact ccatcctcct tccccggcca cacagagcct
41101 ggccctctcc tgataccatt cactttcaac tttaccatca ccaacctgca ttatgaggaa
41161 aacatgcaac accctggttc caggaagttc aacaccacgg agagggttct gcagggtctg
41221 ctcaagccct tgttcaagaa caccagtgtt ggccctctgt actctggctg cagactgacc
41281 ttgctcagac ctgagaagca tgaggcagcc actggagtgg acaccatctg tacccaccgc
41341 gttgatccca tcggacctgg actggacagg gagcggctat actgggagct gagccagctg
41401 accaacagca ttaccgaact gggaccctac accctggaca gggacagtct ctatgtcaat
41461 ggcttcaacc ctcggagctc tgtgccaacc accagcactc ctgggacctc cacagtgcac
41521 ctggcaacct ctgggactcc atcctccctg cctggccaca cagcccctgt ccctctcttg
41581 ataccattca ccctcaactt taccatcacc aacctgcatt atgaggaaaa catgcaacac
41641 cctggttcca ggaagttcaa caccacggag agggttctgc agggtctgct caagcccttg
41701 ttcaagaaca ccagtgttgg ccctctgtac tctggctgca gactgacctt gctcagacct
41761 gagaagcatg aggcagccac tggagtggac accatctgta cccaccgcgt tgatcccatc
41821 ggacctggac tgnacagnga gcngctntac tgggagctna gccanctgac caannncatc
41881 nnngagctgg gncctacac cctggacagg nacagtctct atgtcaatgg tttcacccat
41941 cnganctctg ngcccaccac cagcactcct gggacctcca cagtgnacnt nggnacctcn
42001 gggactccat cctccntccc cngccncaca tctgctggcc ctctcctggt gccattcacc
42061 ctcaacttca ccatcaccaa cctgcagtac gaggaggaca tgcatcaccc aggctccagg
42121 aagttcaaca ccacggagcg ggtcctgcag ggtctgcttg gtcccatgtt caagaacacc
42181 agtgtcggcc ttctgtactc tggctgcaga ctgaccttgc tcaggcctga gaagaatggg
42241 gcagccactg gaatggatgc catctgcagc caccgtcttg accccaaaag ccctggactc
42301 gacagagagc agctgtactg ggagctgagc cagctgaccc atggcatcaa agagctgggc
42361 ccctacaccc tggacaggaa cagtctctat gtcaatggtt tcacccatcg gagctctgtg
42421 gccccacca gcactcctgg gacctccaca gtggaccttg ggacctcagg gactccatcc
42481 tccctcccca gccccacaac agctgttcct ctcctggtgc cgttcaccct caactttacc
42541 atcaccaatc tgcagtatgg ggaggacatg cgtcaccctg gctccaggaa gttcaacacc
42601 acagagaggg tcctgcaggg tctgcttggt cccttgttca agaactccag tgtcggccct
42661 ctgtactctg gctgcagact gatctctctc aggtctgaga aggatggggc agccactgga
42721 gtggatgcca tctgcaccca ccaccttaac cctcaaagcc ctggactgga cagggagcag
42781 ctgtactggc agctgagcca gatgaccaat ggcatcaaag agctgggccc ctacaccctg

```
42841 gaccggaaca gtctctacgt caatggtttc acccatcgga gctctgggct caccaccagc
42901 actccttgga cttccacagt tgaccttgga acctcaggga ctccatcccc cgtccccagc
42961 cccacaactg ctggccctct cctggtgcca ttcaccctaa acttcaccat caccaacctg
43021 cagtatgagg aggacatgca tcgccctgga tctaggaagt tcaacgccac agagagggtc
43081 ctgcagggtc tgcttagtcc catattcaag aactccagtg ttggccctct gtactctggc
43141 tgcagactga cctctctcag gcccgagaag gatggggcag caactggaat ggatgctgtc
43201 tgcctctacc accctaatcc caaaagacct ggactggaca gagagcagct gtactgggag
43261 ctaagccagc tgacccacaa catcactgag ctgggccccc acagcctgga cagggacagt
43321 ctctatgtca atggtttcac ccatcagagc tctatgacga ccaccagaac tcctgatacc
43381 tccacaatgc acctggcaac ctcgagaact ccagcctccc tgtctggacc tacgaccgcc
43441 agccctctcc tggtgctatt cacaatcaac tgcaccatca ccaacctgca gtacgaggag
43501 gacatgcgtc gcactggctc caggaagttc aacaccatgg agagtgtcct gcagggtctg
43561 ctcaagccct tgttcaagaa caccagtgtt ggccctctgt actctggctg cagattgacc
43621 ttgctcaggc ccaagaaaga tggggcagcc actggagtgg atgccatctg cacccaccgc
43681 cttgacccca aaagccctgg actcaacagg gagcagctgt actgggagct aagcaaactg
43741 accaatgaca ttgaagagct gggcccctac accctggaca ggaacagtct ctatgtcaat
43801 ggtttcaccc atcagagctc tgtgtccacc accagcactc ctgggacctc cacagtggat
43861 ctcagaacct cagggactcc atcctccctc tccagcccca caattatgnc nnctgnccct
43921 ctcctgntnc cnttcaccnt caacttnacc atcaccaacc tgcantangn ggannacatg
43981 cnncncccng gntccaggaa gttcaacacc acngagaggg tcctacaggg tctgctcagg
44041 cccttgttca agaacaccag tgtcagctct ctgtactctg gttgcagact gaccttgctc
44101 aggcctgaga aggatggggc agccaccaga gtggatgctg cctgcaccta ccgccctgat
44161 cccaaaagcc ctggactgga cagagagcaa ctatactggg agctgagcca gctaacccac
44221 agcatcactg agctgggacc ctacaccctg gacagggtca gtctctatgt caatggcttc
44281 aaccctcgga gctctgtgcc aaccaccagc actcctggga cctccacagt gcacctggca
44341 acctctggga ctccatcctc cctgcctggc cacacancnn ctgnccctct cctgntnccn
44401 ttcaccntca acttnaccat caccaacctg cantangngg annacatgcn ncncccnggn
44461 tccaggaagt tcaacaccac ngagagggtt ctgcagggtc tgctcaaacc cttgttcagg
44521 aatagcagtc tggaatacct ctattcaggc tgcagactag cctcactcag gccagagaag
44581 gatagctcag ccatggcagt ggatgccatc tgcacacatc gccctgaccc tgaagacctc
44641 ggactggaca gagagcgact gtactgggag ctgagcaatc tgacaaatgg catccaggag
44701 ctgggccccc acaccctgga ccggaacagt ctctacgtca atggtttcac ccatcggagc
44761 tctgggctca ccaccagcac tccttggact tccacagttg accttggaac ctcagggact
44821 ccatcccccg tccccagccc cacaactgct ggccctctcc tggtgccatt caccctcaac
44881 ttcaccatca ccaacctgca gtatgaggag gacatgcatc gccctggttc caggaggttc
44941 aacaccacgg agagggttct gcagggtctg ctcacgccct tgttcaagaa caccagtgtt
45001 ggccctctgt actctggctg cagactgacc ttgctcagac ctgagaagca agaggcagcc
45061 actggagtgg acaccatctg tacccaccgc gttgatccca tcggacctgg actggacaga
45121 gagcggctat actgggagct gagccagctg accaacagca tcacagagct gggaccctac
45181 accctggata gggacagtct ctatgtcaat ggcttcaacc cttggagctc tgtgccaacc
45241 accagcactc ctgggacctc cacagtgcac ctggcaacct ctgggactcc atcctccctg
45301 cctggccaca cagcccctgt ccctctcttg ataccattca ccctcaactt taccatcacc
45361 gacctgcatt atgaagaaaa catgcaacac cctggttcca ggaagttcaa caccacggag
45421 agggttctgc agggtctgct caagcccttg ttcaagagca ccagcgttgg ccctctgtac
45481 tctggctgca gactgacctt gctcagacct gagaaacatg gggcagccac tggagtggac
45541 gccatctgca ccctccgcct tgatcccact ggtcctggac tggacagaga gcggctatac
45601 tgggagctga gccagctgac caacagcgtt acagagctgg gcccctacac cctggacagg
45661 gacagtctct atgtcaatgg cttcacccat cggagctctg tgccaaccac cagtattcct
45721 gggacctctg cagtgcacct ggaaacctct gggactccag cctccctccc tggccacaca
45781 gcccctggcc ctctcctggt gccattcacc ctcaacttca ctatcaccaa cctgcagtat
45841 gaggaggaca tgcgtcaccc tggttccagg aagttcagca ccacggagag agtcctgcag
45901 ggtctgctca agcccttgtt caagaacacc agtgtcagct ctctgtactc tggttgcaga
45961 ctgaccttgc tcaggcctga gaaggatggg gcagccacca gagtggatgc tgtctgcacc
46021 catcgtcctg accccaaaag ccctggactg gacagagagc ggctgtactg gaagctgagc
46081 cagctgaccc acggcatcac tgagctgggc ccctacaccc tggacaggca cagtctctat
46141 gtcaatggtt tcacccatca gagctctatg acgaccacca gaactcctga tacctccaca
46201 atgcacctgg caacctcgag aactccagcc tccctgtctg gacctacgac cgccagccct
46261 ctcctggtgc tattcacaat taacttcacc atcactaacc tgcggtatga ggagaacatg
46321 catcaccctg gctctagaaa gtttaacacc acggagagag tccttcaggg tctgctcagg
46381 cctgtgttca agaacaccag tgttggccct ctgtactctg gctgcagact gaccacgctc
46441 aggcccaaga aggatggggc agccaccaaa gtggatgcca tctgcaccta ccgccctgat
```

```
46501 cccaaaagcc ctggactgga cagagagcag ctatactggg agctgagcca gctaacccac
46561 agcatcactg agctgggccc ctacacccag gacagggaca gtctctatgt caatggcttc
46621 acccatcgga gctctgtgcc aaccaccagt attcctggga cctctgcagt gcacctggaa
46681 acctctggga ctccagcctc cctccctggc cacacagccc ctggccctct cctggtgcca
46741 ttcaccctca acttcactat caccaacctg cagtatgagg aggacatgcg tcaccctggt
46801 tccaggaagt tcaacaccac ggagagagtc ctgcagggtc tgctcaagcc cttgttcaag
46861 agcaccagtg ttggccctct gtactctggc tgcagactga ccttgctcag gcctgaaaaa
46921 cgtggggcag ccaccggcgt ggacaccatc tgcactcacc gccttgaccc tctaaaccca
46981 ggactggaca gagagcagct atactgggag ctgagcaaac tgacccgtgg catcatcgag
47041 ctgggcccct acctcctgga cagaggcagt ctctatgtca atggtttcac ccatcggacc
47101 tctgtgccca ccaccagcac tcctgggacc tccacagtgg accttggaac ctcagggact
47161 ccattctccc tcccaagccc cgcancnnct gnccctctcc tgntnccntt caccntcaac
47221 ttnaccatca ccaacctgca ntangnggan nacatgcnnc ncccnggntc caggaagttc
47281 aacaccacng agagggtcct gcagactctg cttggtccta tgttcaagaa caccagtgtt
47341 ggccttctgt actctggctg cagactgacc ttgctcaggt ccgagaagga tggagcagcc
47401 actggagtgg atgccatctg cacccaccgt cttgacccca aaagccctgg agtggacagg
47461 gagcaactat actgggagct gagccagctg accaatggca ttaaagaact gggcccctac
47521 accctggaca ggaacagtct ctatgtcaat gggttcaccc attggatccc tgtgcccacc
47581 agcagcactc ctgggacctc cacagtggac cttgggtcag ggactccatc ctccctcccc
47641 agccccacaa ctgctggccc tctcctggtg ccgttcaccc tcaacttcac catcaccaac
47701 ctgaagtacg aggaggacat gcattgccct ggctccagga agttcaacac cacagagaga
47761 gtcctgcaga gtctgcttgg tcccatgttc aagaacacca gtgttggccc tctgtactct
47821 ggctgcagac tgaccttgct caggtccgag aaggatggag cagccactgg agtggatgcc
47881 atctgcaccc accgtcttga ccccaaaagc cctggagtgg acagggagca gctatactgg
47941 gagctgagcc agctgaccaa tggcatcaaa gagctgggtc cctacaccct ggacagaaac
48001 agtctctatg tcaatggttt cacccatcag acctctgcgc ccaacaccag cactcctggg
48061 acctccacag tggaccttgg gacctcaggg actccatcct ccctccccag ccctacancn
48121 nctgnccctc tcctgntncc nttcaccntc aacttnacca tcaccaacct gcantangng
48181 gannacatgc nncncccngg ntccaggaag ttcaacacca cngagngngt nctgcagggt
48241 ctgctnnnnc ccntnttcaa gaacnccagt gtnggccntc tgtactctgg ctgcagactg
48301 acctnnctca ggncngagaa gnatggngca gccactggan tggatgccat ctgcanccac
48361 cnncntnanc ccaaaagncc tggactgnac agngagcngc tntactggga gctnagccan
48421 ctgaccaann ncatcnnnga gctgggnccc tacaccctgg acaggnacag tctctatgtc
48481 aatggtttca cccattggat ccctgtgccc accagcagca ctcctgggac ctccacagtg
48541 gaccttgggt cagggactcc atcctccctc cccagcccca caactgctgg ccctctcctg
48601 gtgccgttca ccctcaactt caccatcacc aacctgaagt acgaggagga catgcattgc
48661 cctggctcca ggaagttcaa caccacagag agagtcctgc agagtctgct tggtcccatg
48721 ttcaagaaca ccagtgttgg ccctctgtac tctggctgca gactgacctc gctcaggtcc
48781 gagaaggatg gagcagccac tggagtggat gccatctgca cccaccgtgt tgaccccaaa
48841 agccctggag tggacaggga gcagctatac tgggagctga gccagctgac caatggcatc
48901 aaagagctgg gtccctacac cctggacaga aacagtctct atgtcaatgg tttcacccat
48961 cagacctctg cgcccaacac cagcactcct gggacctcca cagtgnacnt nggnacctcn
49021 gggactccat cctccntccc cngccncaca tctgctggcc ctctcctggt gccattcacc
49081 ctcaacttca ccatcaccaa cctgcagtac gaggaggaca tgcatcaccc aggctccagg
49141 aagttcaaca ccacggagcg ggtcctgcag ggtctgcttg gtcccatgtt caagaacacc
49201 agtgtcggcc ttctgtactc tggctgcaga ctgaccttgc tcaggcctga gaagaatggg
49261 gcaaccactg gaatggatgc catctgcacc caccgtcttg accccaaaag ccctggactg
49321 nacagngagc ngctntactg ggagctnagc canctgacca annncatcnn ngagctgggn
49381 ccctacaccc tggacaggna cagtctctat gtcaatggtt tcacccatcn ganctctgng
49441 cccaccacca gcactcctgg gacctccaca gtgnacntng gnacctcngg gactccatcc
49501 tccntccccn gccncacanc nnctgnccct ctcctgntnc cnttcaccnt caacttnacc
49561 atcaccaacc tgcantangn ggannacatg cnncncccng gntccaggaa gttcaacacc
49621 acngagaggg ttctgcaggg tctgctcaaa cccttgttca ggaatagcag tctggaatac
49681 ctctattcag gctgcagact agcctcactc aggccagaga aggatagctc agccatggca
49741 gtggatgcca tctgcacaca tcgccctgac cctgaagacc tcggactgga cagagagcga
49801 ctgtactggg agctgagcaa tctgacaaat ggcatccagg agctgggccc ctacaccctg
49861 gaccggaaca gtctctatgt caatggtttc acccatcgaa gctctatgcc caccaccagc
49921 actcctggga cctccacagt ggatgtggga acctcaggga ctccatcctc cagccccagc
49981 cccacgactg ctggccctct cctgatacca ttcaccctca acttcaccat caccaacctg
50041 cagtatgggg aggacatggg tcaccctggc tccaggaagt tcaacaccac agagagggtc
50101 ctgcagggtc tgcttggtcc catattcaag aacaccagtg ttggccctct gtactctggc
```

```
50161 tgcagactga cctctctcag gtctgagaag gatggagcag ccactggagt ggatgccatc
50221 tgcatccatc atcttgaccc caaaagccct ggactcaaca gagagcggct gtactgggag
50281 ctgagccaac tgaccaatgg catcaaagag ctgggccccc acaccctgga caggaacagt
50341 ctctatgtca atggtttcac ccatcggacc tctgtgccca ccaccagcac tcctgggacc
50401 tccacagtgg accttggaac ctcagggact ccattctccc tcccaagccc cgcaactgct
50461 ggccctctcc tggtgctgtt caccctcaac ttcaccatca ccaacctgaa gtatgaggag
50521 gacatgcatc gccctggctc caggaagttc aacaccactg agagggtcct gcagactctg
50581 cttggtccta tgttcaagaa caccagtgtt ggccttctgt actctggctg cagactgacc
50641 ttgctcaggt ccgagaagga tggagcagcc actggagtgg atgccatctg cacccaccgt
50701 cttgacccca aaagccctgg actgnacagn gagcngctnt actgggagct nagccanctg
50761 accaannnca tcnnngagct gggncctac accctggaca ggnacagtct ctatgtcaat
50821 ggtttcaccc atcnganctc tgngcccacc accagcactc ctgggacctc cacagtgnac
50881 ntnggnacct cngggactcc atcctccntc cccngccnca cancnnctgn ccctctcctg
50941 ntnccnttca ccntcaactt naccatcacc aacctgcant angngganna catgcnncnc
51001 ccnggntcca ggaagttcaa caccacngag agagtccttc agggtctgct caggcctgtg
51061 ttcaagaaca ccagtgttgg ccctctgtac tctggctgca gactgacctt gctcaggccc
51121 aagaaggatg gggcagccac caaagtggat gccatctgca cctaccgccc tgatcccaaa
51181 agccctggac tggacagaga gcagctatac tgggagctga gccagctaac ccacagcatc
51241 actgagctgg gcccctacac ccaggacagg gacagtctct atgtcaatgg cttcacccat
51301 cggagctctg tgccaaccac cagtattcct gggacctctg cagtgcacct ggaaaccact
51361 gggactccat cctccttccc cggccacaca gagcctggcc ctctcctgat accattcact
51421 ttcaacttta ccatcaccaa cctgcgttat gaggaaaaca tgcaacaccc tggttccagg
51481 aagttcaaca ccacggagag ggttctgcag ggtctgctca cgcccttgtt caagaacacc
51541 agtgttggcc ctctgtactc tggctgcaga ctgaccttgc tcagacctga gaagcaggag
51601 gcagccactg gagtggacac catctgtacc caccgcgttg atcccatcgg acctggactg
51661 gacagagagc ggctatactg ggagctgagc cagctgacca acagcatcac agagctggga
51721 ccctacaccc tggataggga cagtctctat gtcgatggct tcaacccttg gagctctgtg
51781 ccaaccacca gcactcctgg gacctccaca gtgcacctgg caacctctgg gactccatcc
51841 cccctgcctg gccacacagc ccctgtccct ctcttgatac cattcaccct caactttacc
51901 atcaccgacc tgcattatga agaaaacatg caacaccctg gttccaggaa gttcaacacc
51961 acggagaggg ttctgcaggg tctgctcaag cccttgttca agagcaccag cgttggccct
52021 ctgtactctg gctgcagact gaccttgctc agacctgaga aacatggggc agccactgga
52081 gtggacgcca tctgcaccct ccgccttgat cccactggtc ctggactgga cagagagcgg
52141 ctatactggg agctgagcca gctgaccaac agcatcacag agctgggacc ctacacccctg
52201 gatagggaca gtctctatgt caatggcttc aacccttgga gctctgtgcc aaccaccagc
52261 actcctggga cctccacagt gcacctggca acctctggga ctccatcctc cctgcctggc
52321 cacacaactg ctggccctct cctggtgccg ttcaccctca acttcaccat caccaacctg
52381 aagtacgagg aggacatgca ttgccctggc tccaggaagt tcaacaccac agagagagtc
52441 ctgcagagtc tgcatggtcc catgttcaag aacaccagtg ttggccctct gtactctggc
52501 tgcagactga ccttgctcag gtccgagaag gatggagcag ccactggagt ggatgccatc
52561 tgcacccacc gtcttgaccc caaaagccct ggactgnaca gngagcngct ntactgggag
52621 ctnagccanc tgaccaannn catcnnngag ctgggnccct acaccctgga caggnacagt
52681 ctctatgtca atggtttcac ccatcnganc tctgngccca ccaccagcac tcctgggacc
52741 tccacagtgn acntnggnac ctcngggact ccatcctccn tccccngccn cacancnnct
52801 gnccctctcc tgntnccntt caccntcaac ttnaccatca ccaacctgca ntangnggan
52861 nacatgcnnc ncccnggntc caggaagttc aacaccacng agngngtnct gcagggtctg
52921 ctnnnnnccn tnttcaagaa cnccagtgtn ggccntctgt actctggctg cagactgacc
52981 tnnctcaggn cngagaagna tggngcagcc actggantgg atgccatctg canccaccnn
53041 cntnanccca aaagncctgg actgnacagn gagcngctnt actgggagct nagccanctg
53101 accaacagca tcacagagct gggaccctac accctggata gggacagtct ctatgtcaat
53161 ggtttcaccc atcgaagctc tatgcccacc accagtattc ctgggacctc tgcagtgcac
53221 ctggaaacct ctgggactcc agcctccctc cctggccaca cagcccctgg ccctctcctg
53281 gtgccattca ccctcaactt cactatcacc aacctgcagt atgaggagga catgcgtcac
53341 cctggttcca ggaagttcaa caccacggag agagtcctgc agggtctgct caagcccttg
53401 ttcaagagca ccagtgttgg ccctctgtac tctggctgca gactgacctt gctcaggcct
53461 gaaaaacgtg gggcagccac cggcgtggac accatctgca ctcaccgcct tgacccctcta
53521 aaccctggac tgnacagnga gcngctntac tgggagctna gccanctgac caannncatc
53581 nnngagctgg gnccctacac cctggacagg nacagtctct atgtcaatgg tttcacccat
53641 cnganctctg ngcccaccac cagcactcct gggacctcca cagtgnacnt nggnacctcn
53701 gggactccat cctccntccc cngccncaca ncnnctgncc ctctcctgnt nccnttcacc
53761 ntcaacttna ccatcaccaa cctgcantan gnggannaca tgcnncnccc nggntccagg
```

```
53821 aagttcaaca ccacngagng ngtnctgcag ggtctgctnn nncccntntt caagaacncc
53881 agtgtnggcc ntctgtactc tggctgcaga ctgacctnnc tcaggncnga gaagnatggn
53941 gcagccactg gantggatgc catctgcanc caccnncntn ancccaaaag ncctggactg
54001 nacagngagc ngctntactg ggagctnagc canctgacca annncatcnn ngagctgggn
54061 ccctacaccc tggacaggna cagtctctat gtcaatggtt ttcaccctcg gagctctgtg
54121 ccaaccacca gcactcctgg gacctccaca gtgcacctgg caacctctgg gactccatcc
54181 tccctgcctg gccacacagc ccctgtccct ctcttgatac cattcaccct caactttacc
54241 atcaccaacc tgcattatga agaaaacatg caacaccctg gttccaggaa gttcaacacc
54301 acggagcggg tcctgcaggg tctgcttggt cccatgttca agaacacaag tgtcggcctt
54361 ctgtactctg gctgcagact gaccttgctc aggcctgaga agaatggggc agccactgga
54421 atggatgcca tctgcagcca ccgtcttgac cccaaaagcc ctggactgna cagngagcng
54481 ctntactggg agctnagcca nctgaccaan nncatcnnng agctgggncc ctacaccctg
54541 gacaggnaca gtctctatgt caatggtttc acccatcnga nctctgngcc caccaccagc
54601 actcctggga cctccacagt gnacntnggn acctcnggga ctccatcctc cntccccngc
54661 cncacancnn ctgnccctct cctgntnccn ttcaccntca acttnaccat caccaacctg
54721 cantangngg annacatgcn ncncccnggn tccaggaagt tcaacaccac ngagngngtn
54781 ctgcagggtc tgctnnnncc cntnttcaag aacnccagtg tnggccntct gtactctggc
54841 tgcagactga cctnnctcag gncngagaag natggngcag ccactggant ggatgccatc
54901 tgcanccacc nncntnancc caaaagncct ggactgnaca gngagcngct ntactgggag
54961 ctnagccanc tgaccaannn catcnnngag ctgggnccct acaccctgga caggnacagt
55021 ctctatgtca atggtttcac ccatcagaac tctgtgccca ccaccagtac tcctgggacc
55081 tccacagtgt actgggcaac cactgggact ccatcctcct tccccggcca cacagagcct
55141 ggccctctcc tgataccatt cactttcaac tttaccatca ccaacctgca ttatgaggaa
55201 aacatgcaac accctggttc caggaagttc aacaccacgg agagggttct gcagggtctg
55261 ctcacgccct tgttcaagaa caccagtgtt ggcccctctgt actctggctg cagactgacc
55321 ttgctcagac ctgagaagca ggaggcagcc actggagtgg acaccatctg tacccaccgc
55381 gttgatccca tcggacctgg actgnacagn gagcngctnt actgggagct nagccanctg
55441 accaannnca tcnnngagct gggnccctac accctggaca ggnacagtct ctatgtcaat
55501 ggtttcaccc atcnganctc tgngcccacc accagcactc ctgggacctc cacagtgnac
55561 ntnggnacct cngggactcc atcctccntc cccngccnca cancnnctgn ccctctcctg
55621 ntnccnttca ccntcaactt naccatcacc aacctgcant angngganna catgcnncnc
55681 ccnggntcca ggaagttcaa caccacngag ngngtnctgc agggtctgct nnnnccccntn
55741 ttcaagaacn ccagtgtngg ccntctgtac tctggctgca gactgacctn nctcaggncn
55801 gagaagnatg gngcagccac tggantggat gccatctgca nccaccnncn tnancccaaa
55861 agncctggac tgnacagnga gcngctntac tgggagctna gccanctgac caannncatc
55921 nnngagctgg gnccctacac cctggacagg nacagtctct atgtcaatgg tttcacccat
55981 cggagctctg tgccaaccac cagcagtcct gggacctcca cagtgcacct ggcaacctct
56041 gggactccat cctccctgcc tggccacaca gcccctgtcc ctctcttgat accattcacc
56101 ctcaacttta ccatcaccaa cctgcattat gaagaaaaca tgcaacaccc tggttccagg
56161 aagttcaaca ccacggagag ggttctgcag ggtctgctca agcccttgtt caagagcacc
56221 agtgttggcc ctctgtactc tggctgcaga ctgaccttgc tcagacctga gaaacatggg
56281 gcagccactg gagtggacgc catctgcacc ctccgccttg atcccactgg tcctggactg
56341 nacagngagc ngctntactg ggagctnagc canctgacca annncatcnn ngagctgggn
56401 ccctacaccc tggacaggna cagtctctat gtcaatggtt tcacccatcn ganctctgng
56461 cccaccacca gcactcctgg gacctccaca gtgnacntng gnacctcngg gactccatcc
56521 tccntccccn gccncacanc nnctgnccct ctcctgntnc cnttcaccnt caacttnacc
56581 atcaccaacc tgcantangn ggannacatg cnncncccng gntccaggaa gttcaacacc
56641 acngagngng tnctgcaggg tctgctnnnn cccntnttca agaacnccag tgtnggccnt
56701 ctgtactctg gctgcagact gacctnnctc aggncngaga agnatggngc agccactgga
56761 ntggatgcca tctgcancca ccnncntnan cccaaaagnc ctggactgna cagngagcng
56821 ctntactggg agctnagcca nctgaccaan nncatcnnng agctgggncc ctacaccctg
56881 gacaggnaca gtctctatgt caatggtttc acccatcgga cctctgtgcc caccaccagc
56941 actcctggga cctccacagt gcacctggca acctctggga ctccatcctc cctgcctggc
57001 cacacagccc ctgtccctct cttgatacca ttcaccctca actttaccat caccaacctg
57061 cagtatgagg aggacatgca tcgccctgga tctaggaagt tcaacaccac agagagggtc
57121 ctgcagggtc tgcttagtcc cattttcaag aactccagtg ttggccctct gtactctggc
57181 tgcagactga cctctctcag gcccgagaag gatggggcag caactggaat ggatgctgtc
57241 tgcctctacc accctaatcc caaaagacct gggctggaca gagagcagct gtactgcgag
57301 ctaagccagc tgacccacaa catcactgag ctgggccctt acagcctgga cagggacagt
57361 ctctatgtca atggtttcac ccatcagaac tctgtgccca ccaccagtac tcctgggacc
57421 tccacagtgt actgggcaac cactgggact ccatcctcct tccccggcca cacancnnct
```

```
57481 gnccctctcc tgntnccntt caccntcaac ttnaccatca ccaacctgca ntangnggan
57541 nacatgcnnc ncccnggntc caggaagttc aacaccacng agngngtnct gcagggtctg
57601 ctnnnncccn tnttcaagaa cnccagtgtn ggccntctgt actctggctg cagactgacc
57661 tnnctcaggn cngagaagna tggngcagcc actggantgg atgccatctg canccaccnn
57721 cntnanccca aaagncctgg actgnacagn gagcngctnt actgggagct nagccanctg
57781 accaannnca tcnnngagct gggnccctac accctggaca ggnacagtct ctatgtcaat
57841 ggtttcaccc attggagctc tgggctcacc accagcactc cttggacttc cacagttgac
57901 cttggaacct cagggactcc atcccccgtc cccagcccca caactgctgg ccctctcctg
57961 gtgccattca ccctaaactt caccatcacc aacctgcagt atgaggagga catgcatcgc
58021 cctggatcta ggaagttcaa cgccacagag agggtcctgc agggtctgct tagtcccata
58081 ttcaagaaca ccagtgttgg ccctctgtac tctggctgca gactgacctt gctcagacct
58141 gagaagcagg aggcagccac tggagtggac accatctgta cccaccgcgt tgatcccatc
58201 ggacctggac tgnacagnga gcngctntac tgggagctna gccanctgac caannncatc
58261 nnngagctgg gnccctacac cctggacagg nacagtctct atgtcaatgg tttcacccat
58321 cnganctctg ngcccaccac cagcactcct gggacctcca cagtgnacnt nggnacctcn
58381 gggactccat cctccntccc cngccncaca ncnnctgncc ctctcctgnt nccnttcacc
58441 ntcaacttna ccatcaccaa cctgcantan gnggannaca tgcnncnccc nggntccagg
58501 aagttcaaca ccacngagng ngtnctgcag ggtctgctnn nncccntntt caagaacncc
58561 agtgtnggcc ntctgtactc tggctgcaga ctgacctnnc tcaggncnga gaagnatggn
58621 gcagccactg gantggatgc catctgcanc caccnncntn ancccaaaag ncctggactg
58681 nacagngagc ngctntactg ggagctnagc canctgacca annncatcnn ngagctgggn
58741 ccctacaccc tggacaggna cagtctctat gtcaatggtt tcacccatcg gagctttggg
58801 ctcaccacca gcactccttg gacttccaca gttgaccttg gaacctcagg gactccatcc
58861 cccgtcccca gccccacaac tgctggccct ctcctggtgc cattcaccct aaacttcacc
58921 atcaccaacc tgcagtatga ggaggacatg catcgccctg gctccaggaa gttcaacacc
58981 acggagaggg tccttcaggg tctgcttacg cccttgttca ggaacaccag tgtcagctct
59041 ctgtactctg gttgcagact gaccttgctc aggcctgaga aggatggggc agccaccaga
59101 gtggatgctg tctgcaccca tcgtcctgac cccaaaagcc ctggactgna cagngagcng
59161 ctntactggg agctnagcca nctgaccaan nncatcnnng agctgggncc ctacaccctg
59221 gacaggnaca gtctctatgt caatggtttc acccatcnga nctctgngcc caccaccagc
59281 actcctggga cctccacagt gnacntnggn acctcnggga ctccatcctc cntccccngc
59341 cncacancnn ctgnccctct cctgntnccn ttcaccntca acttnaccat caccaacctg
59401 cantangngg annacatgcn ncncccnggn tccaggaagt tcaacaccac ngagngngtn
59461 ctgcagggtc tgctnnnncc cntnttcaag aacnccagtg tnggccntct gtactctggc
59521 tgcagactga cctnnctcag gncngagaag natggngcag ccactggant ggatgccatc
59581 tgcanccacc nncntnancc caaaagncct ggactgnaca gngagcngct ntactgggag
59641 ctnagccanc tgaccaannn catcnnngag ctgggnccct acaccctgga caggnacagt
59701 ctctatgtca atggtttcac ccattggatc cctgtgccca ccagcagcac tcctgggacc
59761 tccacagtgg accttgggtc agggactcca tcctccctcc ccagccccac aactgctggc
59821 cctctcctgg taccattcac cctcaacttc accatcacca acctgcagta tggggaggac
59881 atgggtcacc ctggctccag gaagttcaac accacagaga gggtcctgca gggtctgctt
59941 ggtcccatat tcaagaacac cagtgttggc cctctgtact ctggctgcag actgacctct
60001 ctcaggtccg agaaggatgg agcagccact ggagtggatg ccatctgcat ccatcatctt
60061 gaccccaaaa gccctggact gnacagngag cngctntact gggagctnag ccanctgacc
60121 aannncatcn nngagctggg nccctacacc ctggacaggn acagtctcta tgtcaatggt
60181 ttcacccatc nganctctgn gcccaccacc agcactcctg ggacctccac agtgnacntn
60241 ggnacctcng ggactccatc ctccntcccc ngccncacan cnnctgnccc tctcctgntn
60301 ccnttcaccn tcaacttnac catcaccaac ctgcantang nggannacat gcnncncccn
60361 ggntccagga agttcaacac cacngagngn gtnctgcagg gtctgctnnn ncccntnttc
60421 aagaacncca gtgtnggccn tctgtactct ggctgcagac tgacctnnct caggncngag
60481 aagnatggng cagccactgg antggatgcc atctgcancc accnncntna ncccaaaagn
60541 cctggactgn acagngagcn gctntactgg gagctnagcc anctgaccaa nnncatcnnn
60601 gagctgggnc cctacaccct ggacaggnac agtctctatg tcaatggttt cacccatcag
60661 acctttgcgc ccaacaccag cactcctggg acctccacag tggaccttgg gacctcaggg
60721 actccatcct ccctccccag ccctacatct gctggccctc tcctggtgcc attcaccctc
60781 aacttcacca tcaccaacct gcagtacgag gaggacatgc atcacccagg ctccaggaag
60841 ttcaacacca cggagcgggt cctgcagggt ctgcttggtc ccatgttcaa gaacaccagt
60901 gtcggccttc tgtactctgg ctgcagactg accttgctca ggcctgagaa gaatggggca
60961 gccaccagag tggatgctgt ctgcacccat cgtcctgacc ccaaaagccc tggactgnac
61021 agngagcngc tntactggga gctnagccan ctgaccaann ncatcnnnga gctgggnccc
61081 tacaccctgg acaggnacag tctctatgtc aatggtttca cccatcngan ctctgngccc
```

```
61141 accaccagca ctcctgggac ctccacagtg nacntnggna cctcngggac tccatcctcc
61201 ntccccngcc ncacagcccc tgtccctctc ttgataccat tcaccctcaa ctttaccatc
61261 accaacctgc attatgaaga aaacatgcaa caccctggtt ccaggaagtt caacaccacg
61321 gagagggttc tgcagggtct gctcaagccc ttgttcaaga gcaccagcgt tggccctctg
61381 tactctggct gcagactgac cttgctcaga cctgagaaac atggggcagc cactggagtg
61441 gacgccatct gcaccctccg ccttgatccc actggtcctg gactggacag agagcggcta
61501 tactgggagc tgagccagct gaccaacagc gttacagagc tgggccccta caccctggac
61561 agggacagtc tctatgtcaa tggcttcacc cagcggagct ctgtgccaac caccagtatt
61621 cctgggacct ctgcagtgca cctggaaacc tctgggactc cagcctccct ccctggccac
61681 acagcccctg gccctctcct ggtgccattc accctcaact tcactatcac caacctgcag
61741 tatgaggtgg acatgcgtca ccctggttcc aggaagttca acaccacgga gagagtcctg
61801 cagggtctgc tcaagccctt gttcaagagc accagtgttg gccctctgta ctctggctgc
61861 agactgacct tgctcaggcc tgaaaaacgt ggggcagcca ccggcgtgga caccatctgc
61921 actcaccgcc ttgaccctct aaaccctgga ctggacagag agcagctata ctgggagctg
61981 agcaaactga cccgtggcat catcgagctg ggcccctacc tcctggacag aggcagtctc
62041 tatgtcaatg gtttcaccca tcggaacttt gtgcccatca ccagcactcc tgggacctcc
62101 acagtacacc taggaacctc tgaaactcca tcctccctac ctagacccat agtgcctggc
62161 cctctcctgg tgccattcac cctcaacttc accatcacca acttgcagta tgaggaggcc
62221 atgcgacacc ctggctccag gaagttcaat accacggaga gggtcctaca gggtctgctc
62281 aggcccttgt tcaagaatac cagtatcggc cctctgtact ccagctgcag actgaccttg
62341 ctcaggccag agaaggacaa ggcagccacc agagtggatg ccatctgtac ccaccaccct
62401 gaccctcaaa gccctggact gaacagagag cagctgtact gggagctgag ccagctgacc
62461 cacggcatca ctgagctggg cccctacacc ctggacaggg acagtctcta tgtcgatggt
62521 ttcactcatt ggagccccat accgaccacc agcactcctg ggacctccat agtgaacctg
62581 ggaacctctg ggatcccacc ttccctccct gaaactacan cnnctgnccc tctcctgntn
62641 ccnttcaccn tcaacttnac catcaccaac ctgcantang nggannacat gcnncncccn
62701 ggntccagga agttcaacac cacngagagg gttctgcagg gtctgctcaa gcccttgttc
62761 aagagcacca gtgttggccc tctgtattct ggctgcagac tgaccttgct caggcctgag
62821 aaggacggag tagccaccag agtggacgcc atctgcaccc accgccctga ccccaaaatc
62881 cctgggctag acagacagca gctatactgg gagctgagcc agctgaccca cagcatcact
62941 gagctgggac cctacaccct ggatagggac agtctctatg tcaatggttt cacccagcgg
63001 agctctgtgc ccaccaccag cactcctggg actttcacag tacagccgga aacctctgag
63061 actccatcat ccctccctgg ccccacagcc actggccctg tcctgctgcc attcaccctc
63121 aattttacca tcactaacct gcagtatgag gaggacatgc atcgccctgg ctccaggaag
63181 ttcaacacca cggagagggt ccttcagggt ctgcttatgc ccttgttcaa gaacaccagt
63241 gtcagctctc tgtactctgg ttgcagactg accttgctca ggcctgagaa ggatggggca
63301 gccaccagag tggatgctgt ctgcacccat cgtcctgacc ccaaaagccc tggactggac
63361 agagagcggc tgtactggaa gctgagccag ctgacccacg gcatcactga gctgggcccc
63421 tacaccctgg acaggcacag tctctatgtc aatggtttca cccatcagag ctctatgacg
63481 accaccagaa ctcctgatac ctccacaatg cacctggcaa cctcgagaac tccagcctcc
63541 ctgtctggac ctacgaccgc cagccctctc ctggtgctat tcacaattaa cttcaccatc
63601 actaacctgc ggtatgagga gaacatgcat caccctggct ctagaaagtt taacaccacg
63661 gagagagtcc ttcagggtct gctcaggcct gtgttcaaga acaccagtgt tggccctctg
63721 tactctggct gcagactgac cttgctcagg cccaagaagg atggggcagc caccaaagtg
63781 gatgccatct gcacctaccg ccctgatccc aaaagccctg gactggacag agagcagcta
63841 tactgggagc tgagccagct aacccacagc atcactgagc tgggccccta caccctggac
63901 agggacagtc tctatgtcaa tggtttcaca cagcggagct ctgtgcccac cactagcatt
63961 cctgggaccc ccacagtgga cctgggaaca tctgggactc cagtttctaa acctggtccc
64021 tcggctgcca gccctctcct ggtgctattc actctcaact tcaccatcac caacctgcgg
64081 tatgaggaga acatgcagca ccctggctcc aggaagttca acaccacgga gagggtcctt
64141 cagggcctgc tcaggtccct gttcaagagc accagtgttg gccctctgta ctctggctgc
64201 agactgactt tgctcaggcc tgaaaaggat gggacagcca ctggagtgga tgccatctgc
64261 acccaccacc ctgaccccaa aagccctagg ctggacagag agcagctgta ttgggagctg
64321 agccagctga cccacaatat cactgagctg ggccactatg ccctggacaa cgacagcctc
64381 tttgtcaatg gtttcactca tcggagctct gtgtccacca ccagcactcc tgggacccca
64441 acagtgtatc tgggagcatc taagactcca gcctcgatat ttggcccttc agctgccagc
64501 catctcctga tactattcac cctcaacttc accatcacta acctgcggta tgaggagaac
64561 atgtggcctg gctccaggaa gttcaacact acagagaggg tccttcaggg cctgctaagg
64621 cccttgttca agaacaccag tgttggccct ctgtactctg gctccaggct gaccttgctc
64681 aggccagaga aagatgggga agccaccgga gtggatgcca tctgcaccca ccgccctgac
64741 cccacaggcc ctgggctgga cagagagcag ctgtatttgg agctgagcca gctgacccac
```

```
64801 agcatcactg agctgggccc ctacacactg gacagggaca gtctctatgt caatggtttc
64861 acccatcgga gctctgtacc caccaccagc accggggtgg tcagcgagga gccattcaca
64921 ctgaacttca ccatcaacaa cctgcgctac atggcggaca tgggccaacc cggctccctc
64981 aagttcaaca tcacagacaa cgtcatgaag cacctgctca gtcctttgtt ccagaggagc
65041 agcctgggtg cacggtacac aggctgcagg gtcatcgcac taaggtctgt gaagaacggt
65101 gctgagacac gggtggacct cctctgcacc tacctgcagc ccctcagcgg cccaggtctg
65161 cctatcaagc aggtgttcca tgagctgagc cagcagaccc atggcatcac ccggctgggc
65221 ccctactctc tggacaaaga cagcctctac cttaacggtt acaatgaacc tggtctagat
65281 gagcctccta caactcccaa gccagccacc acattcctgc ctcctctgtc agaagccaca
65341 acagccatgg ggtaccacct gaagaccctc acactcaact tcaccatctc caatctccag
65401 tattcaccag atatgggcaa gggctcagct acattcaact ccaccgaggg ggtccttcag
65461 cacctgctca gacccttgtt ccagaagagc agcatgggcc ccttctactt gggttgccaa
65521 ctgatctccc tcaggcctga gaaggatggg gcagccactg gtgtggacac cacctgcacc
65581 taccaccctg accctgtggg ccccgggctg gacatacagc agctttactg ggagctgagt
65641 cagctgaccc atggtgtcac ccaactgggc ttctatgtcc tggacaggga tagcctcttc
65701 atcaatggct atgcacccca gaatttatca atccggggcg agtaccagat aaatttccac
65761 attgtcaact ggaacctcag taatccagac cccacatcct cagagtacat caccctgctg
65821 agggacatcc aggacaaggt caccacactc tacaaaggca gtcaactaca tgacacattc
65881 cgcttctgcc tggtcaccaa cttgacgatg gactccgtgt tggtcactgt caaggcattg
65941 ttctcctcca atttggaccc cagcctggtg gagcaagtct ttctagataa gaccctgaat
66001 gcctcattcc attggctggg ctccacctac cagttggtgg acatccatgt gacagaaatg
66061 gagtcatcag tttatcaacc aacaagcagc tccagcaccc agcacttcta cctgaatttc
66121 accatcacca acctaccata ttcccaggac aaagcccagc caggcaccac caattaccag
66181 aggaacaaaa ggaatattga ggatgcgctc aaccaactct tccgaaacag cagcatcaag
66241 agttatttttt ctgactgtca agtttcaaca ttcaggtctg tccccaacag gcaccacacc
66301 ggggtggact ccctgtgtaa cttctcgcca ctggctcgga gagtagacag agttgccatc
66361 tatgaggaat ttctgcggat gacccggaat ggtacccagc tgcagaactt caccctggac
66421 aggagcagtg tccttgtgga tgggtattct cccaacagaa atgagccctt aactgggaat
66481 tctgaccttc ccttctgggc tgtcatcctc atcggcttgg caggactcct gggactcatc
66541 acatgcctga tctgcggtgt cctggtgacc acccgccggc ggaagaagga aggagaatac
66601 aacgtccagc aacagtgccc aggctactac cagtcacacc tagacctgga ggatctgcaa
66661 tgactggaac ttgccggtgc ctggggtgcc tttcccccag ccagggtcca aagaagcttg
66721 gctggggcag aaataaacca tattggtcgg aaaaaaaaaa aaaaa
```

SEQ ID NO. 3

hk5 amino acid

```
MATARPPWMWVLCALITALLLGVTEHVLANNDVSCDHPSNTVPSGSNQDLGAGAGEDARSDDSSSRIINGSD
CDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMFQGVKSIPHPG
YSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKR
CEDAYPRQIDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQET
IQANS
```

SEQ ID NO. 4

KLK5 CDS

```
ggtgtctgtg cgtcctgcac ccacatcttt ctctgtcccc tccttgccct gtctggaggc
tgctagactc ctatcttctg aattctatag tgcctgggtc tcagcgcagt gccgatggtg
gcccgtcctt gtggttcctc tctacttggg gaaatcaggt gcagcggcca tggctacagc
aagacccccc tggatgtggg tgctctgtgc tctgatcaca gccttgcttc tgggggtcac
agagcatgtt ctcgccaaca atgatgtttc ctgtgaccac ccctctaaca ccgtgccctc
tgggagcaac caggacctgg gagctggggc cggggaagac gcccggtcgg atgacagcag
cagccgcatc atcaatggat ccgactgcga tatgcacacc cagccgtggc aggccgcgct
gttgctaagg cccaaccagc tctactgcgg ggcggtgttg gtgcatccac agtggctgct
cacggccgcc cactgcagga agaaagtttt cagagtccgt ctcggccact actccctgtc
accagtttat gaatctgggc agcagatgtt ccaggggtc aaatccatcc cccaccctgg
ctactcccac cctggccact ctaacgacct catgctcatc aaactgaaca gaagaattcg
tcccactaaa gatgtcagac ccatcaacgt ctcctctcat tgtccctctg ctgggacaaa
```

gtgcttggtg tctggctggg ggacaaccaa gagcccccaa gtgcacttcc ctaaggtcct
ccagtgcttg aatatcagcg tgctaagtca gaaaaggtgc gaggatgctt acccgagaca
gatagatgac accatgttct gcgccggtga caaagcaggt agagactcct gccagggtga
ttctgggggg cctgtggtct gcaatggctc cctgcaggga ctcgtgtcct ggggagatta
cccttgtgcc cggcccaaca gaccgggtgt ctacacgaac ctctgcaagt tcaccaagtg
gatccaggaa accatccagg ccaactcctg agtcatccca ggactcagca caccggcatc
cccacctgct gcagggacag ccctgacact cctttcagac cctcattcct tcccagagat
gttgagaatg ttcatctctc cagcccctga ccccatgtct cctggactca gggtctgctt
cccccacatt gggctgaccg tgtctctcta gttgaaccct gggaacaatt tccaaaactg
tccagggcgg gggttgcgtc tcaatctccc tggggcactt tcatcctcaa gctcagggcc
catcccttct ctgcagctct gacccaaatt tagtcccaga aataaactga gaagtggaaa
aaaaaaa

SEQ ID NO. 5

KLK5 nucleic acid

gggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt ggcttgagtc
tcccctgcct aaaatgcagg gagagggagg cagaaagaca gggaagagga aggggtgggg
aagaaagaga gagagagaga gagacagaat aacacaacta cagaaacaca gagagaacac
acagagagcc tgggacacag ggacacacag agtcagagag aaaagagaag atagagaaag
acacaaatgg agacacagag gtgtaaagaa agagagatta acagagtccc agatacacgc
aaaggggcag aagcacagtt ttcagggtgg tgtctatgat catcttcttt ttttttttt
ttttttttt ttttgagac ggagtctcgc tctgtcgccc aggctggagt gcagtggcgg
gatctcggct cactgcaagc tccgcctccc gggttcacgc cattctcctg cctcagcctc
ccaagtagct gggactacag gcgcccgcca ctacgcccgg ctaatttttt tgtattttta
gtagagacgg ggtttcaccg ttttagccgg gatggcctcg atctcctgac ctcgtgatcc
gcccgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccgcg cccggccatg
atcatcttct tgactatgct gatgtgacaa gtacctaaag ccatcagact ctacccttta
aatatgcagt ttgggccagg caccgtggct catgcctgta attccagcac tttgggaggc
agaggtgggt gaatcacttg aggccaggag tttgagacca gcctggccaa catggtgaaa
ctctgtcttt actaaaaaaa aaaaaaaaaa aaaaaaaatc agccgggtgt cgtggggcac
acctgtaatc ccagctatgc tggaggctga ggcacgagag tcacttgaac cctggaggcg
gaggttgcag tgggccgaga tcacatcacc gccctccagc ctgggcgaca gagcaagact
ctgtctcaaa taaataaata aacaaacgaa caagcagttt gttgtacctt agttatatct
aaaaaaaaaa tgctgtcaac aaatagagca gaagtgaaat aaaggaaaat aaatgggcca
agaactctaa ggtatatttg acaaatcatt cagaaccttt aaaaaagaaa gaatcacaga
ggcatagaaa gacagggagg aacagggaga cagaaacacc tgtggcccaa ggagaacaaa
acaaggctcc taagacagac aggaggagag agagagagag tgagtgagag acagacagag
aaaaagacag agagagagag acagagacag agagacagag aggcgagagg gatagaaaga
gagagagggg tggagagaga cacgagatat tgagagagac tcagaaagat agccgaggga
gaaccacaga gagatggaag aagactctga gaaaaaacca gagacaaaga tggaaagagg
agtatcgagg gtgaacagac agtggtggaa tgagcaaaat gcagagaaga aagcaagcaa
tccaggcgcc aagaatagtg acccagagtt ggtgagaagc cagatcctta aggctggggg
aggcagggaa ggggctggcc tggcttccgg agacccctcc ccattctccg ggccagggag
gtagggagtg acattccgga ctgggtgggg ggtgctctgg gggtggagat aggggagca
ggaggagcta ttgctaaggc ccgataggca cctcattgcc cgggaatgtg ccccagggag
cagtgggtgg ttataactca ggcccggtgc ccagagccca ggaggaggca gtggccagga
aggcacaggc ctgagaagtc tgcggctgag ctgggagcaa atcccccacc ccctacctgg
gggacagggc aagtgagacc tggtgagggt ggctcagcag gcagggaagg agaggtgtct
gtgcgtcctg cacccacatc tttctctgtc ccctccttgc cctgtctgga ggctgctaga
ctcctatctt ctgaattcta tagtgcctgg gtctcagcgc agtgccgatg gtggcccgtc
cttgtggttc ctctctacct ggggaaataa ggtaggggag ggaggggaag tgggttaagg
gctccccgga tcgcctgggc ctcccaaccc tctgacattc cccatccagg tgcagcggcc
atggctacag caagacccca ctggatgtgg gtgctctgtg ctctgatcac agccttgctt
ctgggggtca caggtaacca gaactctggg gtgggagggt tgtgggattg ggaggactgt
ctctgcggca ctagagcgcc tgtcccctgg ggaactgtgt gagcctgggc atgactccgg
gaccgggtga atgtgagtct ctgtctgtac ttgtggttgt gcgatcgtat gtggccctgt

gactgccacg gtgtgtgtcg gggaggggga tgccttttcc catatcaggt gactgtgcgg
caggtggcac tgacccttg aggctgtgtg tgtggttttg tgattgtgtg tgcatttaag
attgtgtgtg gctccacagc tgtgtgggtg aatgcatgta gcactggggg tgttcactgt
gtgtttggct gtgtgtggtg acttggcatt gtatatgact gcaggtatct gcagttcctg
tccctgaggt cccgggattg cgtgcaacaa aagtggtcat caccatggaa agctgtgact
gtgtgctgct tgcaggcgat tatgtgattg tggctgagtg tgacgttatg gatgcccgta
tttgtgaccg tgtgactacc tgaagctctg tgtaggggtg actgtatgtg actgtgtgtg
tctgtgtgag gccgtgtaaa tgctactgta tgtgtgatgg tgcagctgtg tgtctggagt
ttctgtctct gcctggaggg atagagggtg caggggtagc tatctctggg agatgggtgc
caggtgactg acttgcagtg tgtgcctgtg tgcagaagag tatgtggcag tctgaacatc
tgtgcacaca cggcatctgt gcgtggcact gagacactgt ggatgagggt gtgcgatccc
gctaggctgc ccgggagcgt gtgtacctgg agacagagct gtatgttagc tgcacctgtg
gaggcaacat gggcgtgtct gcagaactgc gtgcgtgctt ggctgttact gctgttgtgc
gcgtggttct tggggtgagt tcgtgaatga tggtggtgcc agggccatca gcaagggtaa
gaaccaggcc gggcgcggtg gctcacgcct gtaatcccag ccctttggga ggccgaggca
ggcggatcac ctgaggtcgg gagatcgagg ccagcctgac caacatggag aaccccgtct
ctactaaaaa tacaaaaaat tagctggtgt ggtggcgcgt gcctgtaatc ccagctactc
gggagactgg ggcagaaaaa tcgcttgaac ccgggaggtg gaggttgcgg tgagccgaga
tcgcgccatt gcactccagc ctgggcaaca agagcgaaac tccgtctcga aagaaaaaaa
gaaaaaaaaa agggtaagaa ccagtgaatg ggcacgggag gactgatgat ggagtggggc
atgcatgtag tctgtaggtc tgtgtgtgag aggaggagat tgacaggatt gagaaggcat
gttttcatct gagaattcag aaacctaggc ctgctcttcc cctccatgtg gcccccctaag
ctgagccctt ctttcctggt cctgctttcg gaaccctagc tccgcccatg agctctgacc
ccacctcctt tcctcaacca cgcccctagg ccagactcta gtggaccccg cctaaggcca
cacccctttg ggccaggctc cacccccтat tctgtgggta ccttctagaa ccccccttcaa
agtcagagct ttttttttt ttttttggga gacagtcttg ctctctctcc caggctggag
tgcagtggcg tgatctcggc tcactgcaac ctctgcctcc caggttcaag tgattctcgt
gcctccacct cctgagtagc tgggattaca ggtgcgcgcc accacgcctg gctaattttt
gtgtctttag tagagacagg gtttcacctt gttggccagg ctggtctcaa actcccaacc
tcaggtgatc cgcccacctc ggcctcccag agtgctgggg ttacaggcgt gagccaccgc
ccccagccca aagtcagagc tctttatagg agactctaac atgtaaccct gaccctggcc
ctaactaagt caattccaaa ccccttcctg cctccagccc tgaccccact cactgaggcc
tgaccccact tcttgagacc agttccatcc ctaaagccct ggtctccctc ccatccccag
gctccagccc ccacagcttt ggcactaccc ctgagcttgt ccaggaatcc tgtacccaat
tttaccctca catgtagttc tagccaattc caggaatctg tgaggtccag ttagagtcca
gtaaccctac ctgagcctgg gctctgtcct tgagcttgag cctgggcttg agaggtgcca
ctcttattct ccaggccctg cccctgcccc ctcagcatgt cagacaccca ccctctagct
ggtctggcct cttgagtctg aaacccaccc ccagcccaag ccccgcctct gagccccgcc
caacccattt tccgttccca gagcatgttc tcgccaacaa tgatgtttcc tgtgaccacc
cctctaacac cgtgccctct gggagcaacc aggacctggg agctggggcc ggggaagacg
cccggtcgga tgacagcagc agccgcatca tcaatggatc cgactgcgat atgcacaccc
agccgtggca ggccgcgctg ttgctaaggc ccaaccagct ctactgcggg gcggtgttgg
tgcatccaca gtggctgctc acggccgccc actgcaggaa gaagtgagtg ggagttccaa
gaggagggtt ggtggggacg gggaagtggg ggtgggggtg gggaagtggg ggtgggggtg
tcatggaggt gagggctggt ggggacgggg aagtggggtt gggggtgtca tggaaggtga
gggttggtgg ggatgggttg gggatgtggg agcaggagga ggtcgagttg gggataggac
taaggatgga gttttgcggg ggagcaaggt gggaggatga ggttggagag gggagagtgt
tgtggtaggg aatgggaagg agccaaggat gggttggatt tggggttagg agcatatatt
tgttgaatgg tttgggatgg aggtggaatt gggattggct ttagaattgg gggtgggtga
aaatcgggct ggggtggaaa tgaagatagc atggagatag ggttgagatt gggagcagat
atagaatgaa ggatggggat tggagttttg ggtggggttg gagatggttg gatttgggct
tgagaatgca tatggtgatg gcttctgggt agggaaagaa ttagggttgg gaatgggatg
ggtttggaat tgtgactggg atggggacag gcatgggatt ggagaccaag agggagttga
ggatggtttg gggaccgggg gtggggatgg gggtggggct ggggctgggt gtggggttgg
gattggcgtt ggacgtggag atagagatca gggttggtgg tgacctgccc catcttcctc
agagttttca gagtccgtct cggccactac tccctgtcac cagtttatga atctgggcag
cagatgttcc agggggtcaa atccatcccc caccctggct actcccaccc tggccactct
aacgacctca tgctcatcaa actgaacaga agaattcgtc ccactaaaga tgtcagaccc
atcaacgtct cctctcattg tccctctgct gggacaaagt gcttggtgtc tggctggggg

acaaccaaga gcccccaagg tgagtgtcca ggttcttctt gataccgacc catctctgcc
gccttccatc tttctccact tctcattgtg ttcctgtttg acagtgcact tccctaaggt
cctccagtgc ttgaatatca gcgtgctaag tcagaaaagg tgcgaggatg cttacccgag
acagatagat gacaccatgt tctgcgccgg tgacaaagca ggtagagact cctgccaggt
gaggacacct ctctttattc agcagataca cactgagtgc caactcggta acatggagcg
ttgccaaatt ctgagaatcc agcaattgcc aagacagtca ggacccctgt tctcacagag
ctcataccct agagtagtgg tgtttagtag aaataatgct gagctgctta tgtcatttcc
agtttttag tagccacatt aaaacaggta aaaaaggctg ggcgcagtgg ctcacacctg
taatcccagc actttgggag gctgaggcag gcagatcacc tttggtcagg agtttgagac
tagcctggcc aacatggcga aactctgtct ctaaaaaaaa atacaaaaat tagcctggca
tggtggcggg cgcctgtaat ctcagctgct caggaggccg agacacaaga atcacttaaa
cccaggaggt ggaggttgca gtgagctgag atcgtgccac tcactccaac ctgggagaca
gagtgacact tttgtctcaa aaagaaaaaa aaaaacaagt aaaaaagaaa caggtgaagt
taactttaat aacccaatgt atcccaaata caatcatttc aaagtgtaat taatataaaa
caattatgaa tgagatactt tacattcttt tcttgttttc atattaagtc tttgaaagtg
agtatatatg ttatgctgac agcacatctc aatttggact agctacattt caggtgctca
gtagccacat gtggctagca gttactgtat tggatggcac ggatctagag ggaaagatca
gggctgtttt gtatggttgg gcaggttgtg cactgcataa agataccata tctaataggg
gcactccgtg ttacagatgt cagttttggc agttttcagg cgtgtggtag ttaagtgtct
tgtttcaaca aaatctgtaa tatgacagtt ttctagcaag tgctggtaaa atatcttgag
gaaggaaaag agaaatctgg taggtatttt tacaagagaa tatttaatac aggggattaa
ttgcaaagct gctggaaggg ctggaggaac aaagttaaaa aataaaaaac tctgtggtca
agaatctgca taaatagggc aatttcagag agtggtaaag gttaacccca aaataaaaca
tggttttagg atagtaaaca ataagggcca atattcaaaa aggtggtcag gggagcctcc
ttggagaggt ggcatttgag cagagaatgg atgacacaaa gaagctaaac tcgtgaagtt
taaggggaaa gaaaaggcac gtgcaaaggc cctgaggcag taaggaattt ggctgattca
aagaagaaga ggaaaccaat gcaactggag aacaaaagtg ggggcaacag tagaaagtga
cgctggaggt gtaggcaggg gcgaatgctc tgcaagtatt tcttggtcac caacacagag
cttccctatg ttctaatgga agctgtatct gttgaggaag acagaattta aaatcaaact
gttacatcaa ccagcaccct tctctgtatt caggctccca agggatctag aaggacgtaa
gttaacaagc tctcattagc agggtgtgtg tttcaacagt agttaggaag ctggggattc
aggagtactc cagtcccatg gctatgaaaa gctcccccca aattgtacaa acctgacaaa
tgcaacacct ccccagctct ccccatttct tctctgtgcc ctgggtgtgg gggggtgggt
tgcgaggggg aaaactttta acagaagaaa gcacatctcg gccgggcgtg gtggctcaca
cctgtaatcc caacactttg ggaggccgag gcgggtggat cactaggtca ggagatggag
accatcctgg ctgacacggt gaaaccctgt ctctactaaa aacacaaaaa attagccggg
cgtggtggca ggcgcctgta gtcccagcta ctcgggaggc tgaggcagga gaatggcctg
aacccgggag gcggaacttg cagtgagccg aggttgcacc actgcactcc agcctgggca
acacagtgag actccgtctc aaaaaaaaaa aaagaaaaga aaagaaatca catctcattc
aagtggtggc atttaaaact atttagcctt tctgtaggca aggttagtat cttgtttttc
cagacctcaa ggtgtttttt tgtttgtttt ttcataccgg tgtgtggtct gggtgtggcc
actaaaagct acaagcaaga aataataaca actacaacaa tactaatacc aatagtataa
aaataatagc atctggctaa ttgctggaca ctgttttaag tggtttgcat gcctcagctc
attaactcat ttacctgtta ttattggccc tattttacaa acaaggagcc aaggctcaga
gcagttaact aacagcctct caaaagaaac tctgcagaga tattaaattt aaaaaataat
gagagaaatt aaaccacaag aaagttgaaa tttagaggta caggcagcta agcttgtttg
ctttgaaaca gtgtctgcta ctgggaaaaa ggcaagtctt ggctttccta ataattgata
ccaggactct gtaattcata ttttgcatgc atgtaagtaa gaaatgaagc cgggtgcaat
ggcacatgcc agtaatccca gcactctggg agactgaagt gggaagatca cttgagctca
ggagttcaag accagcctgg gcaactaaaa attaaaaaaa taaaaatact aattgttttt
attttagtag attttattca taccacttac atcattattg tagtatgtac atatttattt
cttttctttt cttttctttt ctttttgag acggagtctc gctctgtcac ccaggctgga
gtgcaatggc accatatcag ctcactgcag catgcgcctc ctgggttcaa gcatttcttc
cacctcagcc tcccaagtag ctgggataac aggcacccac caccatgcct ggctatttt
ttttttccgt agagatgggg ttccaccatg ttggccaggc tggtcttgaa ctcctgacct
ccagtgatct gcctgcctcg gcctcccaaa ttgctggtat tacaggtgtg agccaccgtg
cccaggtggg agatagacat ttctctctac ctcaaacaga ggtccactca agctactttt
cattttcttc ataaatatta gccgagtggc tattttgcac caggaatggt tccaggtgct
gtggatatgg catcaggcaa aacagaccaa aaacttcctg ccgcgtggac ctcatgttcc

ccaagtggaa gacaggcaat aaagagatag ataaatatgt agtaaattaa aaaaaaaaaa
aattagccgg gtgtggtggc ttgcacctgt agttccagct acttgggagg ctgaggtggg
agaattgctt gagcccaaac gtttgaggct gcggtaagcc atgactgcac tgctgcactc
cagacagcag cctgggtgac aaagcaagac gtttttgtca gaaagaaaaa aaaaagagac
gaagggagga aggagagaga aaggaaggaa ggaaggagaa agaaaggaag gaaggagaaa
gaaaggaagg aaggaaggag aaagaaagga agaaagagaa agaaagaaaa agaaagaaag
aaagaagaaa gaaaagagag aggaaggaag gaaagaagga aaagagggaa aaaaatgact
gttgaagagc agtgagtatt attataggag ggtaattata gggaggtatg gggaattgaa
gacaggaaac acaaattagt ccaagcgaat ggatttctat tgggagtgat tctgccccta
gaagacactg gcaataccag gagacatttt tggttgtcac aactatatgg aggggcatta
ctggcaacta atggatagat gccaagtgtg ctgttcaaca tgctatgatg cacacggcag
gcctccacaa caaaccatta tccagcttca gatgcccaca gtgcccagat cgaggaaccc
tcatccaggg gctgagaacc gtatttttgc agaagggagg tataaggatg ggttggtgga
gaatggggaa ggaaggtgtg tgtccagtaa gagaaataag gcctgcacag gctggagggg
agagtgagag agaaagggag gcggagagat acacgatgag ggagacaggc tggaacagaa
agtagagacg aagattcgag atgtggagag gaagggtcac agacccccc gaaatgatgt
gtggacaaca ggaatctgga agaggaagat ggagtggaga gtgacaaatg gggtctaaag
gttgaacttg gaggccaggc atggtggctc acgcctgtaa tcccaacact ttggaggctg
aggtgggcga atcacttgag gccaggagtt cgagaccagc ctggccaaca tggtgaaacc
ccgtctctac aaaaaaaata caaaaaatta gccgggtgtg gtgatggaca cctgtagtca
cagctacttg ggaggctgag gcaggagaat tgcttgaacc cgggagatgg aggctgcagt
gagctgaggt caggccactg cgctccaacc tgggcaacag agtaagactc catctcaaaa
aaaaaaaagc tggatttgga gtgaaatatt aataacattc tccctctctc tccttttgcc
tgtgtctcca tctctgtctt tttctgcatt tcttcatctc tgtactttcc atctctgtgt
gtctgttccc atctgcttct ccatctatgg gcatctctgg gtctctcatg tctccttctg
cccactttgc cacatctctg cctctctcat gccccccttt ctctcctgca gggtgattct
gggggcctg tggtctgcaa tggctccctg cagggactcg tgtcctgggg agattaccct
tgtgcccggc ccaacagacc gggtgtctac acgaacctct gcaagttcac caagtggatc
caggaaacca tccaggccaa ctcctgagtc atcccaggac tcagcacacc ggcatcccca
cctgctgcag ggacagccct gacactcctt tcagaccctc attccttccc agagatgttg
agaatgttca tctctccagc ccctgacccc atgtctcctg gactcagggt ctgcttcccc
cacattgggc tgaccgtgtc tctctagttg aaccctggga acaatttcca aaactgtcca
gggcgggggt tgcgtctcaa tctccctggg gcactttcat cctcaagctc agggcccatc
ccttctctgc agctctgacc caaatttagt cccagaaata aactgagaag

SEQ ID NO. 6

hk6 amino acid

MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFL
GKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWG
KTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNI
PC GSKEKPGVYTNVCRYTNWIQKTIQAK

SEQ ID NO. 7

KLK6 nucleic acid

CDS 147.. 881

gtcgacccac gcgtccggct ggctggctcg ctctctcctg gggacacaga ggtcggcagg
cagcacacag agggacctac gggcagctgt tccttccccc gactcaagaa tccccggagg
cccggaggcc tgcagcagga gcggccatga agaagctgat ggtggtgctg agtctgattg
ctgcagcctg ggcagaggag cagaataagt tggtgcatgg cggaccctgc gacaagacat
ctcaccccta ccaagctgcc ctctacacct cgggccactt gctctgtggt ggggtcctta
tccatccact gtgggtcctc acagctgccc actgcaaaaa accgaatctt caggtcttcc
tggggaagca taaccttcgg caaagggaga gttcccagga gcagagttct gttgtccggg
ctgtgatcca ccctgactat gatgccgcca gccatgacca ggacatcatg ctgttgcgcc
tggcacgccc agccaaactc tctgaactca tccagcccct tcccctggag agggactgct

cagccaacac caccagctgc cacatcctgg gctggggcaa gacagcagat ggtgatttcc
ctgacaccat ccagtgtgca tacatccacc tggtgtcccg tgaggagtgt gagcatgcct
accctggcca gatcacccag aacatgttgt gtgctgggga tgagaagtac gggaaggatt
cctgccaggg tgattctggg ggtccgctgg tatgtggaga ccacctccga ggccttgtgt
catggggtaa catcccctgt ggatcaaagg agaagccagg agtctacacc aacgtctgca
gatacacgaa ctggatccaa aaaaccattc aggccaagtg accctgacat gtgacatcta
cctcccgacc taccacccca ctggctggtt ccagaacgtc tctcacctag accttgcctc
ccctcctctc ctgcccagct ctgaccctga tgcttaataa acgcagcgac gtgagggtcc
tgattctccc tggttttacc ccagctccat ccttgcatca ctggggagga cgtgatgagt
gaggacttgg gtcctcggtc ttacccccac cactaagaga atacaggaaa atcccttcta
ggcatctcct ctccccaacc cttccacacg tttgatttct tcctgcagag gcccagccac
gtgtctggaa tcccagctcc gctgcttact gtcggtgtcc ccttgggatg taccttttctt
cactgcagat ttctcacctg taagatgaag ataaggatga tacagtctcc ataaggcagt
ggctgttgga aagatttaag gtttcacacc tatgacatac atggaatagc acctgggcca
ccatgcactc aataaagaat gaattttatt atgaaaaaaa aaaaaaaaaa aaaaaaaaaa
agggcggccg c

SEQ ID NO. 8

KLK6 nucleic acid

mRNA join(2001..2185,3084..3135,3559..3606,4346..4502,
8122..8369,9791..9927,11805..12483)

CDS join (3567..3606,4346..4502,8122..8369,9791..9927, 11805..11957)

acacttaaaa aatcttctga cttaaaaaaa aaagtatggt gattggaaaa tgtaaatgtg
catgcgtgct tggcatcaca tttcattggc caggacttcc ctggatgcta aaggtcctca
aatgccaggc tgggggctg ggacttggtc ccaagggaga tggggaccca gggcacgtct
gtgagaggag gggcaaggtc agcacaaggc acaggaaggt ctctctgggg caagggatac
agagaacaga gggatcctgg tccaggtggg agaggtgcag ctctgagttg gggttgaggg
tgtgggtaca gagaggaagg gacccccag agagaggagg cagagggata gggcctggtc
actgggttgt gcaacatcag acttgctgtc tgtgaagata gcacgtcctg agaagaaggt
gctgaggtca gtggggacca aatgtgagag ggagcacccg gagagtatac tgaataccga
agtagtcttc atccctggag tgatgggggg tgcacaatgc aagatgacaa ttagattcaa
tgcaagacaa agaaaagggt tggctgggaa cagtggctca tgcctatggt cccagctcct
gggaagactg aggcgggagg gtcgcttgag cccaggaggg ttgaggctgc cacgagcaag
gatcgtgcca ctgcactcca gcctaggcga cagaacaaga ccttgtctca aaagaaaaaa
gaacttttt ttttaagtta cctgtagtgc ccagcccaag caggtgctga gccagacttc
attcctatca ttgtccttat tacgcagtga cttccccctc ctcatttctc tccactctgc
cacgcacaca ccctcaccct ccagcccata ccaaccaccc caaccactgc ctgtggtttc
ccatgtgcac ccaggccagg cattttcacg gcctttcctc ctgacctacg cctggctcag
ctttctaggc ccaagttcaa agacacctcc ctaaatcttc ccagatccct ctgctactgc
ccagcaccac catcttatca cagccccacg tcgttcccaa gtgctctccg atttctgctt
aactccatgc ctctcgctgt gtgtccgcat ctcatcaata agtcctcaag tcctcttcca
tcctgctagc ttcctcatcg ctcgggaatc atccccgcta cttcctgggg aaactgactc
ccttctgggc acacacagtg ctacccccgg ggaaatctaa gaagagaccc aggagaagat
aagcacggag agtcagagaa tcaaggggaa agaaagggag agaggccggg cacagtggct
cacacctgta atccagcact ttgggaggcc aaggtgggtg gatcacctga ggtcaggagt
ttgagaccag cctggccaac atggtgaaac ctcttcccta ctaaaaatac aaaaaacatt
tagccgggcg tggtggtggg tgcctgtaat cccagctact tgggaagctg aggcaggaga
actgcttgaa ctcaggaggc ggaggttgca gtgaactgag atcacaccac tgcactccag
cctgagtgac agagcaagac tccgtcaaaa aaaaagaaag aaagaaagaa aagaaggaag
gaaagaaaga aggaaggaag gaagggagga agggagagag gaagggagag aggaagggag
agagagaaaa aaagagggag agagacacaa atacagagac tgagatggga gagagagaga
gatggaagct ccctcccctc catggccagg gagacagatg gagcaagaga cctcaggggt
gggcagactt ggaggagaag gaccaggagg atgtggagtg ccgaaatctc cagtcagggc
caggtgggca gtcagagact gcaaaggagg actgtcagac agggacaaaa ggaagccatt
gatgtaaccg ccctcccgcc tgcccgccgg aagagaggtt gaggccggag ctgctgggag
catggcactg gggtgctggg aggcggacaa agcccgattg ttcctgggcc ctttccccat

cgcgcctggg cctgctcccc agcccggggc aggggcgggg gccagtgtgg tgacacacgc
tgtagctgtc tccccggctg gctggctcgc tctctcctgg ggacacagag gtcggcaggc
agcacacaga gggacctacg ggcaggtgtg tgagtcaccc caaccgcact gaacctgggc
aggctgcttc ccagtgccgg agggctctag agcccggagt gagggcctgc aggtccctgg
gtggcacaga gagtgctggg ggtgcaggga ggcctggggc accatctgct tgccccagag
gccggaattt gtcttcagac actttctttc tccaaaaccc ggaggtctaa ggactgagcc
gactagaact tcctctgcct cagattcagg ccccagcccc tcctccctca gacccaggag
tttaggtcct agcccctcct ccctcagacc caggagtcca agttcccacc tcctccctca
gactcaggag tccaggcccc cagcccctcc tccctcagac ccaggagtcc aagttctcac
ctcctccctc agacccagga gtccaggccc caagccctc ctccctcaga cgcaagggtc
caggccccca gcccctcctc cctcagactc aggagtccag gcccccaagc ccctcctccc
tcagacccag gagtccaggc cctcactgca ctcagggacc agtgctccct tccctggagg
cctggtcagg ggtcaccaag agcagagcgt gggggcggga ggaatgtgtg tgggaggcct
gggtaaggag gaaaagggtg tagccagtct cctggctcag ggacctgaga gacaggggtt
aaaaggacgt tccagaagca tctggggaca gaaccagcct cttccaggga ggcctgggag
ctgggggtgt gtgtctggca gtccctgcag ccctgggctc tgcggcccct gcgtcctccg
cttggctctg ccactgcatc tgagtgtctt ctctcctcac ggctccccgc atttctaact
ctttctgcct cctcgtctca aagctgttcc ttcccccgac tcaagaatcc ccggaggccc
ggaggcctgc agcaggtgag atcacagaca tcacagaacc tgccgggtgg gcggggtggg
tggccattgc gcacagagcc aggctccgag gaaaactccc atacagagga agaacgctag
ggccccctat ggtaaccctc tcctgtcgac aggaaggcaa atcagtgccc aagaaagtag
aaagatctaa tcagaatctc accatgggtt actggaccag tggacgtagt tgaattctct
ttggcactgt tttcgtggat cctcttggaa gatgtgggct gaggaagaat aaatcaggag
gctagatggg aaggacagag gtcaaggcag gagaccatag caggccagga aggaaggaga
ggatgcagag ggagcagaca gagggatggg gggagggtcg aggcagtgac taatggacca
tgtggcttcc cctctcagga gcggccatga agaagctgat ggtggtgctg agtctgattg
ctgcaggtgg ggaaagggca tttggatggg ggaggcttgc agacagggtt gggcttgttg
atggagaaga ggctggtatt ggggatgggg atatgcacag ggttggggtg ggggagcttt
gaaatgagga agacgttggg gattaggcta agggtgggga atacagatag ggagggtggt
gggaggtggg tttgaagata tgagggtttg gggtggggtt ggctttaggg atggggatct
aaacatagaa gaggtaggag gtaggttgga aagttggaga gagcccggga atagggggata
cagttgggtt tgtaatggga atggggtaag tttgggagtg gaaatacaga gaagcttttt
ttttttgaga cagggtctca ctctgtcacc caggctggag tgtagtggca tgatccatag
ttcactgcag acttgaactc ttgggtctca agtgaccctc ccacctcagc ctcccaagta
gctgggacta caggcgtatg ccaccatacc ctgctaattt gtgtgtgtgt gtgtgtgtgt
gtgtgtgtgt gtgtgtgtgg agatgaggtc tcactgtgtt accgaggctg gtctcaaact
cctgggctca agcgatcctc ctgcctcagc tgggattaca ggcataagcc actgcacctg
accaatcttg actggagttc atgttgaggg ggatgcgctt ggtttctcca gaactcctct
ctgactcaga tcttctctcc ctcagcctgg gcagaggagc agaataagtt ggtgcatggc
ggaccctgcg acaagacatc tcacccctac caagctgccc tctacacctc gggccacttg
ctctgtggtg gggtccttat ccatccactg tgggtcctca cagctgccca ctgcaaaaaa
ccgtgagtct acactgtaaa tgaacagcag atgcgactga accctgaggg tgtcttatag
atgtcaggca ggaggtgaca taggcatccc ccccatccca gcacgaggcc atctgatagc
caggtgcatt cggctgttgc ttaattgagt acttaatgtg tgccaggccc tgcgggcata
gcagtggaaa agaaaataaa aaaaagaaaa caaaaaaaaa caagcaaaat tgctgttttc
ctgaacttac tttctaatgg gggaattgga tcatttgggg acctgcaggg cgtgatgggc
atttggattt aattctgagc acagtaggaa gccactgggc agttttgttt ttgttgtttg
tttgtttttt gagacacagt ctcgctctgt cacccaggct ggagtgtagt ggcatgatct
cagctcactg caacctctgc ctcccaggtt ccagcgattc tcctgcctca gcaccccaag
tagctgagat tacaggtgtg caccaccttg cctggctaat ttttgtatgt ttggtagaga
cggggtttca ccatgttggc caggctggtc tcgaactcct gacctcaggt gatccgcccg
cctcgccctc ccaaagagct gggattacag gcatgagcca ccaccacacc cagcctgatt
tacattttta caagcaccct ggctaccacg tggaacgtgg tctgggcaag agagagggag
ggaggcccac gtgggggctg ttgctttcat ccggcgacat aggagggtgg cttgaaccca
ggcggtcgca gtggggatgg agggatgttg aatatcttgg gatgtggaat tctgagactg
agccagcaga atctggcaac gaggaacagg agggagagga agaagcacgg ctggcttccg
tgtatttgtc ctgaacaact gggtgttttg ccacgtcttt ctctgagttg tgggagaggg
aaagagaaac aggccgggtg taggcagggg agcatctgac attttgcttt agccacgatg
agttggagat gccggggaga tgtcccagca gggaggccag ggaggactct ggagctcaga

ggagaggtca gggctggagg ttaaaatgaa ggcatcgtca gcaaacaggt gtatttaaag
ccatgggact agatgagatc atccaaaaag ctggcatagt tggaggagct ggagggccca
ggacaaaaac cctgggcgct gatcctcact agtcagattc acgacagctg ccacttgttt
gatgctaact accaatcagg tgctgagtga aaccatgtac acacctttcc tggaatgccc
accacaaggg actcttggca ccattttgca aatgaggaaa ctgaggtgca gggaaatagc
aagtgacaat ccctggggtg gttcccctga ccccaaggag accttggatg actctcacca
ccatcattca ttcctttgat gtacattgac taagagcacc tgctaagtgc cacattcgag
ttgggcagtg gagattcagc aatggatggg acacacacgt catccctgcc ctcgggagca
caaggacaga aaggtgcaga caagcaaagt gagggctggg catggtggct cacgcctgta
atcccagcac tttgggaggc cgaggtgggt ggattacctg agttcgagac cagcttggcc
aacatggctc aaccctgtct ctactgaaaa tacaaaaaat tagccaggcg tggtggtggg
cttctgtaat tccagcaact tgggaggcta aggcaggaga attgcttgaa cgtgggaggc
ggaggttgca gtgagccgag atcgcgccac tgcactccag cctgaaccac agagcgagac
tctgtctaaa aaaaaaaaaa ggaaagaaag aagcagcaaa ttgggctggc cgtggtggct
catgcctgta atcccagcac tttgggaggc cgaggcgggt ggatcactcg agcccaggag
tacaaagctg cagtgagctg tgatctacag aacaccactg cagatccagc ctgggtgaca
gagcgagacc ctgtctcaaa aaaacaaaca aacaaaagaa gcaaaccctt caaaacccca
tataattaca aattatgaag gaaaagaata cgggtaccta ctttagatgg aggagggtca
ggaaggactt tctaatgaga taaaatccaa gcggaggcat gaagatggga aaaggaatgt
tcagggcaga ggaaaggctg tgataacacc cctgaggtga gaaccgtctt gagtattctc
agaaaataaa atttcccgtt cactgggggg cagaaggtgc tgggagataa ggttggaaag
tgactacagc cagatcacac aggggctcca gtgccaagtg gaggagccca ggctttattc
ttaggacaat ggggagccat gggtgatgtc tgagcaaggg agtgactctc tgtttcagga
atatgtatca aacacctatc ctgtgccagg tgctgatcaa cgcactggag atactatatc
tgaatagaac aaaaatcccc atcttgacat cctagagctg cactgtctaa tatggtagcc
atcagccaca tatagcaaat tacattgaaa ttaatgaaat ggaaaatcca caagccacat
ttcaagtact cagcagccac ctgtagcttg tggttccccc agccacctct ggacagtgca
gatcgagatc atggcatcgt agcatttagt ggacagcatt gctctgcaag gaggagaaat
aacacaatga gtaaatattt aacaataaat atatagcagg tcggatgatt gtgataggtt
ctctggtgga acagaaagca ggggagggag ataggaattg cctactaaca ggtatttgta
ttttaattgg gcaactaagg aaggcttccc tgagaggcga catttaaagg aagtgaggga
gtgagctatg cagatacttg gaggacagac ttgctggcag agggaacagc agtgcaaagg
ccctgaggtg ggaagatcac tattgtgttc aaggcaagac agggaagcca gcgtttggct
ggagcagagg gagagaaggg gagagtggga ggagaagatg tctgtgagat gatggggcag
tgcttgcaag gcctggtgtg ccacgttgag aactttggct ttgattctga gtgagatggg
agtcatagga ggggctgagc agaggaggca caggaccaac ttacattgtt aaaatatctc
tggttgcttt gtggaggatg gactgtgggg gaccagagac agagcaggga gcccagtgag
gaggctactg ctctagttca ggtaggaagt gaaaaggcag ctcaaaccaa gatggtagcc
gtgggaaagg tgagatgtgg ccagattctg gatatgcttc agagaggcaa aaggaattct
ggacagcttg gatgtagggc atgaaataaa gagagtgaag aatagccccc aagattattc
tgaaaggatg gaattgccat ttacccagct ggggaagact gtgggaggag caggccagcg
attcatgact tcccagccct ctctgaagcc tcaactgcag cccaagggct ccaggtgaga
cccagccctc ttccttccca ggaatcttca ggtcttcctg gggaagcata accttcggca
aagggagagt tcccaggagc agagttctgt tgtccgggct gtgatccacc ctgactatga
tgccgccagc catgaccagg acatcatgct gttgcgcctg gcacgcccag ccaaactctc
tgaactcatc cagccccttc ccctggagag ggactgctca gccaacacca ccagctgcca
catcctgggc tggggcaaga cagcagatgg tcagtagtgg gaggctggtg gggagcaggc
tactggctac ttggggaagt gtgccaaagg atggggagtg ggaaaattgg tgaggggcca
tgggaagatg ggctaatggt gaggaccaat gggacagggt ttcaatggga gaaaggtcaa
gggggaggga gagtgaattt gggagctggg ccagtgagtg aacagccaat ggaaaatgta
gaccaatggg tgaatagcat gggagagatg gaacataaga tgaaggttca ataaagaggg
aaggtcagtg gggagatgct aatcaggaag gatgtcaaag gtcaaagggg actgatcagg
attcattgaa cagcaggaag gaataatgga gaaggaactg atggaagaag agaaaccaat
aaagcacaaa agccaactga aggatgtgaa ttgagacagt gaatgggggt atagctgatg
gaagagggac taaggggaaa ggatcaatgg tccagaggag tcactagagg aaaaaacagg
tccaatagat cagcaggatc catgaaggtg ggcctgtgtg tgaagggcca ataagaaagg
tgaaccattg gatgaagggc cagtgggaag gcagagacaa tgggggagga tgcggcaagt
tagaaaagga ccaatgaggg aggtggacca ttggatgaag ggctaatagg aagggagagc
cagtgggggа tggtgaggcc agttagaaaa ggaccaagga gggaagcaga ccaataggaa

gagagagcca atgagggagg gcagggccag ttaggaaagg accaatgagg aaggtagacc
attggaggaa gggccaatag aaagggagga tccatgaggg agggtgggga cagttagaaa
aggaccaatg atggaggtgg accattggat gaagaaccaa tagaaaggaa gaaccaatgg
gagagggcat ggccagttag gaaaagacca atggtcacag agtgaccaat caagatgaat
caatgggcag gaagtgtcca atgaagaatg gactactgat caggaggggt acagtagagg
agggcgtaac agaggaagag tcctccaggt caactgaaac tactgaagaa ggtgggacca
gtggaagaga gaaaagtgga ggagggacct aagagaaaag gaaaaccaat aggaaatgag
gactcctgga gaagagacta ttaatgagga agacagccaa tgggggggaa gaatgataga
aagagggacc aattaggagg cagggacgat ggtaatgaga tgtaagaatg agagacaaac
aggaagaggg gtgccaatag aaaagaggga ccaatagagg atggaggact tataggggtt
ggggggtgac tggggaggat gaggggagtg caaggcctgg gctgagtctg gcccatctct
cccctaacag gtgatttccc tgacaccatc cagtgtgcat acatccacct ggtgtcccgt
gaggagtgtg agcatgccta ccctggccag atcacccaga acatgttgtg tgctggggat
gagaagtacg ggaaggattc ctgccaggtg aggtgacccg gatctgccac ttacacagcc
agggacagga cgaagtcaca aaaacatggc cagacacagg aagagagaga cacaggccaa
aagagagctt tacagagaca gatagagaca ggctgaggga gaacccaagc cttgaaaaga
agagacttag ttcaacacac agagacacag tcagggatat gcagagatat aaagacacag
ccagcagaga caggaagtgc agagacaagg atggaggccg cgggatcaag aaccagagag
gccaggagca gcggctcatg cctgtaatcc cggcactttg ggaggccgaa gcaggaggat
cacctagggt caggagttcg agaccagcct gatcaacatg gtgaaaccct atctctacta
aaaatacaaa aattaggatg ggcacagtgg ctcatgcctg taatcccagc accttgggag
gccgaagcag gaggatcacc tggggtcagg agttcgagac cagcctgatc aacatggtga
aaccctatct ctactaaaaa tacaaaaatt aggatgggca cagtggctca tgcctgtaat
cccagcacct tgggaggccg aagcaggagg atcacctggg gtcaagagat tgagaccagc
ctggccgata tggtgaaacc ctatctctac taaaaataca aaaattagct gggcctggtg
caggcgcctg tagtcccagc tactcaggag gctgtggcag gagaatcact tgaacctgga
ggcggaggtt gttgcagtga gtcgagatca tgctactgca ctccagcctg gcaacagagc
aagattccgt ctcaaaaaaa aaccaaaaaa caaaaattac gcaagcatgg tgggacacac
ctgtagtccc agctactcgg gaggctgagg ctggagaatt gcttaaaccc aggaggcaga
ggctgcagtg agctgagatc acgccactgc actccagcct ggggacagag ccagactctg
tctaaaaaca aaaagaacca aagagaagta gtaaggaagc agatggtgtg aggggactgt
ccttcctcaa acagagcccc cacgagtcct gctcagaaac gaccaggctc tggaggaggg
agacactagc tggggaaagg ggactccctc ccgaatactt taacttgggt ttcctccatt
gtcatccatc caggctctcc tctttatgcc agaatgacta atgcactgag ggatgtgcag
agaccaacca agggggagac acaggcagaa acggagacac aggcagaaac agggacagag
acagggaaag cgatacatag caagttggac gcaaagaaag ggcaggtggg cgagactgtc
ctcaagacac gaggtggaga ggtgtccctg gacagaatag tgccaggcat atctctccct
gggccctccc tacctctccc acctgggtct tatcgtctcc tcctcccct cctccctctc
ctcctcttcc tcctcctcct cctccctcat catcttcttc ttttctctct ctctccatcg
gtctctacac ctctgcctct ctccacacct ctcagtctcc attcttaaat tgtttctctt
tcttgctctc tatgttcctc tgcatcttgg cattcctatc tctgtgtctt tgagtctcct
ttattctctc tctaccattc tctctctgtg cctttgtgtg tcttactgtc tctctctctg
tctctctgtc cctgagtctt tctctccatc tttcagtaag tacctctgtc cctttctacc
tctctctctg tcacacacac acacacacac acacacacac acacacacac acacacagtc
tctgggtttc tatctgtatc tgactttctc cctctttcct gcagggtgat tctgggggtc
cgctggtatg tggagaccac ctccgaggcc ttgtgtcatg gggtaacatc ccctgtggat
caaaggagaa gccaggagtc tacaccaacg tctgcagata cacgaactgg atccaaaaaa
ccattcaggc caagtgaccc tgacatgtga catctacctc ccgacctacc accccactgg
ctggttccag aacgtctctc acctagacct tgcctccccc cctctcctgc ccagctctga
ccctgatgct taataaacgc agcgacgtga gggtcctgat tctccctggt tttaccccag
ctccatcctt gcatcactgg ggaggacgtg atgagtgagg acttgggtcc tcggtcttac
ccccaccact aagagaatac aggaaaatcc cttctaggca tctcctctcc ccaacccttc
cacacgtttg atttcttcct gcagaggccc agccacgtgt ctggaatccc agctccgctg
cttactgtcg gtgtcccctt gggatgtacc tttcttcact gcagatttct cacctgtaag
atgaagataa ggatgataca gtctccataa ggcagtggct gttggaaaga tttaaggttt
cacacctatg acatacatgg aatagcacct gggccaccat gcactcaata aagaatgaat
ttt

SEQ ID NO. 9

KLK6 nucleic acid

CDS 246..980

aggcggacaa agcccgattg ttcctgggcc ctttccccat cgcgcctggg cctgctcccc
agcccggggc aggggcgggg gccagtgtgg tgacacacgc tgtagctgtc tccccggctg
gctggctcgc tctctcctgg ggacacagag gtcggcaggc agcacacaga gggacctacg
ggcagctgtt ccttcccccg actcaagaat ccccggaggc ccggaggcct gcagcaggag
cggccatgaa gaagctgatg gtggtgctga gtctgattgc tgcagcctgg gcagaggagc
agaataagtt ggtgcatggc ggaccctgcg acaagacatc tcacccctac caagctgccc
tctacacctc gggccacttg ctctgtggtg gggtccttat ccatccactg tgggtcctca
cagctgccca ctgcaaaaaa ccgaatcttc aggtcttcct ggggaagcat aaccttcggc
aaagggagag ttcccaggag cagagttctg ttgtccgggc tgtgatccac cctgactatg
atgccgccag ccatgaccag gacatcatgc tgttgcgcct ggcacgccca gccaaactct
ctgaactcat ccagcccctt cccctggaga gggactgctc agccaacacc accagctgcc
acatcctggg ctggggcaag acagcagatg gtgatttccc tgacaccatc cagtgtgcat
acatccacct ggtgtcccgt gaggagtgtg agcatgccta ccctggccag atcacccaga
acatgttgtg tgctggggat gagaagtacg ggaaggattc ctgccagggt gattctgggg
gtccgctggt atgtggagac cacctccgag gccttgtgtc atggggtaac atcccctgtg
gatcaaagga gaagccagga gtctacacca acgtctgcag atacacgaac tggatccaaa
aaaccattca ggccaagtga ccctgacatg tgacatctac ctcccgacct accaccccac
tggctggttc cagaacgtct ctcacctaga ccttgcctcc cctcctctcc tgcccagctc
tgaccctgat gcttaataaa cgcagcgacg tgagggtcct gattctccct ggttttaccc
cagctccatc cttgcatcac tggggaggac gtgatgagtg aggacttggg tcctcggtct
taccccccacc actaagagaa tacaggaaaa tcccttctag gcatctcctc tccccaaccc
ttccacacgt ttgatttctt cctgcagagg cccagccacg tgtctggaat cccagctccg
ctgcttactg tcggtgtccc cttgggatgt acctttcttc actgcagatt tctcacctgt
aagatgaaga taaggatgat acagtctcca tcaggcagtg gctgttggaa agatttaaga
tttcacacct atgacataca tgggatagca cctgggccgc catgcactca ataaagaatg
tatttt

SEQ ID NO. 10

hk7 amino acid

MARSLLLPLQILLLSLALETAGEEAQGDKIIDGAPCARGSHPWQ
VALLSGNQLHCGGVLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSFRHP
GYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFP
SDLMCVDVKLISPQDCTKVYKDLLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGL
VSWGTFPCGQPNDPGVYTQVCKFTKWINDTMKKHR

SEQ ID NO. 11

KLK7 nucleic acid

CDS 16..777

ggatttccgg gctccatggc aagatccctt ctcctgcccc tgcagatcct actgctatcc
ttagccttgg aaactgcagg agaagaagcc cagggtgaca agattattga tggcgcccca
tgtgcaagag gctcccaccc atggcaggtg gccctgctca gtggcaatca gctccactgc
ggaggcgtcc tggtcaatga gcgctgggtg ctcactgccg cccactgcaa gatgaatgag
tacaccgtgc acctgggcag tgatacgctg ggcgacagga gagctcagag gatcaaggcc
tcgaagtcat tccgccaccc cggctactcc acacagaccc atgttaatga cctcatgctc

gtgaagctca atagccaggc caggctgtca tccatggtga agaaagtcag gctgccctcc
cgctgcgaac cccctggaac cacctgtact gtctccggct ggggcactac cacgagccca
gatgtgacct ttccctctga cctcatgtgc gtggatgtca agctcatctc cccccaggac
tgcacgaagg tttacaagga cttactggaa aattccatgc tgtgcgctgg catccccgac
tccaagaaaa acgcctgcaa tggtgactca gggggaccgt tggtgtgcag aggtaccctg
caaggtctgg tgtcctgggg aactttccct tgcggccaac ccaatgaccc aggagtctac
actcaagtgt gcaagttcac caagtggata aatgacacca tgaaaaagca tcgctaacgc
cacactgagt taattaactg tgtgcttcca acagaaaatg cacaggagtg aggacgccga
tgacctatga agtcaaattt gactttacct ttcctcaaag atatatttaa acctcatgcc
ctgttgataa accaatcaaa ttggtaaaga cctaaaacca aaacaaataa agaaacacaa
aaccctcaa

SEQ ID NO. 12

KLK7 nucleic acid

mRNA
join(1756..1785,3179..3309,3722..3869,4566..4813,5129..5265,7362..8265)
/product="stratum corneum chymotryptic enzyme" /note="alternatively
spliced"

mRNA join(1756..1785,3179..3309,3722..3869,4566..4813,
5129..5265,7362..7991) /note="alternatively spliced"

mRNA
join(1821..1864,3179..3309,3722..3869,4566..4813,5129..5265,7362..8265)
/product="stratum corneum chymotryptic enzyme" /note="alternatively
spliced"

mRNA
join(1821..1864,3179..3309,3722..3869,4566..4813,5129..5265,7362..7991)
/note="alternatively spliced"

CDS join(3237..3309,3722..3869,4566..4813,5129..5265, 7362..7517)

ggcatggtgg tgcacgcctg taatccagct actcaggact ctgaggcagg agaatcactt
gaacacgggg gagtggaggt tgcagtgagc cgagatcgtg ccattgcact ccagcctggg
tgacagagcc agagtccatc aaaaaaaaaa aaaaataaga aagattcttc tctcctctat
gtgtccatgc agtctcatca tttagctacc acttgtaagt aggaacatgc catatctggt
tttctgttcc tgctttagtt tgtaagggta atggcctcca gctccattca cgtccctaca
aaggacatga tcgtgttctt ttttatggct acgtagtatt caattgtgta tacgtaccac
attttcttaa tccagtctat cactgatgga catttaggtt gattccctgt gtttgctgtt
gtcaatagtt ctacaatgaa cgtacgtgtc catgtgtctt taaacagaat gatttatatt
cctttgggta cacacactgg ggcttatgag agggtggaga gtgggaggaa ggagaggatc
agaaaaaaat aactaatggg tactaggctt aatacctggg tgattaaata atctgtataa
caaaccccca tggcgcacgt tcacctacgc aacaaacctg cacatcctgc acatgtaccc
ccgaactgaa aagttaaaaa aagaaaaata aatatttgct tataaattaa taaatgaagc
cctcaaaaat gttctattag ataatgttaa gtacagacat ttttgttata aatacataat
atacaaagaa atctatgtat aacatgatta aaatgaccat aagaacatag atcctaaaca
tggcaaatat tagtggggtg gggttaggga aagcgttgtt tttaacttac acctctctgt
tagagttggg aatgggttca ggcgtaatta caggcacgac tgggatcagc ttggacaagt
tcccccaggc gggccagaat taggatgtag ggtctaggcc acccctgaga gggggtgagg
gcaagaaaat ggccccagaa gccgggcgca gtggctcacg cctgtaatcc cagcactttg
cggggccgag gcgggcacat catgaggtca ggagatcgag accattctgg ccaacatagt
gaaacccggt ctctactaaa aatacaaaaa ttagctggga gtggtggtgc gtgcctgtaa
tcccaggtac tcgggaggct gaggcaggag aatcacttga acctgggagg cggagctggc
agtgagccga gatcgcgcca ccgcactcca gcctggcgat agagagagac tccatccaaa
aaaaagaaag gaagggaggg agggaggagg gaagaaagaa agaaaaccgc cccagagaag

gacccgagcc agagcctatt ctctgagctc agcgactgct tgaatcccgc tcctgcccct
cagacccagc gcaccgggtc cctcccccga gagcagccag gagggactgt gggaccagaa
tgtgcggggg cgcaggagct gggcaccgcc cgtccttcgg agggagggtg gagagagagt
gcagtggtgc caattgctct cgctgcgtca gggttccaga taaccagaac cgcaaatgca
ggcgggggtg tcccagagtc ggctccgcct gcaccccagg gcgctggggc cgggcatggg
gcgggggggtg atataagagg acggcccagc agagggatga agattttgga gcccagctgt
gtgccagccc aagtcggaac ttggatcaca tcagatcctc tcgaggtgag aagaggcttc
atcaagggtg cacctgtagg ggagagggtg atgctggctc caagcctgac tctgctctcg
agaggtaggg gctgcagcct agactcccgg tcctgagcag tgagggcctg gaagtctgca
atttggggcc ttttagggaa aaacgaacta cagagtcaga agtttgggtt ccacagggaa
gggcaagatc ggagcctaga ttcctgggtc tctagggatc tgaagaacag gaattttggg
tctgagggag gaggggctgg ggttctggac tcctgggtct gagggaggag ggcctggggg
cctggactcc tgggtctgag ggaggagggg ctgggggtct cgactcctgg gtctgaggga
ggaggggctg ggggcctgga ctcctgggtc tgagggagga ggggctggga cctggactcc
taggtctgag ggaggaggag ctggggcctg gactcctggg tctgagggag gaggggctgg
ggcctggact cctgggtctg agggaggagg ggctggggcc tggactcctg ggtctgaggg
aggaggggct ggggcctgga ctcctgggtc tgagggagga ggggctgggg cctggactcc
tgggtctgag ggaggagggg ctggggcctg gactcctggg cctgagggag gagggactga
gacctggact cctaggtctg agggaggagg gactgggacc tggactcctg ggtctgaggg
aggaggagct gggggcctgg actcctgggt ctgagggagg aggggctggg gcctggactc
ctgggtctga gggaggaggg gttggggcct ggactcctga gcctgaggga ggagggactt
ggacctggac tcctaggtct gagggaggag gagctggggg cctggactcc taggtctgag
ggaggcgggg ctgggggcct ggactcctgg gtctgaggga ggaggggttg gggcctggac
tcctgagcct gagggaggag ggacttggac ctggactcct aggtctgagg gaggaggagc
tgggggcctg gactcctagg tctgagggag gaggggctgg gggcctggac tcctgggtct
gagggaggaa ggtgctaggg tctggactct tgggtatgag ggaggaggag gttaggggtc
tggacttctg agtgtaagga aggagaggcc agagaaagga atttctgggt ctgagggagg
aggggctggg gttctggacc cctaggtctg agggaggagg ggctggggcc tggacccctg
ggtctgaggg aggaggggct ggggccggta ctcctgggtc tgtgggggga ggggctgggg
cctggacccc tgggtctgag tggggagggg ctgggcctga atgctttctc cttctcagct
ccagcaggag aggcccttcc tcgcctggca gcccctgagc ggctcagcag ggcaccatgg
caagatccct tctcctgccc ctgcagatct tactgctatc cttagccttg gaaactgcag
gagaagaagg tgaaagctgg actgggaagt ctgacctcac ctcagggccc ccactgaccc
tctccaagga gtccctgagt cagaaccctt ccctcctcaa acagcttcca tcctgggagg
accagactgt cggctgaagc ccccgctctt cctgcttctg ctgactcagg gggtctctgt
cccctccagg ccctgcctcc tgtgctcagg gtctctctgt ggttccccag atgagatgcg
cctcctgggt ttctgagtgg gctccttctg tctgtctcta tccctatctc ttgctttctc
tgtatttctc cacacatttt catctgtctc tgtccatctc tgactctggg aatccctgag
gtgcagcctc agccttcccc taatgctagc tacccacgtg ctcctccatg tctccatcca
gcccagggtg acaagattat tgatggcgcc ccatgtgcaa gaggctccca cccatggcag
gtggccctgc tcagtggcaa tcagctccac tgcggaggcg tcctggtcaa tgagcgctgg
gtgctcactg ccgcccactg caagatgaag taggtgccgc ccaagtctct gctggaggtg
caccagcgtc tccagctcgc tatgggggtg gaagggcagt ctttctgtgc ctacggctct
attctcctct ctctgggtct ctgtcctcct ctctctgggc ctctgtaccc cctctccctg
gggctctgtc cccctctctc cctggctctc tgtctccctc tctctgggtc tctgtccccc
tctctctgga tctctgttcc cctctctctg tgtctctgtt ccccattctc tctaggtctc
tgttcccccct cctctctctc tgggtctctg tccctctctc tctggatctc tgtccccctc
tctctctggg tctctgttcc cctctctctg ggtctctgtc ccctctcctc tctctgtgtc
tctctccccc ctcctctctc tgtgtctctg tccccctcc tatctctgtg tctctctccc
ccctcctctc tctgggtctc tgtcccccc tctctgggtc tctgtctccc tctctctggg
gctctgtccc cctctctctc tggatctctg ttcccctctc tctgggtctc tgtctccct
cctctctctg tgtctctgtc ccccctcctc tctctgggtc tctgtcccca ccccgtcccc
caggtctttg cacaccctct ctgtcacagt gtctcttctg aatctgtgaa tgtcactcct
cgcagtgagt acaccgtgca cctgggcagt gatacgctgg gcgacaggag agctcagagg
atcaaggcct cgaagtcatt ccgccacccc ggctactcca cacagaccca tgttaatgac
ctcatgctcg tgaagctcaa tagccaggcc aggctgtcat ccatggtgaa gaaagtcagg
ctgccctccc gctgcgaacc ccctggaacc acctgtactg tctccggctg gggcactacc
acgagcccag atggtaggtg gcctcagtga cccaggagtg caggccccag ccctcctccc
tcagacccag gagtccaggc ccccagcccc tcctccctca gacccaggag tccaggcctc

agcccctcct ccctcagacc caggagtcca ggcccccagc ccctcctccc tcagacccgg
gagtccagac cccagcccct cctccctcag acccagcagt cctgggcccc agaccctcct
ccctcggaac caggagcctg aacaacagcc cttctggtcc tcgcccccat cctctctgac
tgacagctct ccctgctcct ccctgcagtg acctttccct ctgacctcat gtgcgtggat
gtcaagctca tctcccccca ggactgcacg aaggtttaca aggacttact ggaaaattcc
atgctgtgcg ctggcatccc cgactccaag aaaaacgcct gcaatgtgag accctccccc
ccaattcctc cccagtcctg ggtaccctgt ctgcatgccc cagggacaga gcttgacccg
agtgactggg taccaagccc ggccttgccc tccccccagg cctggcctcc tcagcttttt
ccacctcatt ctctgcctag gtcaggggtg ggagtttact taggggccaa tgtggccctg
gggatgagac agagagttta atagggggtga gaaagtgggg gtgggaccag ggaaggagac
tgaggtgctg gcctcaggcc caaaccttaa gggggcacca aaaacctcag tgattgagat
aaatcataat gcaatattta aaaataaaaa taaaaactca tgcagaagtc catgatggac
aaaatgtcac attttaaata aagagcaggt ggatcttact gaattttccc ttgccgtaag
tactagcgtg gctcagcaca gcgctgtact ggcactgtct tcatttaaaa tgtggatacc
atgcccatca tgcagtttta tgtattacat ttgatttcgt taagtactgc attgaagtat
tgtgtattgc agttactgag attttgtgcc tgaagctgat gactcactca cctgaccctg
gccctggtcc cggggaaaac actctttctc tccacctcct ctctgttccc tctttctggc
cttttgtcat cccctctgtt tctgaacagt cttcccacat ctctctttgt gacataattt
catttcattc ttttcctctt tgtttttttct ctgtgttgag ctagcttgct ctccctccct
tgttctctct ccatgccctc ctctctgctc tctgtcttct ccctctttct cttgcttctc
tctctctcct cccctccctc tctcctctcc ctgcccccct gctctctctt ttttcctctc
tctctgtctc ctctctggcc ctctcctctt tctctctctc ccccacttct ctgtctctct
tcatctctct ccctcatctc tccttgcccc ctccttttta ctgtctctct ctttctcttt
cttctatctc tctcctctcc ctgccgctcc cccatctctg tctttctttc tctctcttta
ttctcctcct ctcttccagt ctctctctcc tctccccacc cccaccccat ctctctcccc
acaccttccc ccccttttctc tttgtctctc tcttctccct ctttcttctc caccccccatc
tctctctctc ttctcttccc acaccctccc catctccctc atctctttgt ctgtctctct
tctccctcct tcttttccac ccccatctct ctgtctctct ctctccccat acccttttccc
tcttcctcat ctctctttgt ctctctctcc tttccctctt tcttctccac ctccaactct
ctctgtctct ccacacccat cctccttgct cacatctgca ccttcagctg tcaggggatg
tgggatggtg agtgttaggg atagaggaga tgggagagag atgactgtcc tagagaatag
ggtgttcccc ttctccccctg gtgagggcca gtttcatgaa tgtgcaagct ctgcacggac
acagagcccc acactcagaa gggtctcaaa cttagtctaa tgcattcctg ctgttgtctt
gaaattctca ataatttttg aacaaagggc cctgcatttt cgttttgcac caagtcctgt
aaattatgta actggtcttc accctggtct ccgagaccat cgtgtccccc tttcctgcgc
cacagggcac gcatccaccc cttggagatg atgttccttc tcccactagc ttggagcagg
gtccttaaca ttggaaaata aagagtgctc tgatcctgga agccccaccc cttctctgca
attggtctca ttggccaagg gtcaaaccag tgtcttcaaa ggacctagtg tgtccctagc
actagctctc ccattagtcc ccagagacaa tgagtctctt ctcattggct atggtggaag
tccataatct gcaagacaaa gaccgataac tgaggaatgt atgagaatga gttgggcttt
gatctgaagc caaagttaat ctccggctct attccctcta gggtgactca gggggaccgt
tggtgtgcag aggtaccctg caaggtctgg tgtcctgggg aactttccct tgcggccaac
ccaatgaccc aggagtctac actcaagtgt gcaagttcac caagtggata aatgacacca
tgaaaaagca tcgctaacgc cacactgagt taattaactg tgtgcttcca acagaaaatg
cacaggagtg aggacgccga tgacctatga agtcaaattt gactttacct ttcctcaaag
atatatttaa accaacctca tgccctgttg ataaaccaat caaattggta aagacctaaa
accaaaacaa ataaagaaac acaaaaccct cagtgctgga gaagagtcag tgagaccagc
actctcaaac actggaactg gacgttcgta cagtctttac ggaagacact tggtcaacgt
acaccgagac ccttattcac caccttttgac ccagtaactc taatcttagg aagaacctac
tgaaacaaaa aaaatccaaa atgtagaaca agacttgaat ttaccatgat attatttatc
acagaaatga agtgaaacca tcaaacatgt tccaaaagta ccagatggct taaataatag
tctggcttgg cacaacgatg tttttttttct ttgagacaga gtctctgttg cttgggctgc
aatgcagtga tgcaatcttg gctcactgca acctccgcct cctgggttca agtgattctc
gtgcttcagc ctcccaagta cctgggacta caggtgtgca ccaccacacc aggctaattt
tttgtgtatt tttactagag acagggtttc accatgttgg ccagcatggt cttgaacgcc
tgacctcaga tgatccaccc accttggcct cccaaagtgc tgggattaca ggcatgagcc
accacggcca gcccacaatg atattacaaa cctattaaaa atgatactta gacagaattg
tcagtattat tcaagaacat ttaggctata ggatgttaaa tgacaaaagg aaggacaaaa
atatatatgt atgtgaccct acccataaaa aatgaaatat tcacagaatc agatctgaaa

acacatgtcc cagactgcat actggggtcg tcatgaggtg tctccttcct tctgtgtact
tttccttgaa tgtgcacttt tataacatga aaaataaagg tggggaaaaa agtctgaaga
tctaagattg gagagaggtg acctttcagg aagggagact agaaagaaat atgtgcctgg
ttttgagccc tggtcctgcc ggccctgttc cagggcatat ttccatttcc cagatctcag
ttttttcctgt ctgtaaaatg ggagagagag gaaaggatgg agagaggaag aaggaaggga
ggagggagga gagaacaggc caacttcatc agcgtgggaa ggggtgtgaa agtgtttctg
agcatctcac gagtgacaag tgaggaggga ggctggcggt tttcagaggg attgggatga
cagtagacag gacacagggg tcccacgggg gtctgccaga agtaagcaaa cagtgccgga
ggaagatggt ggcacctgct ccccaagaag ggagggaaag gaacctcggg aagcgggtag
gatgagggag gagtcctctg tgactcagag cctggccaca gccccagcca tctaacatca
aagatcctct gtgtggtcac acctcagacg ctgctgaccg aggagccact ccagcccagg
acacgccctc ctacctgttc ttcctgtttt tctcccagaa ttccctcccc accaagatcc
tccagatcct tcccctcctt atctcatctc cctctgagtc tctcctaacc caggcaccac
agccctgtca tattgcagaa attctgcagc cgctaattct gattctccca tataggaggc
taacacagaa aacgcaggag tccaggcccc cagcccctcc ttcctcagac ccaggagtcc
agaccccccg ccccaacccc tcctccctca gacccaggag cccaggtccc cagccccttc
tgtttctggg cctgtcaagt ttaagaatgt caaacatttt cgaccagtca ttcccctgaa
gttttagcaa cattttctct ctcttctgca aggcactcca acattcaatc tggaatttta
aaaagtaaca aaacattgca tttgcactaa gtcagcctgg agatccctgg ccctggccct
ctgctctcct atacgcaagc tacaggtaga ttggtttgca atgactgaga tggtactaat
gttgattttt tttaagtaat tcatttttct ttgggtaagc agtatagtgt ggtagttaag
ggactagctc tggatcttgg cttcttgggt tcaaatccca gttctagtcc ctacaagcta
ttttccttta agctcattac ttcccctgtc cctgttcctt catccttgaa atgggagaaa
aagcacctac tttctagggt tattacagag attcaataag ttaatataca gaaagtgctc
aaacattgt

SEQ ID NO. 13

Hk8 amino acid

MGRPRPRAAKTWMFLLLLGGAWAGHSRAQEDKVLGGHECQPHSQ
PWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSLQNKDGPEQEIPVVQ
SIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQPGQKCTVSGWGTV
TSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSKGADTCQGDSGGPLVC
DGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSKG

SEQ ID NO. 14

KLK8 nucleic acid

CDS 35..817

gtgaccccgc ccctggattc tggaagacct caccatggga cgcccccgac ctcgtgcggc
caagacgtgg atgttcctgc tcttgctggg gggagcctgg gcaggacact ccagggcaca
ggaggacaag gtgctggggg gtcatgagtg ccaaccccat tcgcagcctt ggcaggcggc
cttgttccag ggccagcaac tactctgtgg cggtgtcctt gtaggtggca actgggtcct
tacagctgcc cactgtaaaa aaccgaaata cacagtacgc ctgggagacc acagcctaca
gaataaagat ggcccagagc aagaaatacc tgtggttcag tccatcccac acccctgcta
caacagcagc gatgtggagg accacaacca tgatctgatg cttcttcaac tgcgtgacca
ggcatccctg gggtccaaag tgaagcccat cagcctggca gatcattgca cccagcctgg
ccagaagtgc accgtctcag gctggggcac tgtcaccagt ccccgagaga attttcctga
cactctcaac tgtgcagaag taaaaatctt tccccagaag aagtgtgagg atgcttaccc
ggggcagatc acagatggca tggtctgtgc aggcagcagc aaaggggctg acacgtgcca
gggcgattct ggaggccccc tggtgtgtga tggtgcactc cagggcatca catcctgggg
ctcagacccc tgtgggaggt ccgacaaacc tggcgtctat accaacatct gccgctacct
ggactggatc aagaagatca taggcagcaa gggctgattc taggataagc actagatctc
ccttaataaa ctcacaactc tctggttc

SEQ ID NO. 15

KLK8 nucleic acid

CDS join (<1..39, 418..712, 878..>946)
Exon <1..39
Exon 418..712
Exon 878..946

tcttcggttc ccggttactg gcagcagccc cctcctccca caaaagatca ggttccaagc
ttctcctttt aaaagtactt agaattcagc ccccagctct ctcctccctc acacccagga
atccaggccc ctagcccctc ctccctcaga cccaggagtc ctggccccta gcagcccct
cctccctcag acccaggagt ctgggccccc agcccctcct cggtcagacc taaatcccag
gtcccagtcc ctcctccctt agatttagga gtccaggccc ccagcctctc ctccctcaga
cccaggaatc caggccccca gcctcctccc ctctcagaac taaaatcttg gcccccagcc
ctttatgttt cagatcgtag agtctcagca ccgagtccct cctctcccta gcctcaggag
tctgagattc cagcccctcc tccctcaaga tttcacgttc aatcccctcc gcccccttctc
actcacaccc agtgttccag ttcccagaag ctccccaggc tctagtgcag gaggagaagg
aggaggagca ggaggtggag attcccagtt aaaaggctcc agaatcgtgt accaggcaga
gaactgaagt actggggcct cctccactgg gtccgaatca gtaggtgacc ccgcccctgg
attctggaag gtgaggtgca gaggtactca gatacagaca tcaggccccg gaccctcctt
ctccagattc caggacccca gcctcagatg cccttctctg tcgagatcca gcagtctgga
ccccggcttc ctcctctccc taatttagga gtcccagctc ccagctccct gtcccctcag
acccagacat cgaggactcc cccctccctt ggaatgtagg aatccagtcc cccagcctcc
tccttcctcc agagaagccc agaacagccc cagatactct cggctgcctc cccagtgccc
aaatccagaa ctgggagctc aggctcctcc ttcctgttta ccggccccgc cctctccatt
tcccagacct caccatggga cgcccccgac ctcgtgcggc caagacgtgg atgttcctgc
tcttgctggg gggagcctgg gcaggtgagg agggttgcgg aggcctccgg aggggaggga
tctgaaggca gcagtggcgc tggggagtct gtgggaatgc cgcgggggtt atgtgggtgc
gtgtgcacgg atgtgaagag tgcgatacgg tgcaggagcc tctgtgggct ttcctcaggg
tggacagagg caagaaacag gtagcagcag gtaggagtag gttccgtgat gctgtaaatt
gtctgaatag ctacagcctt tgggggctgc ttgcttgggg gcatagattc acctgggagt
actcggggcc tgtagactca tgtggaagca tgtgggggca ttcttgggtg tgtgactctt
gtatgatgac acatggactg aaatgagtgt ccccgtgtgg cagcgtgtgg aagcctggac
ctcctcacta agttgtatgc ggagaacttg ccgtgtgtcc atttgaaccc acagtggcct
tcccagccct cgcactgccc cagagggtgg cgatccaacc ctctccctcc tgctgcagga
cactccaggg cacaggagga caaggtgctg gggggtcatg agtgccaacc ccattcgcag
ccttggcagg cggccttgtt ccagggccag caactactct gtggcggtgt ccttgtaggt
ggcaactggg tccttacagc tgcccactgt aaaaaaccgt gagtggatga tgggggcaga
ggtcagctgg ggcttaagga aagagggggc tggggtttcg actcaggaag gagagagctg
aggactggac tcctgggtct gaaggaggag ggggctgggg gcaatacccc tgcctgggtc
ccaaactatc cccaccatta caggaaatac acagtacgcc tgggagacca cagcctacag
aataaagatg gcccagagca agaaatacct gtggttcagt ccatcccaca cccctgctac
aacagcagcg atgtggagga ccacaaccat gatctgatgc ttcttcaact gcgtgaccag
gcatccctgg ggtccaaagt gaagcccatc agcctggcag atcattgcac ccagcctggc
cagaagtgca ccgtctcagg ctggggcact gtcaccagtc cccgaggtag tgggcttgtc
cactaatggg agggagagga ggagctggtt ggcccagtgg aacccaagct attggcaaag
cttggtcccc cagagggaga caaagaaggg aaagtgatca tgatgttgag attcacaagc
aggagtcata tgagaagcct cgaagatctg actactaaca agagtggtga gagaaagaac
caactagcag attgttaagc agggccagaa aagcccatcc tgtatggcgg agagcactac
cctatgggac ctttggttgt ataggatttt atataatctt aacacacttg ggatattttg
gacttctcag aggcccagga aaacaggctc ctaagcacct tctcccccac ctccctcctt
ttttttttt ttttttttt ttttgcaggg ggacacagtt tcactcaatc gcccaggctg
gagtgcagtg gcacaatctc agctcactac aatctctgcc tcctgggttt aagcgattct
cgaacctcag cctcccgagt agctgggatt acaggcaccc gccaccacgc gagctaattt
ttgtatttgt tgtagagaca gggtttcgcc atgttgacca ggctggtctc gaactcctga
cctcaagtga tctgcccgcc tcggcctacc aaagtgctgg gattacaagc atgagccacc
gcccctggcc tttttctcct tcttgaaccc aggaaacctg ggccctggtc acctcttccc

tcagacccgg gagtctaggc ccttcttctc ccaggaccca gcagtcctag ctccctcttg
actctggacc ccaaaatctg gacctccaat gaagctgtcc ctttgggact ccagaatcca
gagagcccct cgccttcctt cacagtgaaa acattgggac tcacctaaga gagtcaagga
gcttctccag gaagtggcaa agtcagcatt caggtccctg cctgcctcac tcctgctctg
aatgctttgg atgagacagt ttgcggctgt ggaaacacac gtgctcgcaa atcaagtaga
tcagttcaaa ctatggctct gccctttctc cctgggcaaa ttcctttcca tctctgagcc
tcactttcct tatctgcaaa atgggaatca ttaaccaata gatttttag ctacgtgagg
gttcaggtta catcagtttt cttcattgtg ttctcctagt gctcagaatg gtgcctgcta
catggtagat gctcaataaa tatttgttga atggatgacc tgatgaataa ataatgaaat
gaatgaatgc atctctcctt caaagcgctg ttgtgaggat taaatgagat tatgagcata
ttgcttttgg cacgtagaga tgccagatgg aagtttttcc ccctcaaaga ggctttggag
aagtctattc ctcaaaagag gttaataaaa aagatcaatt ccaccttcaa tcattaattc
aactcttatt tactgagcac ctagtatgcc tgaggtgctg ttgcaggcgc tggatataca
gccatgagca aactgtacaa agtccttgtc gttatggagt tgcaagctag gtgggagaaa
tagacaataa acaaatacac ataaaataaa acattaggca aagtgctgta aggaaatatt
gtggagcgta aaaggatagg gagtaatgga gggatggtat tttttaattc gagtggtcag
ggaaggcttc caggaggagg tgacacttgg aaggagcagg atttagcaca gattgaggac
ccggttgtct gagggcagga agactggaaa gagagggtca gaggtatcat aaaggggcac
ctccaagtaa cccccagccc cttgatttga aaatggctca gggtaagaaa aaacacgtga
gatccaaggg cccctctcta gatggagaaa gcccaatagc aacaagtaca gcttcgttta
atgtggtgag aagtgatgtc ccctgtgcac agtgtcagaa aattccccca tgcagctgga
aaactccccc attacatcct ggaaagaaag ggggttagat ccagacaggg atggaggcaa
agggctgctc tctcagggaa ccttacaacc tcttcccccc cagagaattt tcctgacact
ctcaactgtg cagaagtaaa aatctttccc cagaagaagt gtgaggatgc ttacccgggg
cagatcacag atggcatggt ctgtgcaggc agcagcaaag gggctgacac gtgccaggtg
agcaatttct gaaatccttc tcctcacaca tccctcattg ccctctcgag gttcaaggct
tggatggggg tgggggtggt aagggagtga ccccaaagac ttggcacccg gagtgttcac
ccctatctct acggattggg agccaggttc agagaagcca aactctctct ctgaaagtca
cactgcatag ggattaggag cattgaattg ctgctgctgt tttctttcga acgcttaact
acaggatggg atgcagagtt gggggctata gagggtgggg tagatgtcca gcaaggagag
agtctgaggc tagagtttag acgagttgcc tgctctctgg ttcccagcat tacatcgtgg
aatttgtgcc gactttacca ccggcccggt ggtcagccac ttttctttga gaccgggcta
gaatcccaag gctggttccc ttctcctgtg attggttcct tgggagacaa tggtgtcttc
ccagttggct ggagtaaatg gtgccattga cttcagtgct tcctcaatga gctccaatcc
ctttctcttg ggatttgtca tagatataac tctctcttct aactgcaact tcgttgttcc
tagcactttc ccctggcttt gtccacttcc tggaagcccc accacctttg ccaatgactg
gtccctaaat acaatgcttt cttccccatt ggccaaaaat ggagtcgttt ccatcagcga
tactgccatg aaagccagtc tctggattgt tctgtagaga tagtggtctc ttccacaaat
atttcagcca tggtctcttg gggatatggt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt
gtgtgtgtgt gtgtccataa gaatcttgat cctttctcct atgtttggca actgcaatca
atgatgcctt cactattggc caggaacaga ggaaacttca gctcagtcct ctccaagtaa
tccctactgt cttctccctg gattggaccc tcgagaactc ttttttttt ttttttgaga
cagggtctcg ctctgtcccc caagctggaa tgcagtggca caatcttggc tcactgcagc
ctctgcctcc cagttcaagc aattctccca cctcagcctc ccgagtagct gtgattacag
gtgtgcacca ccacacccag ctagtttttg tatttttagt agagacaggg attcaccatg
ttggccaggc tggtctggaa cgcctgactt caagtgatct accgcctcgg cctcccaaag
tgccgggatt gcaggtgtga gccaccaagc ctgtctggga tttcattctt tcccctcttc
tgtcagtgtt ttgaccacta cccttagaca ccatgtctgt ctgtacatgg aagccccaag
ccctgtcctg actggtctca ggggacaatg cttttacccc cattggctac aggggaccaa
tcatgccaaa gaactggtaa aacgctggga cagcaggaaa agggacgttg tggacatctc
agatgcaagg ctgttctcat tctccctgtc tagggcgatt ctggaggccc cctggtgtgt
gatggtgcac tccagggcat cacatcctgg ggctcagacc cctgtgggag gtccgacaaa
cctggcgtct ataccaacat ctgccgctac ctggactgga tcaagaagat cataggcagc
aagggctgat tctaggataa gcactagatc tcccttaata aactcacaac tctctggttc
cttgcctgtc tctgttttgg ccctgtgggg agggctggat ggggatccgg gattgttcct
gctggcagac taggtgggga tgtgcagaaa ccaagttctc atggtcactt tggccatcac
cactgcctaa agtgatccct cgttttctgg aagaacttgg gtaagagctt tatttcaggg
gagaaaatac atacaaaggt cttcaaacat tcagtgggct ggtatgtgaa agacagtttt
gaaagagttt gtgtttagtt ttcctgagca aagcatttac aagctttgga gataaaattt

tccccccttta aaaaataatt

SEQ ID NO. 16

Hk10 amino acid

MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLD
PEAYGAPCARGSQPWQVSLFNGLSFHCAGVLVDQSWVLTAAHCGNKPLWARVGDDHLL
LLQGEQLRRTTRSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVPGPRVRALQLPY
RCAQPGDQCQVAGWGTTAARRVKYNKGLTCSSITILSPKECEVFYPGVVTNNMICAGL
DRGQDPCQSDSGGPLVCDETLQGILSWGVYPCGSAQHPAVYTQICKYMSWINKVIRSN

SEQ ID NO. 17

KLK10 nucleic acid

Gene 1…1580
CDS 220…1050

catcctgcca cccctagcct tgctggggac gtgaaccctc tccccgcgcc tgggaagcct
tcttggcacc gggacccgga gaatccccac ggaagccagt tccaaaaggg atgaaaaggg
ggcgtttcgg gcactgggag aagcctgtat tccagggccc ctcccagagc aggaatctgg
gacccaggag tgccagcctc acccacgcag atcctggcca tgagagctcc gcacctccac
ctctccgccg cctctggcgc ccgggctctg gcgaagctgc tgccgctgct gatggcgcaa
ctctgggccg cagaggcggc gctgctcccc caaaacgaca cgcgcttgga ccccgaagcc
tatggctccc cgtgcgcgcg cggctcgcag ccctggcagg tctcgctctt caacggcctc
tcgttccact gcgcgggtgt cctggtggac cagagttggg tgctgacggc cgcgcactgc
ggaaacaagc cactgtgggc tcgagtaggg gatgaccacc tgctgcttct tcagggagag
cagctccgcc ggaccactcg ctctgttgtc catcccaagt accaccaggg ctcaggcccc
atcctgccaa ggcgaacgga tgagcacgat ctcatgttgc tgaagctggc caggcccgta
gtgctggggc cccgcgtccg ggccctgcag cttccctacc gctgtgctca gcccggagac
cagtgccagg ttgctggctg gggcaccacg gccgcccgga gagtgaagta caacaagggc
ctgacctgct ccagcatcac tatcctgagc cctaaagagt gtgaggtctt ctaccctggc
gtggtcacca acaacatgat atgtgctgga ctggaccggg gccaggaccc ttgccagagt
gactctggag gcccccctggt ctgtgacgag accctccaag gcatcctctc gtggggtgtt
taccccctgtg gctctgccca gcatccagct gtctacaccc agatctgcaa atacatgtcc
tggatcaata aagtcatacg ctccaactga tccagatgct acgctccagc tgatccagat
gttatgctcc tgctgatcca gatgcccaga ggctccatcg tccatcctct tcctccccag
tcggctgaac tctccccttg tctgcactgt tcaaacctct gccgccctcc acacctctaa
acatctcccc tctcacctca ttcccccacc tatccccatt ctctgcctgt actgaagctg
aaatgcagga agtggtggca aaggtttatt ccagagaagc caggaagccg gtcatcaccc
agcctctgag agcagttact ggggtcaccc aacctgactt cctctgccac tccctgctgt
gtgactttgg gcaagccaag tgccctctct gaacctcagt ttcctcatct gcaaaatggg
aacaatgacg tgcctacctc ttagacatgt tgtgaggaga ctatgatata acatgtgtat
gtaaatcttc atggtgattg tcatgtaagg cttaacacag tgggtggtga gttctgacta
aaggttacct gttgtcgtga

SEQ ID NO. 18

KLK10 nucleic acid

Gene 1..5574
mRNA join(48..120,605..701,2455..2635,3589..3863,4195..4328, 4793..5474)
CDS join(614..701,2455..2635,3589..3863,4195..4328,4793..4945)
Promoter 1…47
5'UTR join(48..120,605..613)
exon 48…120

exon 605...701

ttggggtcaa aagggaaggt cccgccaggg gtccctgggc agaggatacc agcggcagac
cacaggcagg gcagaggcac gtctgggtcc cctccctcct tcctatcggc gactcccagg
tgaagctacc tgcaccccac ccgggttggg gtggattgcg agaggatggg tgggaacccc
cgggccacag gcaggagccg gcttagagcc tcggtttctc cactgcggga cgcggaagtc
cccccgctgt gaggttgaga aagaggctcc cactggctcc gagcctcgga tccccacccc
gcgcgtgaag gaggggggaaa cctcgggcgc ggcgtggctg cagccagggt agctggggcg
cggagagcgc tccactcggg cacagggagg acgggaagat gccgcgaggg gcgtcattag
ggtaattgtg cccattaccg tgttccagcc cgaatctccc gtctgccagc ccctggggtt
atcggctgca ggtcaaaagg gtgcttgcgg gctggggtgg cccaggctgg gcggatgagc
gcggcgaggt gggggtctct aacggagcat ctgttttaac ccgcccctgc acacacccca
gcagatcctg gccatgagag ctccgcacct ccacctctcc gccgcctctg gcgcccgggc
tctggcgaag ctgctgccgc tgctgatggc gcaactctgg ggtaaggtgg gggacagggg
gcggggagag gcgccggtgg gaggcacggg cgggagggca atgtgttccc gtcaccaagc
cccgcgcacc tctcctcccc cgagacccca gcacccaccc agcgctccgg agcacggccc
gcccccaagt cagctgggcc cttcttctgg ctcggcccct gggtgacccg ccccactcag
gccctgtccg atttctgcca cccggatcct cgctcttccg tggactcttc ggcgtgttct
ttctcctcct cttacgccgc cccatcccgg ccccgctcca ttttacacta ccgtgttttg
ttttgtttgt ttgtttgttt gagacggagt ctcgctctgt cgcccaggct ggagtgcagt
ggcgcgatct cggctcactg caagctccgc ctcccgggtt cacaccattc tcctgcctca
gcctcccgag tagctgggac tacaggcgcc cgccaccaag cccggctagt tttttgtatt
tttagtagag atgggatttc accgtggtct cgatctcctg gcctcgtgat ccgcctgcct
cggcctccca aagtgctggg attacaagcg tgagccaccg ctcccggcca caccacagtg
ttttatcctg agtcttgcct taccgctttt tgccctctcc cctcactttt tttcttcctc
tttccctttc tctctctttt ttctttttct ttctttcttt tctttctttc gttcttcttt
tccttccttc ctttccttcc ttcctttcgt ttgtttcttc tttcttgttt tactttctct
cttatttttt cttctttctt tcttgttttt tttctttctc tctctttttc tttccttctt
ttttttttct ttttttgag acagggcagt gctctgtctc cgtggctgga gtacagtggc
ccaatcagag ctcactgcag cctcgacctc ctgggctcaa gcgatactca gcctccagag
tagctggtac cacaggcatg caccaccaca tccggctttt ttttttttct ttttttttct
ttttttgag acagggtctc actctgtcgc ccagactgga gtgcagtggc ccaatctcgg
ctcattgcaa cctccacctc ctgggctcaa gcgatcctcc cacctcagcc tcccaggtag
ctgtgactac aggcgcatgc ctccgcgact actttttgt tgttgttgtt gtttgtttgt
ttttgtagag actgggtctt gctgtgttgc ccgggctggt cttgaattcc cgagctcaag
cggtccaacc gcctcggctt cccaaagtgc tgggattaca ggcgtaaacc actgcgcccc
acccctctcc tggttttcaa tcccgttttg ttattcacac cccttcctct ccccgatccc
cgagttctat ccccgcaccc ttacctcccc gccgcgttca atccccgccc ctctatcgac
cagcgacgtt ctagccagct ctccaggcgc gctgcgttca gtccctgccc tccagaccca
ccctattctg tctcattact ccacgctacc ctatcccagc ttccttccac tttcacgcgc
ttcttctcct cccattcctt cggtgcacgc gaaaccccca atatttccct accaccctcg
cgttctggct gcgtcccccg tccccgaacg cagtccagtg ccacagccca gctccaaccc
caaacccaga ccctgccctc cgtgctttga ttccgtcccc tttctttctc ccagccgcag
aggcggcgct gctcccccaa aacgacacgc gcttggaccc cgaagcctat ggcgccccgt
gcgcgcgcgg ctcgcagccc tggcaggtct cgctcttcaa cggcctctcg ttccactgcg
cgggtgtcct ggtggaccag agttgggtgc tgacggccgc gcactgcgga aacaagtagg
aggagatcca tccccgagga cgccacgggg ggctgtggag gcggcctcca gggaggagcg
ggcagggcgg ggtctctcgg aactcccaca gctggaggtg cggtccccgg tgtccttcca
gcaggaggag agaccgggct tgcgctgtgg ccgccagggg acggtgtggt ccttttccgc
atttctgggc ccgtcactcc tctcccgctg attctccttg agctctagga ggaggtggtt
gcctgcaacg gatagaagcc agggtccggt gtggtcagga atttagaact aaaggaaaag
gttcacttcg tgagtccccg ttgaaggagg aagggttggg tattaccaca gagaaaatgt
ggagttgggc tgggctcggt ggctcacgcc tgtaatccca gcactttggg aggccaaggc
gggtggatca cctgaggtca ggagttcaag accagcctgg ccaacatggt gaaaccactt
ctcaactaaa aataaaataa aataaaaaat aaaaaatttt aaaaaaatta aaaaaaaaaa
aaggctgggt gtggtggcgg gtgcctgtaa tcccagctac tcaggaagga ggctgaggca
ggagaactgc ttgaacctgg gaggtggagg ttgcagtgag ccgagattgc gccattgcat
tctagcctgg gtgacaagag cgaaactctg tttcaacaaa gaaaagaaaa agagaaaaga
aaatgtggaa ggcttaccta ggtgtccagg cccccagccc tcctcaattc ctgcagatcc

tcagagctca aacaactgat tcctcctccc catgtccact gaggtcccct tctcccacaa
ggccctcttc cctcagactc ttcctatctc caggccctgc ttcactgccc acctgctttc
ccagtccctg tgaagggttt gccttcacat gcctcttcct tcccccaggc cactgtgggc
tcgagtaggg gatgaccacc tgctgcttct tcagggcgag cagctccgcc ggacgactcg
ctctgttgtc catcccaagt accaccaggg ctcaggcccc atcctgccaa ggcgaacgga
tgagcacgat ctcatgttgc taaagctggc caggcccgta gtgccggggc cccgcgtccg
ggccctgcag cttccctacc gctgtgctca gcccggagac cagtgccagg ttgctggctg
gggcaccacg gccgcccgga gaggcaagag ctggggctct gaggccagaa cctcaggagg
agggggctga gggcctgaac ccctgggtct gaggaaggat gggctgggga ctggattcct
ggatctgagg gaggacgggc tggggtccta gatgcctggg tctgtgagtc tgaggggagg
aggggctggg ggcctggact cctgggtcta agtggggagg ggctggggcc aggattcttg
agtctgaagg aggaggggct ggggcttagg atagaaacgg tcttgtatct ggactcctgg
ctccccaagg attgggggct ggacccaggg attactggca tattctccct tcagtgaagt
acaacaaggg cctgacctgc tccagcatca ctatcctgag ccctaaagag tgtgaggtct
tctaccctgg cgtggtcacc aacaacatga tatgtgctgg actggaccgg ggccaggacc
cttgccaggt agggtctgaa cagggagagt ctctgactcc tgggagggag gacagggagg
ttatgggaaa agagcagacc ctgtgcccga tcccaaactc cattcccaaa cccatccttg
accccaactc ttacccagac ctaacccct cctcatccct atcctcaatc ccatttccat
cctaacccca ccccattccc atctccaagc ccattttcat cccctcacct tccatgaact
acaatcccaa cccaagtctc actgtgcctt cattctcatc ccccagccca acctcccata
acctgaagtc cacctccatt cctaccttcc agctcatacc taattccaac cccatcccat
cctcgtcttt atcccaaccc aacccccttcc ttccccacca ctgccccaga tcccaaagtg
acagctctca cgttggcaca tttatttgat ctctcctttc tgccaccccc agagtgactc
tggaggcccc ctggtctgtg acgagaccct ccaaggcatc ctctcgtggg gtgtttaccc
ctgtggctct gcccagcatc cagctgtcta cacccagatc tgcaaataca tgtcctggat
caataaagtc atacgctcca actgatccag atgctacgct ccagctgatc cagatgttat
gctcctgctg atccagatgc ccagaggctc catcgtccat cctcttcctc cccagtcggc
tgaactctcc ccttgtctgc actgttcaaa cctctgccgc cctccacacc tctaaacatc
tcccctctca cctcattccc ccacctatcc ccattctctg cctgtactga agctgaaatg
caggaagtgg tggcaaaggt ttattccaga gaagccagga agccggtcat cacccagcct
ctgagagcag ttactggggt cacccaacct gacttcctct gccactcccc gctgtgtgac
tttgggcaag ccaagtgccc tctctgaacc tcagtttcct catctgcaaa atgggaacaa
tgacgtgcct acctcttaga catgttgtga ggagactatg atataacatg tgtatgtaaa
tcttcatgtg attgtcatgt aaggcttaac acagtgggtg gtgagttctg actaaaggtt
acctgttgtc gtgatctgac cacgtcccgg tgaaagcgtg tgtccaggga agaagtgcac
agggtagccc ccaatcccaa ccttccatcc ccaaccctta gggatgatgg aaga

SEQ ID NO. 19

Hk11 amino acid

MQRLRWLRDWKSSGRGLTAAKEPGARSSPLQAMRILQLILLALA
TGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTAAHCLKPRYIV
HLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSITWAVRP
LTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPGNITDTM
VCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQ ETMKNN

SEQ ID NO. 20

Hk11 amino acid

MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTR
LLCGATLIAPRWLLTAAHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSL
PNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHT
LRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIIS
WGQDPCAITRKPGVYTKVCKYVDWIQETMKNN

SEQ ID NO. 21

KLK11 nucleic acid

aggaatctgc gctcgggttc cgcagatgca gaggttgagg tggctgcggg actggaagtc 61
atcgggcaga ggtctcacag cagccaagga acctggggcc cgctcctccc ccctccaggc 121
catgaggatt ctgcagttaa tcctgcttgc tctggcaaca gggcttgtag ggggagagac 181
caggatcatc aaggggttcg agtgcaagcc tcactcccag ccctggcagg cagccctgtt 241
cgagaagacg cggctactct gtggggcgac gctcatcgcc cccagatggc tcctgacagc 301
agcccactgc ctcaagcccc gctacatagt tcacctgggg cagcacaacc tccagaagga 361
ggagggctgt gagcagaccc ggacagccac tgagtccttc ccccaccccg gcttcaacaa 421
cagcctcccc aacaaagacc accgcaatga catcatgctg gtgaagatgg catcgccagt 481
ctccatcacc tgggctgtgc gacccctcac cctctcctca cgctgtgtca ctgctggcac 541
cagctgcctc atttccggct ggggcagcac gtccagcccc cagttacgcc tgcctcacac 601
cttgcgatgc gccaacatca ccatcattga gcaccagaag tgtgagaacg cctaccccgg 661
caacatcaca gacaccatgg tgtgtgccag cgtgcaggaa gggggcaagg actcctgcca 721
gggtgactcc gggggccctc tggtctgtaa ccagtctctt caaggcatta tctcctgggg 781
ccaggatccg tgtgcgatca cccgaaagcc tggtgtctac acgaaagtct gcaaatatgt 841
ggactggatc caggagacga tgaagaacaa ttagactgga cccacccacc acagcccatc 901
accctccatt tccacttggt gtttggttcc tgttcactct gttaataaga aaccctaagc 961
caagaccctc tgcgaacatt ctttgggcct cctggactac aggagatgct gtcacttaat 1021
aatcaacctg gggttcgaaa tcagtgagac ctggattcaa attctgcctt gaaatattgt 1081
gactctggga atgacaacac ctggtttgtt ctctgttgta tccccagccc caaagacagc 1141
tcctggccat atatcaaggt ttcaataaat atttgctaaa tgagtg

SEQ ID NO. 22

KLK11 nucleic acid

gene 2313..7622

mRNA join(2313..2398,4189..4263,5061..5217,5545..5810,
6627..6763,7158..7622)

CDS join(4224..4263,5061..5217,5545..5810,6627..6763, 7158..7310)

tgataatagt gttctctctc ctcattggtc agggccccag ccattgtcct tgagagaatg 61
ctcgactctt tatgttgtct tgacagcctc ccctgagatt ggtcattaat gactgtgctc 121
tctctcctca ttggtcaggg ccccagccat tgtccttgag agaacctctg tcctttatgg 181
agttccaccc ttcttccctg ggattggccc ctagagacag tggttcttct cttttggtta 241
gccattgcca ttgtcctccg ggaaagtgat tatactcttt tgtctaatga ccagacttgg 301
agccctcccc aaggcccagg actgggttga agggttgggg aggaaaacag aaataagatg 361
tctcccttgt tcagacagta cttctcttcc cttccagggt gattctgggg gccccctggt 421
gtgtggggga gtccttcaag gtctggtgtc ctgggggtct gtggggccct gtggacaaga 481
tggcatccct ggagtctaca cctatatttg caagtatgtg gactggatcc ggatgatcat 541
gaggaacaac tgacctgttt cctccacctc cacccccacc ccttaacttg ggtacccctc 601
tggccctcag agcaccaata tctcctccat cacttccccc agctccactc ttgttggcct 661
gggaacttct tggaacttta actcctgcca gcccttctaa gacccacgag cggggtgaga 721
gaagtgtgca atagtctgga ataaatataa atgaaggagg ggccatgtct gtccatttga 781
agtcctcatg ctggttgaga ctggaagaag gactcagcag tttccctatc tcataggagt 841
agaaacagag ctcaaataag gccaggcaca gtggctcaca cctgtaatcc catcactttg 901
ggaagctgag gcaggtggat cacctgaggt caggaactcg ggaccagcct ggtcaacata 961
gtgaaacccc aactctacta aaaatgcaaa aattagccag gcatggtggc gcatgcctgt 1021
aatcccagct actcaggagg ctgagacagg agaatagcat gaacccgtga ggcagaggct 1081
gcagcgagcc gagattgaac cattacactc cagcctgggc gacagagcga gactccatct 1141
caaaaacaaa caaacaaaaa acccagtgct caaataggat gagggtcttc cctgagtagt 1201
tactcagaaa tggagtagaa aaagttactt ttaataatat aggccgggtg cagtggccca 1261
cgcctgtaat cccagcactt tgggaggccg aggtgggagg atggcttgag ctcagatttc 1321
gagatcagcc tggcaacaca gtgaaatctt gtcactacaa aaacacaaaa aattagctgg 1381

gtgtggtggt gcgtgcctgt agtcccagct acttgggaag ctgaggtggg aggatcaccc 1441
gagccgggga ggtggaggct gcaaagagcc gagatcatgc cactgcactc cagcctgggc 1501
aataaagtga gaccttgtct caaaaacaaa aacccagcaa tataaataag acacatgttt 1561
cttcatctgg cataatagaa atagtgccca gagcttataa gcttttcaag agtccacaaa 1621
agacccgaaa aagaaaaaga aaattgttag ctccaaaata ccagatgaaa gctgcaaagt 1681
caacatttat gaccatttaa tccaatgtcc ataaaacgta gcattctttc cactagccaa 1741
ctgcagttta ctttcttgta atgaagcata cattgtatct ttaatgtggg acgtggcttt 1801
gttctaataa gacgaagggt ggagtgcagg cttggaaagc aggagagctc agcctacgtc 1861
tttaatcctc ctgcccaccc cttggattct gtctccactg ggactcaaga ggtgaggaga 1921
gaccatctcc ccaaatgcac tgaagggaaa ctggaggagg gagggagtga ggggtgatca 1981
taccagcgga ggcacatttg ctgagccccc ccgcagtctg ctctttccaa gtggaccctc 2041
ctggaagcct gatcccaacc tcccctgcaa gcaggtctgt cacccccatc tctcagatga 2101
agaaactgag ccttgcaggg gtggagtccc ttgtccccac gtcataaggg tagtcatagt 2161
agtaggaaga ggaagcacct aggtttgagg ccagggctgg ctgctgtcag aacctaggcc 2221
ctcccctgcc ttgctccaca cctggtcagg ggagagaggg gaggaaagcc aagggaaggg 2281
acctaactga aaacaaacaa gctgggagaa gcaggaatct gcgctcgggt tccgcagatg 2341
cagaggttga ggtggctgcg ggactggaag tcatcgggca gaggtctcac agcagccagt 2401
aagtgaacag ctggactcgg gctgcctggg cggcagggag aagcgggcag gggaagggtc 2461
agcagaggag cgaggcccca gaggagccct ggggtggagc acagccaagg gctctgttcc 2521
ctttcctgga ctcggcttcc acaggccctg acctgcctcc cccaccctcc ggtcctgccc 2581
ctgtgcctgg cagcagcccc acctgtgtga catcccagca caccccccct ctccttgcaa 2641
aggagaaggg agcggcctag gggaggccag gggcccacct gggctggggc tgtggagagg 2701
gagtggctgg gacgggagga aaaagagaga cggagattag atggaagaag agggatttca 2761
agacaaattg ccagagatgc agtcagagag actgactgag agacacaaag atagaaggaa 2821
ttagagaaag ggccacacag agccagacag agagagaaga gtggagatgg agacagggac 2881
gaggacagag aaaggcagac agacacatag ggacagaaag agaaaaatca cacaaagtca 2941
gaattactga atgacaggga atgacacata gaacgagaca cagattcaga gactcagggc 3001
agggaaagga aggctgcaga cagacagaca gacagaggga ggctgagaca cagggagaag 3061
aggggcttgg agaggtggca caggcaggca gccagtgcct cagaggcctc cggggagggc 3121
cctcacacac accccgcccc ggggcattaa ggcagggctt ggaggccagt catcctgggc 3181
ccgcccaggg ccgccccct gccagcccgc ctgcctggtg cctggcacct ggcgctccaa 3241
cccagcctac ctgctgtagc tgccgccact gccgtctccg ccgccactgg gcccccagag 3301
ccccagcccc agagcctgtg agtccaggag gaaagggaag ctgcccctcc ccgtccaggt 3361
gtcagccctc cccaaggaca cctgtcccac tcgggcaccc atttctccct ctgctctgtc 3421
cttctctgct tgggtggggg ttcctggcct ctctctacac ctctcacctc cgatggctgt 3481
ccgcagcctc agttacctct aatctccatg gcttcagctg ctgagctggc cctctgctcc 3541
caccccccgct ggccagggca gcggagggca ctggccctcc cctcgaccag ccccgcccag 3601
ctttgcttgg ctgtccttca aaagggcagg ggtttggcgg acagggcttc agcaagccgg 3661
gtgatggggg tcccagacat tgtctggggc tgagcccccct actcccctcc agcagacctc 3721
aaaggctcca tatcgctctg ctgcgaagac aatgaaaaag gggtggctac ggaacggtgt 3781
ctggttcccc ttgtccttcc accccaagct gctggggcct ggccagctct caaggcaaga 3841
aggaaaacat cctctgacat gtgccgggga ggtcccatgg ctgacttgaa cagggccgaa 3901
ccatggcttg acagctcaaa gcccctccca acgacttcca catggttctt ggtatctcgg 3961
aagcttctag ctgtgaccag gccctctcca aggccaccct agacacctaa gatatatttt 4021
aagtgtttgg agatctgagt gctgtgagaa acaggggatt tccccaacct tgtttctccc 4081
aagtggggag cgggagcagg tgagggagag aggagagggc atgagccagc ccccccctcc 4141
cgatttcccc gtaaagtgat gcggccccat gtccctcctt gttcccagag gaacctgggg 4201
cccgctcctc ccccctccag gccatgagga ttctgcagtt aatcctgctt gctctggcaa 4261
caggtacgca ggggatgggg gcagggcagg atcctccctc ttgaatctct gggatcccct 4321
aaccctctgt gtctggacag tgacagggct gattccaaat tacagaacaa cccataaggc 4381
acctgaactg gagcagtggt catgagggcc tggatgccct tctagataat ccctttaaat 4441
gccaaaggag gagaggtcaa gggggtcgta aagggtcccg tggaggggct gaggaagctg 4501
gagttggggg agcagtcact caaagcgccc aggacagggg ctactgacca accagtatgg 4561
aagtatttcc ttttttttt ttcccagaga caaagtcttg ctctattgtc caggctggag 4621
tgccgtggtg ccaacacggc tcactgcagt cttgacttcc cgggcttaag tgatccttaa 4681
gccatctcag cttccccggt agctgggacc acaggcacct gccaccaagc caggctaatt 4741
gtttaattgt ttgtagagat gggggaggag gtctcactat gtttgcctag gctgatctag 4801
aactcctggg ctcaagtaat cctcccacct tagcctctca aagtgctggg attacaggca 4861
tgagccactg catttgacct tatggaagta ttttcatcct ttaatacccg accccagcat 4921

ccagggcaac ccagagggac accagaccag ggcccagacc acccactctc tttctctcct 4981
ccccaccccc atttctggga gtcctcctgg tctaccacct ctccttcctg agccccttct 5041
tttgctctca ccccctccag ggcttgtagg gggagagacc aggatcatca aggggttcga 5101
gtgcaagcct cactcccagc cctggcaggc agccctgttc gagaagacgc ggctactctg 5161
tggggcgacg ctcatcgccc ccagatggct cctgacagca gcccactgcc tcaagccgtg 5221
ggtgcggggg ctggggcggt gccggggtgg ggggctggga atggggagat ggatggagag 5281
aagctcaggg atagggggtgc tggtaagggg attagagatg gggatgggta gtgtcagcaa 5341
ggttgatggg ctcgagttgg tattgaaggt ggggggatga atggggttgg gatggggcta 5401
tggctgggaa gggggcttcg gtgggagacg tggaagaggt tggaagcaga gcgatgtttc 5461
ttcatcctca aaggtgtcac tcacctctcc cacccatgtc tcccccgacc tttcctcctc 5521
caactactgt ctctcccacc tcagccgcta catagttcac ctggggcagc acaacctcca 5581
gaaggaggag ggctgtgagc agacccggac agccactgag tccttccccc accccggctt 5641
caacaacagc ctccccaaca aagaccaccg caatgacatc atgctggtga agatggcatc 5701
gccagtctcc atcacctggg ctgtgcgacc cctcaccctc tcctcacgct gtgtcactgc 5761
tggcaccagc tgcctcattt ccggctgggg cagcacgtcc agcccccagt gtaggagcac 5821
cagaggggaa cctggcaggg ggtggtgagg agggagtggt caggattgtg gaagggttca 5881
gggcatcaga gatgcggttc acagtgacga tgtgggataa gttgagagga tgtgtggaaa 5941
acgtcaggat agggggggtgg ggacaaaagt tggggccttg gagtcagacg gacgggatat 6001
gcaatcatac atccataacc tcctggttgt aagaccttag gcaagcagct tcacctctct 6061
gaatcttgat tttcttctct ataaaatgag aatgattata cccacctgtc aggattggat 6121
tagagataat gtatatcaag caactgacat aaatcattta ttggatagca ggctgggcac 6181
cgtggctcac gcctgtaatc ccagcacttt gggaggccga ggtgggaaga tcacctgagg 6241
tcaggacttt gataccagcc tggccaacgt ggtgaaatcc catctctact aaaaatgtga 6301
aaattagttg ggcgtggttg tgtgcgcctg taatcccagc tactcgggag gttgaggcag 6361
gagaatcgct taaacttggg agacggaggt tgcagtgagc caagatcacg ccactgcact 6421
ccagcctggg caacagagca agactctgtc tcgaaaaaaa aaaaaaaaaa gctggatagc 6481
attgctgttg ctattgttac aagaagagag gtgagttggc tgcgtctaag gacagggatt 6541
cccccagggg cgggatcaca gcaagcactg cattagggga ggtggcaggg ggctcattcc 6601
cacagcccct cacgctgttt ccacagtacg cctgcctcac accttgcgat gcgccaacat 6661
caccatcatt gagcaccaga agtgtgagaa cgcctacccc ggcaacatca cagacaccat 6721
ggtgtgtgcc agcgtgcagg aaggggggcaa ggactcctgc caggtcagtg tggtctccaa 6781
ccacagcccc atccccatcc ccagcttcaa tgacatcttt accgacatcc acaatttcat 6841
ccccaacctc aacccgccga cccctgcaac tcccaatcca tctcttcccc tgttcccgtt 6901
tctgacctca gcacaaactt cagctccatc cccgtttcca caccatttcc agctccaacc 6961
atccccaaac tcgtttttga gcctaacccc atcctttatc ccacccataa tcccagcttt 7021
atcgctaaac ctatcacctt tcccagtgcc tacccatcct gtctcggccc cactcctaag 7081
caccgtcccc acctcctccc tggctaacac catgctcaac gctttctctg accgacattc 7141
tctctccccg tgcccagggt gactccgggg gccctctggt ctgtaaccag tctcttcaag 7201
gcattatctc ctggggccag gatccgtgtg cgatcacccg aaagcctggt gtctacacga 7261
aagtctgcaa atatgtggac tggatccagg agacgatgaa gaacaattag actggaccca 7321
cccaccacag cccatcaccc tccatttcca cttggtgttt ggttcctgtt cactctgtta 7381
ataagaaacc ctaagccaag accctctacg aacattcttt gggcctcctg gactacagga 7441
gatgctgtca cttaataatc aacctggggt tcgaaatcag tgagacctgg attcaaattc 7501
tgccttgaaa tattgtgact ctgggaatga caacacctgg tttgttctct gttgtatccc 7561
cagccccaaa gacagctcct ggccatatat caaggtttca ataaatattt gctaaatgag 7621
tgaatctact gagtgcttac tatgtgctag accctgatcc aatggctttt attttatttt 7681
atttttgac agagtctcgc tctgtcaccc aggctggagt acagtggtgc tatctctgct 7741
cactgcaacc tccacctcct gggttcaagc aattctcctg cctcagcctc ctgaatagct 7801
gggattacag gtgcctacca ccacatccgg ctaatttttg tatttttag tagagatggg 7861
gcttcaccat gttggccagg ctggtctcga actcctgacc tcagatgatc tgccctcctt 7921
ggcctcccaa actcctggga ttacagacgt gagccaccgc gcccgcccgg ctttcattta 7981
ttaattaaaa gaaattaaat taattaatct atttaggaga cagtcttgct ctgttgccca 8041
ggctggagtg cagtaacaat cacagctcac ggcaatctca atttcctggg gtcaagtgat 8101
tgtcctccct cagcctccag agtagctggg actacaggca catgccacga agcccagcta 8161
atttttgtat ttttcgtaga gacagaggtc tcagtatgtt gccccggcta gtctcaaact 8221
cctgggctca agcagtctgt cctcctcagc ctccaaaagt ggtgagatta caggcatgag 8281
tcgctgtgcc tggcctccaa gcactttcaa atgtatcaac ttaatcctca caaaaccctg 8341
tgaggtcggt actgttttca tacctatttt atagttgaag aaacagacac agagaagcaa 8401
agtcacttgc tcacagtcac gtggctagga gagcaaggat ctgaagcaag gcgatctctt 8461

```
aattaccaag tgatgttcct ggagtaaggc tctgtttgtt tcctttcctg taaaatgctg 8521
catgcaaaag tataacacag taagtaaaga agtcagttag cctgcacata ctaagaccta 8581
accaaaggag cttattgttt ttctccaact tccatgatag gtaattagat agtggagacc 8641
tctgctggcc aatatggtag ccactaaccg cagctggctc ttccaattaa aattacataa 8701
agccagaaat gtaactcctc tgtctcactt gttatatctc caaggctgga tagccacatg 8761
tgactggtgg tggctggatt agctagtgca tataaaacat cactgcagaa agttcagctg 8821
agcagcactg agttagatgg cctctgaaga ggatgtccca cggagagaat ccagaactca 8881
ggatcttttt ttttttttt ctttgcgaca gagtcttgct ctgtcaccca ggctggagtg 8941
cagtggcgtg atctcggctc actgcaactt ctgcctccca ggttcaagca attctcctgc 9001
ctcagcctcc ctagtagctg ggactacagg cctgtgccaa catccccagc taatttttgt 9061
gtctttttag tagagatggg gtttcactat gttggccagg ctggtctcga actcctgacc
```